
<html lang="en"     class="pb-page"  data-request-id="74285856-5e8d-45b3-8f75-1784ea7e4a85"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2020.63.issue-15;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.0c00226"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of 3-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one (JNJ-53718678), a Potent and Orally Bioavailable Fusion Inhibitor of Respiratory Syncytial Virus" /></meta><meta name="dc.Creator" content="Sandrine  Vendeville" /></meta><meta name="dc.Creator" content="Abdellah  Tahri" /></meta><meta name="dc.Creator" content="Lili  Hu" /></meta><meta name="dc.Creator" content="Samuel  Demin" /></meta><meta name="dc.Creator" content="Ludwig  Cooymans" /></meta><meta name="dc.Creator" content="Ann  Vos" /></meta><meta name="dc.Creator" content="Leen  Kwanten" /></meta><meta name="dc.Creator" content="Joke  Van den Berg" /></meta><meta name="dc.Creator" content="Michael B.  Battles" /></meta><meta name="dc.Creator" content="Jason S.  McLellan" /></meta><meta name="dc.Creator" content="Anil  Koul" /></meta><meta name="dc.Creator" content="Pierre  Raboisson" /></meta><meta name="dc.Creator" content="Dirk  Roymans" /></meta><meta name="dc.Creator" content="Tim H. M.  Jonckers" /></meta><meta name="dc.Description" content="Respiratory syncytial virus (RSV) is a seasonal virus that infects the lungs and airways of 64 million children and adults every year. It is a major cause of acute lower respiratory tract infection..." /></meta><meta name="Description" content="Respiratory syncytial virus (RSV) is a seasonal virus that infects the lungs and airways of 64 million children and adults every year. It is a major cause of acute lower respiratory tract infection..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 14, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00226" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00226" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00226" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00226" /></link>
        
    
    

<title>Discovery of 3-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one (JNJ-53718678), a Potent and Orally Bioavailable Fusion Inhibitor of Respiratory Syncytial Virus | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00226" /></meta><meta property="og:title" content="Discovery of 3-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one (JNJ-53718678), a Potent and Orally Bioavailable Fusion Inhibitor of Respiratory Syncytial Virus" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0014.jpeg" /></meta><meta property="og:description" content="Respiratory syncytial virus (RSV) is a seasonal virus that infects the lungs and airways of 64 million children and adults every year. It is a major cause of acute lower respiratory tract infection and is associated with significant morbidity and mortality. Despite the large medical and economic burden, treatment options for RSV-associated bronchiolitis and pneumonia are limited and mainly consist of supportive care. This publication covers the medicinal chemistry efforts resulting in the identification of JNJ-53718678, an orally bioavailable RSV inhibitor that was shown to be efficacious in a phase 2a challenge study in healthy adult subjects and that is currently being evaluated in hospitalized infants and adults. Cocrystal structures of several new derivatives helped in rationalizing some of the structure–activity relationship (SAR) trends observed." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00226"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00226">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00226&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00226&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00226&amp;href=/doi/10.1021/acs.jmedchem.0c00226" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 15</span><span class="cit-fg-pageRange">, 8046-8058</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/15" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01184" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Featured Article</span><a href="/doi/10.1021/acs.jmedchem.9b02073" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 3-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1<i>H</i>-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-one (JNJ-53718678), a Potent and Orally Bioavailable Fusion Inhibitor of Respiratory Syncytial Virus</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Sandrine Vendeville</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sandrine Vendeville</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Pharmaceutica NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sandrine++Vendeville">Sandrine Vendeville</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Abdellah Tahri</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Abdellah Tahri</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Pharmaceutica NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Abdellah++Tahri">Abdellah Tahri</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lili Hu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lili Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Pharmaceutica NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lili++Hu">Lili Hu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Samuel Demin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Samuel Demin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Pharmaceutica NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Samuel++Demin">Samuel Demin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ludwig Cooymans</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ludwig Cooymans</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Pharmaceutica NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ludwig++Cooymans">Ludwig Cooymans</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ann Vos</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ann Vos</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Pharmaceutica NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ann++Vos">Ann Vos</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Leen Kwanten</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Leen Kwanten</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Pharmaceutica NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Leen++Kwanten">Leen Kwanten</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Joke Van den Berg</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joke Van den Berg</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Pharmaceutica NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joke++Van+den+Berg">Joke Van den Berg</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael B. Battles</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael B. Battles</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Cell Biology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire 03755, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+B.++Battles">Michael B. Battles</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jason S. McLellan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jason S. McLellan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Biosciences, The University of Texas at Austin, Austin, Texas 78712, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jason+S.++McLellan">Jason S. McLellan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anil Koul</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anil Koul</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Pharmaceutica NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anil++Koul">Anil Koul</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pierre Raboisson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pierre Raboisson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Pharmaceutica NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pierre++Raboisson">Pierre Raboisson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dirk Roymans</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dirk Roymans</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Pharmaceutica NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dirk++Roymans">Dirk Roymans</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Tim H. M. Jonckers</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tim H. M. Jonckers</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Pharmaceutica NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#e7938d8889848c8295a78e9394c98d898dc984888a"><span class="__cf_email__" data-cfemail="7f0b1510111c141a0d3f160b0c51151115511c1012">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tim+H.+M.++Jonckers">Tim H. M. Jonckers</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3974-822X" title="Orcid link">http://orcid.org/0000-0003-3974-822X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00226&amp;href=/doi/10.1021%2Facs.jmedchem.0c00226" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 15</span><span class="cit-pageRange">, 8046–8058</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 14, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>7 February 2020</li><li><span class="item_label"><b>Published</b> online</span>14 May 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 August 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00226" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00226</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8046%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DSandrine%2BVendeville%252C%2BAbdellah%2BTahri%252C%2BLili%2BHu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D15%26contentID%3Dacs.jmedchem.0c00226%26title%3DDiscovery%2Bof%2B3-%2528%257B5-Chloro-1-%255B3-%2528methylsulfonyl%2529propyl%255D-1H-indol-2-yl%257Dmethyl%2529-1-%25282%252C2%252C2-trifluoroethyl%2529-1%252C3-dihydro-2H-imidazo%255B4%252C5-c%255Dpyridin-2-one%2B%2528JNJ-53718678%2529%252C%2Ba%2BPotent%2Band%2BOrally%2BBioavailable%2BFusion%2BInhibitor%2Bof%2BRespiratory%2BSyncytial%2BVirus%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8058%26publicationDate%3DAugust%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00226"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1904</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">2</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00226" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 3-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one (JNJ-53718678), a Potent and Orally Bioavailable Fusion Inhibitor of Respiratory Syncytial Virus&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Sandrine&quot;,&quot;last_name&quot;:&quot;Vendeville&quot;},{&quot;first_name&quot;:&quot;Abdellah&quot;,&quot;last_name&quot;:&quot;Tahri&quot;},{&quot;first_name&quot;:&quot;Lili&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Samuel&quot;,&quot;last_name&quot;:&quot;Demin&quot;},{&quot;first_name&quot;:&quot;Ludwig&quot;,&quot;last_name&quot;:&quot;Cooymans&quot;},{&quot;first_name&quot;:&quot;Ann&quot;,&quot;last_name&quot;:&quot;Vos&quot;},{&quot;first_name&quot;:&quot;Leen&quot;,&quot;last_name&quot;:&quot;Kwanten&quot;},{&quot;first_name&quot;:&quot;Joke&quot;,&quot;last_name&quot;:&quot;Van den Berg&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;B. Battles&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;S. McLellan&quot;},{&quot;first_name&quot;:&quot;Anil&quot;,&quot;last_name&quot;:&quot;Koul&quot;},{&quot;first_name&quot;:&quot;Pierre&quot;,&quot;last_name&quot;:&quot;Raboisson&quot;},{&quot;first_name&quot;:&quot;Dirk&quot;,&quot;last_name&quot;:&quot;Roymans&quot;},{&quot;first_name&quot;:&quot;Tim&quot;,&quot;last_name&quot;:&quot;H. M. Jonckers&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;14&quot;,&quot;issue&quot;:&quot;15&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;8046-8058&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00226&quot;},&quot;abstract&quot;:&quot;Respiratory syncytial virus (RSV) is a seasonal virus that infects the lungs and airways of 64 million children and adults every year. It is a major cause of acute lower respiratory tract infection and is associated with significant morbidity and mortality. Despite the large medical and economic burden, treatment options for RSV-associated bronchiolitis and pneumonia are limited and mainly consist of supportive care. This publication covers the medicinal chemistry efforts resulting in the identification of JNJ-53718678, an orally bioavailable RSV inhibitor that was shown to be efficacious in a phase 2a challenge study in healthy adult subjects and that is currently being evaluated in hospitalized infants and adults. Cocrystal structures of several new derivatives helped in rationalizing some of the structure–activity relationship (SAR) trends observed.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00226&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00226" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00226&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00226" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00226&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00226" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00226&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00226&amp;href=/doi/10.1021/acs.jmedchem.0c00226" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00226" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00226" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00226%26sid%3Dliteratum%253Aachs%26pmid%3D32407115%26genre%3Darticle%26aulast%3DVendeville%26date%3D2020%26atitle%3DDiscovery%2Bof%2B3-%2528%257B5-Chloro-1-%255B3-%2528methylsulfonyl%2529propyl%255D-1H-indol-2-yl%257Dmethyl%2529-1-%25282%252C2%252C2-trifluoroethyl%2529-1%252C3-dihydro-2H-imidazo%255B4%252C5-c%255Dpyridin-2-one%2B%2528JNJ-53718678%2529%252C%2Ba%2BPotent%2Band%2BOrally%2BBioavailable%2BFusion%2BInhibitor%2Bof%2BRespiratory%2BSyncytial%2BVirus%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D15%26spage%3D8046%26epage%3D8058%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291362" title="Antimicrobial agents">Antimicrobial agents</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=291862" title="Indoles">Indoles</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/15" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/jmcmar.2020.63.issue-15/20200813/jmcmar.2020.63.issue-15.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/medium/jm0c00226_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00226&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Respiratory syncytial virus (RSV) is a seasonal virus that infects the lungs and airways of 64 million children and adults every year. It is a major cause of acute lower respiratory tract infection and is associated with significant morbidity and mortality. Despite the large medical and economic burden, treatment options for RSV-associated bronchiolitis and pneumonia are limited and mainly consist of supportive care. This publication covers the medicinal chemistry efforts resulting in the identification of JNJ-53718678, an orally bioavailable RSV inhibitor that was shown to be efficacious in a phase 2a challenge study in healthy adult subjects and that is currently being evaluated in hospitalized infants and adults. Cocrystal structures of several new derivatives helped in rationalizing some of the structure–activity relationship (SAR) trends observed.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11045" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11045" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Respiratory syncytial virus (RSV) is a negative-stranded ribonucleic acid (RNA) virus belonging to the <i>Pneumoviridae</i> family. In most patients, RSV usually results in upper respiratory tract infections eliciting “common cold”-like symptoms, which might last up to 2 weeks and are usually self-limiting. Nevertheless, RSV is considered the most important virus causing acute lower respiratory tract infection (LRTI) and is a major cause of hospital admissions and death in young children worldwide.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Infants that are born prematurely or close to the RSV season and/or suffering from bronchopulmonary dysplasia or congenital heart disease are at the highest risk of developing severe RSV-related acute LRTI.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In addition, RSV infection results in substantial illness and morbidity in the elderly and adults with underlying chronic illnesses, underlying disorders of cellular immunity, or suppressed immune systems.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Despite the large medical and economic burden, treatment options for RSV-associated bronchiolitis and pneumonia are limited: there is no vaccine, and besides prophylactic passive immunization with the humanized monoclonal antibody palivizumab or treatment with the nonspecific and poorly effective antiviral agent ribavirin, supportive care remains the major treatment option.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8">(5−8)</a> There is therefore an unmet medical need, prophylactically (pre- and postexposure) and therapeutically, for both children and adults.</div><div class="NLM_p">Initial studies in the adult and pediatric population demonstrated that RSV viral load and severity of disease symptoms are closely correlated.<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9−11)</a> Since then, two viral targets, the RSV fusion protein (F) and the RNA-dependent RNA polymerase (L), have been clinically validated with, respectively, the small-molecule inhibitors GS-5806/presatovir (<b>1</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>)<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and ALS-8176/lumicitabine (<b>2</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>),<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> having demonstrated proof-of-concept in a phase 2 human challenge study upon oral dosing. Both compounds decreased viral load and disease symptoms when administered early after infection.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/medium/jm0c00226_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of compounds <b>1</b>–<b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00226&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Moreover, the window between the onset of clinical symptoms (day 1 and day 3 for influenza and RSV, respectively) and peak viral load (day 2 and day 6 for influenza and RSV, respectively) was suggested to be considerably longer for RSV than for influenza,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> increasing the likelihood that RSV treatment with direct antivirals can present a viable therapeutic strategy by achieving high and sustained antiviral responses and thus improve disease outcome. A recent study of presatovir in hematopoietic stem cell transplant recipients, however, has indicated that antiviral treatment may more likely result in clinical benefit in patients at high risk for poor RSV-related outcomes from LRT complications presenting early in the disease course.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p">RSV F protein plays a critical role in establishing and propagating RSV infection by catalyzing membrane fusion and virus entry as well as cell–cell fusion resulting in the formation of syncytia.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> Different chemotypes have been shown to inhibit the RSV F protein by binding into a 3-fold symmetrical central cavity of the prefusion metastable state of F, thereby stabilizing it and preventing it from refolding to the postfusion state which is required for membrane fusion.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In addition to GS-5806, other chemical series have been discovered,<a onclick="showRef(event, 'ref21 ref22 ref23 ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23 ref24 ref25 ref26">(21−26)</a> but only a few molecules have been developed until early development and clinical trials due to nonoptimal efficacy or PK profile, limited safety, or strategic decision. For example, TMC353121 (<b>3</b>), an extremely potent RSV fusion inhibitor, showed a dose-dependent antiviral activity in a non-human primate model upon continuous infusion,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> but side effects at the site of injection prevented this compound to be developed further. Another example is the benzimidazole-based inhibitor BMS-433771 (<b>4</b>), the first orally active RSV fusion inhibitor to show efficacy in the mouse and cotton rat models, as well as primate model.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> Although BMS-433771 was advanced to early development stage based on a promising in vitro and in vivo profile, our internal assessment showed that it suffered from limitations such as (i) moderate in vitro potency, (ii) suboptimal exposure in preclinical species characterized by poor absorption, high clearance, and short half-life, (iii) limited lung distribution,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and (iv) the potential for time-dependent inhibition (TDI) of cytochrome P450 due to the presence of the aminocyclopropyl moiety.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><div class="NLM_p last">In this article, we describe the optimization effort that resulted in the selection of JNJ-53718678, a subnanomolar indole-based fusion inhibitor, having demonstrated evidence of clinical activity in a phase 2a challenge study conducted in healthy adult subjects experimentally infected with RSV and currently being evaluated in both infants and adults.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The synthesis, structure–activity relationships, ADME properties, and PK parameters of the most interesting analogues as well as their efficacy in the cotton rat model after oral dosing are discussed. The cocrystal structures obtained with JNJ-53718678 and other analogues are also presented and help rationalize the obtained SAR.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52526" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52526" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The identification of JNJ-53718678 is the result of an iterative optimization process encompassing several key learnings. <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> outlines some of the important steps leading to the selection of the final candidate. The detailed SAR analysis and optimization strategy are discussed thereunder.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/medium/jm0c00226_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. SAR Summary Leading to JNJ-53718678</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00226&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> SAR and PK Properties Leading to the Selection of the Lead Series</h3><div class="NLM_p">On the basis of the structure of <b>4</b>, azabenzimidazole, azaindole, and indole analogues bearing an hydroxybutyl side-chain or the more chemically inert isoamyl side-chain were prepared as initial exploratory analogues. Adding one extra nitrogen to the bicycle gave <b>4</b> and different azabenzimidazole analogues (compounds <b>5</b>–<b>10</b>). This modification was very well tolerated when at the 4-position of the bicycle, giving compounds <b>5</b> and <b>6</b> with a similar activity compared to <b>4</b>. In the 5-azabenzimidazole system, a potency drop of about 1 log<sub>10</sub> for both the polar hydroxybutyl and isoamyl side-chain derivative was observed (see compounds <b>7</b> and <b>8</b>). The two other isosteres, the 6- and 7-azabenzimidazoles <b>9</b> and <b>10</b>, showed an even stronger loss in potency of about 1.1 and 2.6 log<sub>10</sub> reduction in pEC<sub>50</sub> value, respectively.</div><div class="NLM_p"><a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> shows the <i>in vitro</i> potencies of a first set of isosteres. Antiviral activity was measured in HeLa cells infected with rgRSV224, using a fluorescence readout.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In parallel, cytotoxicity was measured in HeLa cells after a 3-day incubation time and was used to calculate selectivity indices (SI).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Antiviral Activities of New Bicyclic Series in RSV-Infected HeLa Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/medium/jm0c00226_0006.gif" alt="" id="GRAPHIC-d7e478-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center">bicycle</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">no.</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">X<sup>a</sup></th><th class="colsep0 rowsep0" align="center">X<sup>b</sup></th><th class="colsep0 rowsep0" align="center">X<sup>c</sup></th><th class="colsep0 rowsep0" align="center">X<sup>d</sup></th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">pEC<sub>50</sub><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">SI<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">series</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>4</sub>OH</td><td class="colsep0 rowsep0" align="left">8.1</td><td class="colsep0 rowsep0" align="left">>20 × 10<sup>3</sup></td><td class="colsep0 rowsep0" align="left">benzimidazole</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>4</sub>OH</td><td class="colsep0 rowsep0" align="left">8.0</td><td class="colsep0 rowsep0" align="left">>10 × 10<sup>3</sup></td><td class="colsep0 rowsep0" align="left">4-azabenzimidazole</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">8.1</td><td class="colsep0 rowsep0" align="left">>12 × 10<sup>3</sup></td><td class="colsep0 rowsep0" align="left">4-azabenzimidazole</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>4</sub>OH</td><td class="colsep0 rowsep0" align="left">7.3</td><td class="colsep0 rowsep0" align="left">>18 × 10<sup>3</sup></td><td class="colsep0 rowsep0" align="left">5-azabenzimidazole</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">7.5</td><td class="colsep0 rowsep0" align="left">>3 × 10<sup>3</sup></td><td class="colsep0 rowsep0" align="left">5-azabenzimidazole</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">7.0</td><td class="colsep0 rowsep0" align="left">>987</td><td class="colsep0 rowsep0" align="left">6-azabenzimidazole</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">5.9</td><td class="colsep0 rowsep0" align="left">>80</td><td class="colsep0 rowsep0" align="left">7-azabenzimidazole</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>4</sub>OH</td><td class="colsep0 rowsep0" align="left">6.8</td><td class="colsep0 rowsep0" align="left">>613</td><td class="colsep0 rowsep0" align="left">4-azaindole</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>4</sub>OH</td><td class="colsep0 rowsep0" align="left">8.8</td><td class="colsep0 rowsep0" align="left">>57 × 10<sup>3</sup></td><td class="colsep0 rowsep0" align="left">5-azaindole</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>4</sub>OH</td><td class="colsep0 rowsep0" align="left">6.9</td><td class="colsep0 rowsep0" align="left">>76</td><td class="colsep0 rowsep0" align="left">6-azaindole</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left"><4</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">7-azaindole</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>3</sub>SO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="left">8.0</td><td class="colsep0 rowsep0" align="left">>10 × 10<sup>3</sup></td><td class="colsep0 rowsep0" align="left">indole</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">6.4</td><td class="colsep0 rowsep0" align="left">181</td><td class="colsep0 rowsep0" align="left">indole</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">RSV assay in HeLa cells. Data generated from two or more determinations.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Selectivity index.</p></div></div></div><div class="NLM_p">In the azaindole subseries, the 6- and 7-azaindoles <b>13</b> and <b>14</b> also led to a poor antiviral activity (respectively, pEC<sub>50</sub> of 6.9 and <4.0). With the 4-azaindole derivative <b>11</b>, a 10-fold drop in potency was observed, whereas the 5-azaindole derivative <b>12</b> unexpectedly led to a compound 4 times more potent than <b>4</b>, with a single digit nanomolar potency (pEC<sub>50</sub> = 8.8). Finally, the more lipophilic indole core was also evaluated. Combination of the indole with the isoamyl side-chain led to a poorly active compound (compound <b>16</b>, pEC<sub>50</sub> of 6.4). The combination of the indole core with the isoamyl side-chain resulted in a highly lipophilic (clogP of 5.1) and protein bound (0.6% free in human serum) compound which might hamper proper engagement with the target. In order to counterbalance the high lipophilicity, compound <b>15</b> bearing the more polar methylsulfone propyl side-chain was prepared. This combination resulted in an inhibitor with a greatly improved potency (pEC<sub>50</sub> of 8.0), similar to <b>4</b>. Of note, none of these inhibitors reached a 50% maximal cytotoxic concentration (CC<sub>50</sub>) value, the highest concentration tested being 100 μM, and all compounds exhibited high SI, with inhibitor <b>16</b> being a slight exception. This first initial exploration, in which nine different bicycles were evaluated, resulted in three of them (the 4-azabenzimidazole, the 5-azaindole, and the indole) being retained for further optimization as they demonstrated potencies equal to or below 10 nM.</div><div class="NLM_p">As a next step, we investigated substitution on the indole ring itself (see compounds <b>17</b>–<b>25</b> in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Introducing a halogen at the 5-position had a positive impact on potency. The 5-fluoro derivatives <b>17</b> and <b>18</b> had a pEC<sub>50</sub> value of 7.8 and 8.4, respectively. A much more pronounced effect was seen with the 5-chloro and 5-bromo derivatives <b>19</b>–<b>22</b>. Compared to their fluoro analogues, a 10-fold improvement in potency was observed (e.g., compare <b>18</b> with <b>20</b> and <b>22</b>), leading to subnanomolar potent analogues. In contrast, when a chloro substituent was introduced at the 6-position of the indole, a poorly active compound was obtained (compound <b>23</b>, pEC<sub>50</sub> = 6.9). The latter result is in agreement with what was seen in another series, where a 7-chloroimidazo[1,2-<i>a</i>]pyridine proved to be more potent than the nonsubstituted analogue, which itself was more potent than the 6-chloroimidazo[1,2-<i>a</i>]pyridine derivative.<a onclick="showRef(event, 'ref24 ref34'); return false;" href="javascript:void(0);" class="ref ref24 ref34">(24,34)</a> The electron-withdrawing CF<sub>3</sub> group was also introduced at position 5 of the indole to give compound <b>24</b>. Although a single digit nanomolar inhibitor was obtained, the potency dropped compared to the 5-chloro derivative. Finally, introducing the electron-donating methoxy group was found to be detrimental for activity (compound <b>25</b>, pEC<sub>50</sub> = 7.4).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Effect of Indole Substitutions on Antiviral Potency</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/medium/jm0c00226_0007.gif" alt="" id="GRAPHIC-d7e1243-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">no.</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R<sup>3</sup></th><th class="colsep0 rowsep0" align="center">pEC<sub>50</sub><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>4</sub>OH</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">7.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>3</sub>SO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">8.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>4</sub>OH</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">8.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>3</sub>SO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">9.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>4</sub>OH</td><td class="colsep0 rowsep0" align="left">Br</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">8.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>3</sub>SO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="left">Br</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">9.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>4</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">6.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>3</sub>SO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">8.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>4</sub>OH</td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">7.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">RSV assay in HeLa cells. All compounds demonstrated CC<sub>50</sub> values of >50 μM.</p></div></div></div><div class="NLM_p">Having identified the 5-chloro substituent as beneficial, we next studied the effect of the lateral side-chain on potency and metabolic stability. As already reported,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> this side-chain is positioned toward the solvent, and both apolar moieties and alkyl chains with a terminal polar group are tolerated.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> We introduced side-chains of varying degrees of lipophilicity in order to modulate both potency and ADME properties by variation of the overall physicochemical properties of the obtained compounds. <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> summarizes the antiviral potency, metabolic stability, and clogP of these new derivatives <b>26</b>–<b>33</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Appending Side-Chain Optimization in the 5-Chloroindole Subseries</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/medium/jm0c00226_0008.gif" alt="" id="GRAPHIC-d7e1530-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">no.</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center" char=".">pEC<sub>50</sub><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">HLM,<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a>% metab</th><th class="colsep0 rowsep0" align="center" char=".">clogP</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>4</sub>OH</td><td class="colsep0 rowsep0" align="char" char=".">8.7</td><td class="colsep0 rowsep0" align="char" char=".">49</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>3</sub>SO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="char" char=".">9.7</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>3</sub>CMe<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="char" char=".">8.8</td><td class="colsep0 rowsep0" align="char" char=".">56</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>3</sub>CN</td><td class="colsep0 rowsep0" align="char" char=".">9.7</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>4</sub>F</td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char=".">37</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>3</sub>CF<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">9.6</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char=".">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>3</sub>COOH</td><td class="colsep0 rowsep0" align="char" char=".">6.7</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">3.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>3</sub>CONH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">7.3</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">3.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>3</sub>C═NHNHOH</td><td class="colsep0 rowsep0" align="char" char=".">8.6</td><td class="colsep0 rowsep0" align="char" char=".">37</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>3</sub>N-morpholine</td><td class="colsep0 rowsep0" align="char" char=".">8.2</td><td class="colsep0 rowsep0" align="char" char=".">99</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">RSV assay in HeLa cells. Data generated from two or more determinations. All compounds demonstrated CC<sub>50</sub> values of >50 μM.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Human liver microsome turnover, expressed as the percentage of compound metabolized after 15 min incubation.</p></div></div></div><div class="NLM_p">The carboxylic acid moiety was clearly not tolerated on the side-chain and led to a dramatic loss of potency compared to the hydroxyl derivative (compare <b>30</b> and <b>19</b>). The simple amide derivative <b>31</b> also suffered from a very poor potency, whereas the basic hydroxyamidine analogue <b>32</b> led to a potency similar to <b>19</b>. The morpholine derivative <b>33</b> led to a pEC<sub>50</sub> of 8.2 but was found to be highly metabolically unstable, with 99% of the compound metabolized after 15 min in human liver microsomes (HLM). In an attempt to tackle the metabolic lability of the hydroxybutyl derivative <b>19</b>, we synthesized compound <b>26</b>, in which two methyl groups are positioned α to the hydroxyl moiety. This steric hindrance was well tolerated in terms of potency but did not improve metabolic stability in HLM. Replacing the hydroxyl group by a fluoro atom led to compound <b>28</b> with an improved potency below 1 nM, but a suboptimal metabolic stability (37% metabolized after 15 min in HLM). Finally compounds <b>20</b>, <b>27</b>, and <b>29</b>, possessing either a terminal methylsulfone, cyano, or trifluoromethyl group at the end of the propyl side-chain, all led to extremely potent inhibitors, with potencies below 250 pM. These three compounds also had acceptable metabolic stability in HLM. On the basis of its superior ADME profile, especially the intrinsic permeability and solubility, the cyano derivative <b>27</b> was chosen as a representative molecule to evaluate the PK properties of the indole series <i>in vivo</i> in rat (see <i>in vivo</i> PK section below).</div><div class="NLM_p">The transfer of SAR of the indole series to the 4-azabenzimidazole and 5-azaindole series led to the synthesis of derivatives <b>34</b>–<b>44</b> (see <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The following observations were made. First, in the 4-azabenzimidazole series, a decreased potency was observed compared to the indole-based series, even in the presence of the potency-enhancing 5-Cl substitution. pEC<sub>50</sub> values ranged from 8.0 for the cyano derivative <b>37</b> to 9.0 for the trifluorobutyl and isoamyl analogues <b>39</b> and <b>40</b>, respectively. Second, metabolic stability was improved and all derivatives of this 4-azabenzimidazole series, except <b>36</b>, showed minor turnover in HLM. Finally, a substantial permeability was measured for the most lipophilic derivatives <b>38</b>–<b>40</b>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Appending Side-Chain Optimization in the 4-Azabenzimidazole and 5-Azaindole Series</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/medium/jm0c00226_0009.gif" alt="" id="GRAPHIC-d7e1911-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">no.</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">series</th><th class="colsep0 rowsep0" align="center">pEC<sub>50</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">HLM<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a>(% metab)</th><th class="colsep0 rowsep0" align="center">Pab<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a> (×10<sup>–6</sup> cm/s)</th><th class="colsep0 rowsep0" align="center">clogP</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>4</sub>OH</td><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">8.3</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>3</sub>SO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">8.4</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">0.7</td><td class="colsep0 rowsep0" align="left">0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>3</sub>CMe<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">8.8</td><td class="colsep0 rowsep0" align="left">41</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>3</sub>CN</td><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">8.0</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>4</sub>F</td><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">8.7</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>3</sub>CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">9.0</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">9.0</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">3.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>4</sub>OH</td><td class="colsep0 rowsep0" align="left">B</td><td class="colsep0 rowsep0" align="left">8.8</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">3.7</td><td class="colsep0 rowsep0" align="left">1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>3</sub>SO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="left">B</td><td class="colsep0 rowsep0" align="left">9.0</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left"><1</td><td class="colsep0 rowsep0" align="left">0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>4</sub>F</td><td class="colsep0 rowsep0" align="left">B</td><td class="colsep0 rowsep0" align="left">9.3</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>3</sub>CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">B</td><td class="colsep0 rowsep0" align="left">9.6</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">3.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">(CH<sub>2</sub>)<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">B</td><td class="colsep0 rowsep0" align="left">9.6</td><td class="colsep0 rowsep0" align="left">44</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">3.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">RSV assay in HeLa cells. Data generated from two or more determinations. All compounds demonstrated CC<sub>50</sub> values of >50 μM.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Human liver microsome turnover, expressed as the percentage of compound metabolized after 15 min incubation.  ND: not determined.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Apparent permeability measured in LLC-PK1-MDR1 cell line, in the presence of the Pgp inhibitor GF120918. ND: not determined.</p></div></div></div><div class="NLM_p last">In the 5-azaindole series, combination with the more lipophilic side-chains proved to be beneficial for both permeability and potency, with compounds <b>42</b>–<b>44</b> achieving subnanomolar EC<sub>50</sub> values. The fluoro and trifluoro derivatives <b>42</b> and <b>43</b> also demonstrated acceptable metabolic stability in HLM. On the contrary, the more polar compounds <b>12</b> and <b>41</b> exhibited a slightly decreased potency and a low permeability.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> <i>In Vivo</i> PK Studies</h3><div class="NLM_p">For each series, a panel of analogues chosen based on their antiviral potency, acceptable <i>in vitro</i> human metabolic stability and solubility, as well as permeability, were evaluated <i>in vivo</i> in fed male Sprague-Dawley (SD) rats after iv and oral administration at 2 and 10 mg/kg, respectively. Concentrations in the lungs, the target organ, were also measured. <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> summarizes the PK parameters obtained for the best representative of each series.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. PK Parameters of Compounds <b>27</b>, <b>39</b>, and <b>43</b> after Single-Dose Administration in Sprague-Dawley (SD) Rat</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">iv<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">po<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">Cl (L h<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">Vd<sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC (ng·h/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th><th class="colsep0 rowsep0" align="center" char="."><i>L</i>/<i>P</i><a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="char" char=".">2.2</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">1230</td><td class="colsep0 rowsep0" align="char" char=".">3300</td><td class="colsep0 rowsep0" align="char" char=".">73</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">0.82</td><td class="colsep0 rowsep0" align="char" char=".">1690</td><td class="colsep0 rowsep0" align="char" char=".">3370</td><td class="colsep0 rowsep0" align="char" char=".">46</td><td class="colsep0 rowsep0" align="char" char=".">0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td><td class="colsep0 rowsep0" align="char" char=".">532</td><td class="colsep0 rowsep0" align="char" char=".">545</td><td class="colsep0 rowsep0" align="char" char=".">28</td><td class="colsep0 rowsep0" align="char" char=".">11</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Dose and vehicle: 2 mg/kg in 20% HP-β-CD.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Dose and vehicle: 10 mg/kg in 20% HP-β-CD.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Lung/plasma ratio calculated based on AUC<sub>0–last</sub>.</p></div></div></div><div class="NLM_p"><a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> illustrates the direct impact of the type of heterocycle on PK parameters. Indeed indole <b>27</b>, azabenzimidazole <b>39</b>, and azaindole <b>43</b> have a similar metabolic stability in RLM (around 80% of compound metabolized after 15 min) and a similar permeability. A major difference resides in their plasma protein binding properties, however, reflecting their differential lipophilicity, with the indole <b>27</b> being rather highly protein bound in the presence of human plasma (3.6% free fraction), whereas the azabenzimidazole <b>39</b> and azaindole <b>43</b> are much less protein bound (30% and 47.2% free fraction, respectively). Indole <b>27</b> demonstrated a promising PK profile, characterized by a moderate clearance after iv dosing (lower than predicted by rat liver microsome turnover), a high <i>C</i><sub>max</sub> and AUC after oral dosing leading to an absolute bioavailability of 73%, and a favorable distribution to the target organ (ratio lung/plasma of 1.6). Azabenzimidazole <b>39</b> also had an excellent plasma exposure (bioavailability (<i>F</i>) = 46%) associated with a moderate clearance after iv dosing. However, a low distribution to the lung was measured (ratio lung/plasma of 0.4). This latter property was found to be common to all compounds tested in this subseries, which could not be explained only by a lower lipophilicity or the nature of the side-chain. Azaindole <b>43</b> had a moderate exposure (absolute bioavailability (<i>F</i><sub>abs</sub>) of 28%) characterized by a high clearance (more than 100% of rat liver blood flow). However, the compound distributed very well to the lung, probably due to the presence of the basic center on the azaindole. Indeed, it is well-known that basic lipophilic compounds can be sequestered in the acidic lysosomes of the lungs, therefore considerably increasing lung concentration.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> However, this property may not necessarily be a desirable attribute, since it can lead to an overly long half-life due to tissue retention and lipodystrophy.<a onclick="showRef(event, 'ref25 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref25 ref38 ref39">(25,38,39)</a></div><div class="NLM_p last">On the basis of its overall better <i>in vivo</i> profile, the indole compound <b>27</b> was selected as lead molecule for further optimization of the substitution on the azabenzimidazolone bicycle.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Lead Optimization of the Indole Series</h3><div class="NLM_p">Keeping the 5-chloroindole ring fixed, the replacement of the cyclopropyl group in combination with either the cyanopropyl or the methylsulfone propyl side-chains was explored. A major goal was to avoid the potential for time-dependent inhibition (TDI) of cytochrome P450 3A4 (CYP3A4) that could be conferred by the presence of the cyclopropyl moiety.<a onclick="showRef(event, 'ref31 ref40'); return false;" href="javascript:void(0);" class="ref ref31 ref40">(31,40)</a> Indeed, SAR analysis of compounds from the different subseries having this fragment in common showed that TDI liability was attributable to this moiety. As a typical example, compound <b>20</b> demonstrated potential for TDI of CYP3A4-mediated metabolism of testosterone with an 18-fold difference of IC<sub>50</sub> measured in the shift assay.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div><div class="NLM_p">We hypothesized that reactive metabolites could be formed via the removal of the single H atom (C<sub>1</sub>–H) of the cyclopropyl moiety and/or via an oxidative metabolite on the pyridine ring and therefore evaluated three main strategies: (i) close (cyclo) alkyl-based analogues lacking this removable C<sub>1</sub>–H atom, (ii) a diversity exercise involving the replacement of the cyclopropyl by aryls and heterocycles, and (iii) introduction of small substituents on the pyridine ring in order to modulate steric hindrance and electronic properties.</div><div class="NLM_p">Analogues of the lead molecule <b>20</b> having an alkyl moiety in place of the cyclopropyl group are depicted in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Variation of the Cyclopropyl Moiety</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/medium/jm0c00226_0010.gif" alt="" id="GRAPHIC-d7e2675-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/medium/jm0c00226_0011.gif" alt="" id="gr6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">RSV assay in HeLa cells. All compounds demonstrated CC<sub>50</sub> values of >50 μM.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Human liver microsome turnover, expressed as the percentage of compound metabolized after 15 min incubation.</p></div></div><div></div></div><div class="NLM_p">Analogue <b>45</b>, lacking any substitution on the azabenzimidazolone moiety, illustrates the importance of this group to retain potency, since a loss in potency of 1.6 log<sub>10</sub> was observed compared to the cyclopropyl lead compound <b>20</b>. Notably, this compound did not exhibit any TDI of CYP3A4. Next, analogues <b>46</b>–<b>49</b> were synthesized with the goal to obtain TDI-free inhibitors while retaining good potency and trying to improve the metabolic stability of compound <b>20</b>. Replacing a cyclopropyl by its isopropyl analogue is a known strategy to decrease the risk of TDI.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> In our case, the isopropyl derivative <b>46</b> led to almost 1 log<sub>10</sub> drop in potency while eliciting no potential for TDI. However, a strong decrease in metabolic stability was observed. Similar findings were made with the <i>tert</i>-butyl derivative <b>48</b> and oxetane analogue <b>50</b>. Replacing the C<sub>1</sub>–H hydrogen by a methyl (compound <b>47</b>) or introducing a methylene spacer between the bicycle and cyclopropyl moieties (compound <b>49</b>) was well tolerated in terms of potency but led to compounds characterized by higher turnovers in HLM, although devoid of TDI. Azetidine analogue <b>51</b> was not tolerated in terms of potency (pEC<sub>50</sub> = 7.5), but this could be partially reversed by substituting the azetidine nitrogen like in the sulfonamide analogue <b>52</b>. Replacing one of the methyl groups of isopropyl derivative <b>46</b> with a CF<sub>3</sub> led to a very metabolically stable compound, although to some detriment of potency (compound <b>54</b>, pEC<sub>50</sub> = 8.3). Finally, the simple trifluoroethyl derivative <b>53</b> was found to combine both excellent potency (pEC<sub>50</sub> = 9.3) and metabolic stability (only 1% metabolized after 15 min in HLM), whereas the cyano analogue <b>55</b> displayed a loss of potency and metabolic stability. Of note, analogue <b>53</b> did not exhibit any TDI of CYP3A4. When combined with other appending chains, the resulting trifluoroethyl analogues displayed a potency similar to <b>53</b> but higher turnovers in HLM (not shown). As a result, inhibitor <b>53</b> was selected as the most optimal compound from this exercise and was further characterized (see <i>in vivo</i> efficacy section).</div><div class="NLM_p">In a second strategy, we studied the replacement of the cyclopropyl moiety by substituted aryls and heteroaryls (see compounds <b>56</b>–<b>71</b> in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Anticipating that aqueous solubility could become insufficient with this more lipophilic subseries, the cyanopropyl moiety was used instead of the methylsulfone propyl appending chain.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. SAR in the Top Aryl and Heteroaryl Subseries</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/medium/jm0c00226_0012.gif" alt="" id="GRAPHIC-d7e2801-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/medium/jm0c00226_0013.gif" alt="" id="gr7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">RSV assay in HeLa cells. All compounds demonstrated CC<sub>50</sub> values of >50 μM.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">Human liver microsome turnover, expressed as the percentage of compound metabolized after 15 min incubation.</p></div></div><div></div></div><div class="NLM_p">Compared to the initial cyclopropyl derivative <b>27</b>, inhibitors with similar or even superior potency together with similar metabolic stability could be obtained (see compounds <b>59</b>, <b>61</b>, <b>63</b>, and <b>64</b>). The nature of the phenyl substitution was found to have a substantial impact on potency; the least-tolerated substituents were the methyl and trifluoromethoxy on the 4 position of the phenyl (<b>56</b> and <b>60</b>, respectively; both pEC<sub>50</sub> = 8.9). The acid analogue <b>57</b> and the amide derivative <b>58</b> exhibited a slightly lower potency compared to the cyclopropyl analogue <b>27</b> (pEC<sub>50</sub> of 9.3 versus 9.7 for <b>57</b> and <b>58</b> versus <b>27</b>, respectively). Compound <b>59</b>, whose phenyl ring is substituted with a methylsulfonyl moiety in para position, was as potent as <b>27</b>, with a metabolic stability in HLM, however suffering from a very low aqueous solubility. The potency of the 4-OMe derivative <b>61</b> was found to be equal to <b>27</b> and could further be modulated by the introduction of a second substituent, preferably on the position 3 of the phenyl, with the 3,4-dimethoxyphenyl derivative <b>64</b> being the most potent analogue of this subseries (pEC<sub>50</sub> = 10), while the presence of a 2-fluoro or 2-methyl decreased potency (see <b>62</b> and <b>65</b>, respectively).</div><div class="NLM_p">Encouraged by the potency of the phenyl derivatives and in order to maximize solubility, attention was then turned to the synthesis of the heterocyclic derivatives <b>66</b>–<b>71</b>, with an emphasis on nitrogen-containing heterocycles. In this subseries, and contrary to the phenyl subseries described above, a small substitution at the position 2 of the heterocycle conferred a much-improved potency (compare <b>70</b> and <b>71</b>). However, the most potent compound of this subseries <b>71</b> exhibited a suboptimal metabolic stability. Disappointingly, all the other heterocycles tested, <b>66</b>–<b>70</b>, demonstrated much lower potency compared to the cyclopropyl reference compound <b>27</b>, as well as a higher turnover in HLM.</div><div class="NLM_p last">Finally, the third strategy, based on the introduction of small substituents on the pyridine ring in order to modulate steric hindrance and electronic properties, was not successful, resulting in much less potent inhibitors (i.e., a chloro or methyl in meta position to the pyridine nitrogen; data not shown).</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Crystallography</h3><div class="NLM_p">The biological profile including selectivity over other RNA viruses as well as the cocrystal structure of compound <b>53</b> bound to prefusion RSV F has been previously reported.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> It was shown that the inhibitor binds within the central cavity along the 3-fold trimeric axis occupying two of the three equivalent lobes of the binding pocket (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The binding mode involves (i) π–π stacking between Phe488 and Phe140 and the two aromatic bicycles of the inhibitor, (ii) C–H (indole)/π and C–H (azabenzimidazolone)/π interactions with Phe140, (iii) halogen bond with backbone carbonyl oxygen of Thr397, and (iv) water-mediated hydrogen bond between one oxygen of the sulfone moiety and side-chain of Arg339. In addition, the trifluoroethyl group optimally fits into a hydrophobic clamp formed by Phe140, Phe488, and Phe137.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/medium/jm0c00226_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cocrystal structure of JNJ-53718678 bound to prefusion RSV F (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KWW">5KWW</a>): (a) view of the central cavity looking down toward the viral membrane; (b) side view of the central cavity view parallel to the viral membrane. The three RSV F protomers are colored green, pink, and tan. Water molecules are represented as red spheres. JNJ-53718678 (compound <b>53</b>) is shown in ball-and-stick representation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00226&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">New cocrystal structures of compounds <b>39</b>, <b>41</b>, and <b>64</b> bound to prefusion RSV F revealed an essentially similar binding mode but also new features. As previously described, the chloro atom of compounds <b>39</b> and <b>64</b> is engaged in a halogen bond interaction with the backbone carbonyl of Thr397 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>c). This interaction also explains the increase in potency from a fluoro to a chloro or bromo (10-fold potency increase).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(42)</a> On the other hand, the N atom located at the 5 position of azaindole derivative <b>41</b> is too remote from the backbone carbonyl of Thr397 (distance is 4.7 Å) to form a hydrogen bond after protonation. This nitrogen has a measured p<i>K</i><sub>a</sub> value of 7.4 indicating that at physiological pH about 50% of the compound is in its protonated form. This may enhance compound binding by engaging in an electrostatic interaction with Asp489 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>b). The small alkyl chains with CF<sub>3</sub> (compound <b>39</b>), sulfone (compound <b>41</b>), or cyano (compound <b>64</b>) substitutions are pointing toward solvated regions and are probably replacing water molecules with unfavorable binding energies because of the hydrophobic nature of the binding pocket. Furthermore, the top cyclopropyl moieties of compounds <b>39</b> and <b>41</b> display a very similar binding mode compared to the trifluoroethyl group of compound <b>53</b>. For compound <b>64</b>, the bigger 3,4-dimethoxyphenyl substituent results in the strengthening of the interaction with the aromatic side chains of Phe137 and Phe140 and explains the superior antiviral potency of compound <b>64</b>. It also explains why a large diversity of moieties is tolerated in this part of the molecule.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/medium/jm0c00226_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cocrystal structure of compounds <b>39</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VKC">6VKC</a>), <b>41</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VKD">6VKD</a>), and <b>64</b> (code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VKE">6VKE</a>) bound to prefusion RSV F, showing side view of the central cavity, view parallel to the viral membrane. The three RSV F protomers are colored green, pink, and tan. Compounds are shown in ball-and-stick representation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00226&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> <i>In Vivo</i> PK and Efficacy Studies Leading to the Selection of JNJ-53718678</h3><div class="NLM_p">In order to differentiate the best compounds selected after the different optimization phases, the PK profiles of compounds <b>53</b>, <b>61</b>, and <b>64</b> were assessed after iv and oral dosing in fed male SD rat and dog. The resulting PK parameters are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. PK Parameters after Single Administration of Compounds <b>53</b>, <b>61</b>, and <b>64</b> in Rat and Dog</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">rat<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">dog<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R/D/HLM<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a> (% met)</th><th class="colsep0 rowsep0" align="center" char=".">Cl<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a> (L h<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char="."><i>L</i>/<i>P</i><a class="ref internalNav" href="#t8fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)<a class="ref internalNav" href="#t8fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center" char=".">Cl<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a> (L h<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)<a class="ref internalNav" href="#t8fn6" aria-label="f">f</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left">62/28/1</td><td class="colsep0 rowsep0" align="char" char=".">3.9</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="char" char=".">42</td><td class="colsep0 rowsep0" align="char" char=".">0.51</td><td class="colsep0 rowsep0" align="char" char=".">89</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>61</b></td><td class="colsep0 rowsep0" align="left">40/96/20</td><td class="colsep0 rowsep0" align="char" char=".">0.97</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">86</td><td class="colsep0 rowsep0" align="char" char=".">1.49</td><td class="colsep0 rowsep0" align="char" char=".">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64</b></td><td class="colsep0 rowsep0" align="left">74/56/19</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">0.86</td><td class="colsep0 rowsep0" align="char" char=".">26</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">Rat/dog/human liver microsome turnover, expressed as the percentage of compound metabolized after 15 min incubation.</p></div><div class="footnote" id="t8fn2"><sup><sup>b</sup></sup><p class="last">Dose and vehicle: iv, 2.5 mg/kg in PEG400/saline 7/3; po, 10 mg/kg in PEG400–HCl.</p></div><div class="footnote" id="t8fn3"><sup><sup>c</sup></sup><p class="last">Dose and vehicle: iv, 1 mg/kg in HP-β-CD 20%; po, 5 mg/kg in PEG400.</p></div><div class="footnote" id="t8fn4"><sup><sup>d</sup></sup><p class="last">Plasma clearance after iv dosing.</p></div><div class="footnote" id="t8fn5"><sup><sup>e</sup></sup><p class="last">Lung/plasma ratio calculated based on AUC<sub>0–last</sub>.</p></div><div class="footnote" id="t8fn6"><sup><sup>f</sup></sup><p class="last">Oral bioavailability.</p></div></div></div><div class="NLM_p">In dog, plasma clearance after iv dosing correlated well with the measured <i>in vitro</i> metabolic stability in dog liver microsomes. Compound <b>53</b> was the most stable and exhibited a moderate plasma clearance and an excellent bioavailability of 89% after oral dosing. The 2-substituted aryl analogues <b>61</b> and <b>64</b> displayed a higher clearance, 90% and 50% of the dog liver blood flow, respectively, in agreement with their higher turnover in dog liver microsomes. Their bioavailability was consequently also reduced 9% and 26%, respectively. In rat, <i>in vivo</i> clearance was found to be lower than expected based on rat microsomal stability for compounds <b>61</b> and <b>64</b>. The lowest clearance was obtained with analogue <b>61</b>, which displayed an excellent bioavailability of 86%. For analogue <b>53</b>, despite a rather high clearance, a moderate bioavailability of 42% was obtained. In addition, this compound also exhibited the highest distribution to the lung with a lung/plasma ratio of 3.5.</div><div class="NLM_p">Those three compounds were further evaluated in an efficacy study in cotton-rats. In this well-established semipermissive model of RSV infection, animals were infected with an intranasal dose of 10<sup>5</sup> plaque forming units (PFU) Long strain RSV, establishing infection of their lower respiratory tract.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(43)</a> The inhibitor was administered prophylactically 1 h prior to the infection at different single oral doses (1, 4, 10, 40, or 100 mg/kg). Four days after viral challenge (at peak viral replication), the RSV viral titer was determined in the broncho alveolar lavage fluid (BALF) and in the lavaged-lung tissue of the animals by plaque assay. On the basis of these results, a pharmacokinetic/pharmacodynamic (PK/PD) model according to maximum effect (<i>E</i><sub>max</sub>)-fitting was built to estimate the <i>in vivo</i> EC<sub>50</sub>, based on compound exposure measured in plasma at the time of challenge. Results of this PK/PD model are presented in <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. <i>In Vivo</i> Efficacy of Compounds <b>53</b>, <b>61</b>, and <b>64</b> in the Cotton-Rat Model</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> (ng/mL), BALF</th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> (ng/mL), lavaged lung</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="char" char=".">75</td><td class="colsep0 rowsep0" align="char" char=".">81</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>61</b></td><td class="colsep0 rowsep0" align="char" char=".">499</td><td class="colsep0 rowsep0" align="char" char=".">121</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64</b></td><td class="colsep0 rowsep0" align="char" char=".">180</td><td class="colsep0 rowsep0" align="char" char=".">157</td></tr></tbody></table></div></div><div class="NLM_p">A dose-dependent reduction of the viral titers in BALF and lavaged-lung was observed for the three compounds, as well as a decrease of viral RNA production in the lungs. Despite their higher <i>in vitro</i> potency, the 2 aryl derivatives <b>61</b> and <b>64</b> were found to be less efficacious <i>in vivo</i> compared to compound <b>53</b>. This latter inhibitor exhibited a more pronounced effect <i>in vivo</i> with comparable EC<sub>50</sub> values for BALF and lavaged lung (75 ng/mL and 81 ng/mL, respectively). We speculate that this higher efficacy may result from a combination of more favorable parameters such as ADME properties (especially lung distribution) and free fraction (6%, 0.5%, and 0.8% free fraction in human plasma measured for <b>53</b>, <b>61</b>, and <b>64</b>, respectively), although more experiments would be required to extrapolate on the parameters conferring superior efficacy.</div><div class="NLM_p">The <i>in vivo</i> efficacy of <b>53</b> was further evaluated in the neonatal lamb model which is a fully replicative RSV infection model displaying very similar disease symptoms as observed in infants.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> Our experiments demonstrated that once-daily oral administration of JNJ-53718678 completely eliminated an established lower respiratory tract infection in these animals, along with a suppression of virus-induced lung inflammation.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><div class="NLM_p last">On the basis of its superior <i>in vivo</i> efficacy, its exposure in preclinical species supporting a low predicted efficacious QD dose in patients, as well as its favorable safety profile and low potential for drug–drug interaction, compound <b>53</b> (JNJ-53718678) was selected as the clinical candidate. Currently it is being evaluated in phase II studies in both infants and adults. Recently, data from a randomized phase 1b study evaluating the pharmacokinetics, safety, and antiviral effects of <b>53</b> in hospitalized infants were reported.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75576" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75576" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compounds <b>5</b>–<b>71</b> were synthesized following the general pathway shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. In general, a Mitsunobu reaction between the different bicycles <b>I</b> and azabenzimidazolones <b>II</b> afforded intermediates <b>IIIa</b>–<b>e</b> and final compounds <b>6</b>, <b>8</b>–<b>10</b>, <b>13</b>–<b>16</b>, <b>18</b>, <b>20</b>, <b>22</b>, <b>24</b>, <b>27</b>–<b>29</b>, <b>33</b>, <b>35</b>, <b>37</b>–<b>44</b>, <b>46</b>–<b>50</b>, <b>53</b>, <b>54</b>, <b>56</b>, and <b>59</b>–7<b>1</b>.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> While straightforward and generally high yielding, this coupling method also yielded limited (typically less than 10%) amounts of the undesired O-alkylated side-product <b>IV</b>.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> When the appending side-chain also contained an alcohol moiety, its protection as a benzyl ether like in <b>IIIa</b> or silyl ether like in <b>IIIb</b> was necessary to perform the Mitsunobu reaction. Protecting group removal then afforded final compounds <b>5</b>, <b>7</b>, <b>11</b>, <b>12</b>, <b>17</b>, <b>19</b>, <b>21</b>, <b>23</b>, <b>25</b>, <b>26</b>, <b>34</b>, <b>36</b>. Compounds <b>30</b>–<b>32</b> were obtained from the cyano precursor <b>27</b> using the conditions depicted in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The nonsubstituted azabenzimidazolone derivative <b>45</b> was obtained after acidic treatment of the isopropylidene precursor <b>IIIc</b>. Further reaction of <b>45</b> with chloroacetonitrile in the presence of cesium carbonate in DMF gave compound <b>55</b>. Compound <b>51</b> was obtained after TFA treatment of the Boc-azetidin-3-yl precursor <b>IIId</b> and was further reacted with mesyl chloride to give compound <b>52</b>. Carboxylic acid <b>57</b> was obtained from the methyl ester precursor <b>IIIe</b> after treatment with LiOH. Reaction of <b>57</b> with cyclopropylamine and diethyl cyanophosphonate as coupling agent gave amide <b>58</b>. Synthesis of intermediates <b>I</b> and <b>II</b> is described in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00226/suppl_file/jm0c00226_si_002.pdf" class="ext-link">Supporting Information</a>.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/medium/jm0c00226_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Pathway for the Synthesis of Final Compounds <b>5</b>–<b>71</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00226&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (i) <b>I</b>, <b>II</b>, DIAD, Ph<sub>3</sub>P, DMF, or THF, 12–97% yield. (ii) (a) For <b>30</b>: <b>27</b>, KOH, <sup><i>i</i></sup>PrOH, H<sub>2</sub>O, 120 °C, 1 h, 96% yield. (b) For <b>31</b>: <b>27</b>, NH<sub>2</sub>OH, Et<sub>3</sub>N, EtOH, 80 °C, 16 h, 15% yield. (c) For <b>32</b>: <b>27</b>, NH<sub>2</sub>OH, K<sub>2</sub>CO<sub>3</sub>, EtOH, H<sub>2</sub>O, 80 °C. (iii) <b>IIIa</b>, H<sub>2</sub>, Pd/C, CH<sub>3</sub>COOK, MeOH, 50 °C, 32–36% yield. (iv) <b>IIIb</b>, ammonium fluoride, MeOH, 60 °C, 32–95% yield. (v) <b>IIIc</b>, HCl 6 M in <sup><i>i</i></sup>PrOH, H<sub>2</sub>0, 70% yield. (vi) <b>45</b>, ClCH<sub>2</sub>CN, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 62% yield. (vii) <b>IIId</b>, TFA, DCM, 77% yield. (viii) <b>51</b>, ClSO<sub>2</sub>Me, Et<sub>3</sub>N, DCM, 32% yield. (ix) <b>IIIe</b>, LiOH, H<sub>2</sub>O/THF 1/3, 48% yield. (x) <b>57</b>, cyclopropylamine, Et<sub>2</sub>CNPO<sub>3</sub>, Et<sub>3</sub>N, DMF, 68% yield.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57463" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57463" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A medicinal chemistry optimization program based on a formerly disclosed suboptimal benzimidazole series led to novel RSV fusion inhibitors exhibiting greatly improved potencies, as well as superior PK properties after oral dosing. The indole subseries was chosen as lead series for further optimization essentially based on its superior <i>in vivo</i> PK properties and higher distribution to the lung, the target organ. In this context, the presence of a more polar appending chain from the indole moiety proved to be crucial to counterbalance the higher intrinsic lipophilicity of the indole core. Replacement of the cyclopropyl group on the azabenzimidazolone successfully led to analogues devoid of TDI of CYP3A4. Several derivatives exhibited desired antiviral potency and PK profiles in rats and dogs and demonstrated good <i>in vivo</i> efficacy in the cotton rat model. New X-ray cocrystal structures obtained with compounds <b>39</b>, <b>41</b>, and <b>64</b> bound to prefusion RSV F could rationalize the observed SAR. This lead optimization effort culminated in the discovery of compound <b>53</b> (JNJ-53718678), a subnanomolar indole-based inhibitor, with a preliminary PK profile supporting a low predicted efficacious QD oral dose in patients, as well as a favorable safety profile and low potential for drug–drug interaction.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20461" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20461" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Animal care and experiments were performed according to the applicable European Communities Council Directive of November 24, 1986 (86/609/EEC).</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Chemistry. Analytical Methods</h3><div class="NLM_p last">Reagents and solvents were obtained from commercial sources and used as received unless stated otherwise. All final compounds were characterized by <sup>1</sup>H NMR and HRMS. <sup>1</sup>H nuclear magnetic resonance spectra were recorded on a Bruker spectrometer operating at 300 MHz, 360 MHz, and DPX-400 MHz. The purity of all final compounds was ≥95% by LCMS. Chemical shifts are reported in parts per million (δ) units and coupling constants in Hz. Solvents used for the NMR experiments are reported per compound. Details of the various HPLC–MS methods used are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00226/suppl_file/jm0c00226_si_002.pdf" class="ext-link">Supporting Information</a>. Given the large number of final compounds reported in the manuscript, only the characterization data of compounds <b>39</b>, <b>41</b>, <b>53</b>, and <b>64</b> is reported below. Details for the other compounds can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00226/suppl_file/jm0c00226_si_002.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 3-((5-Chloro-1-(4,4,4-trifluorobutyl)-1<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2-yl)methyl)-1-cyclopropyl-1,3-dihydro-2<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-one (<b>39</b>)</h3><div class="NLM_p last">To a stirred solution of (5-chloro-1-(4,4,4-trifluorobutyl)-1<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2-yl)methanol (1.2 g, 4.08 mmol), triphenylphosphine (1.18 g, 4.5 mmol), 1-cyclopropyl-1,3-dihydro-2<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-one (787 mg, 4.5 mmol) in dry THF (100 mL) was added DIAD (1 mL, 4.9 mmol) dropwise at room temperature. The reaction mixture was stirred at room temperature overnight. After completion of the reaction, the mixture was concentrated to dryness and the residue was purified by prep HPLC on a RP Vydac Denali C18, 10 μm column, 250 g, 5 cm, eluting with a mobile phase of 0.25% NH<sub>4</sub>HCO<sub>3</sub> solution in water, MeOH to yield the target compound (1.5 g, 81% yield) as white solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ ppm 1.00 (s, 2 H), 1.12–1.23 (m, 2 H), 1.83–1.99 (m, 2 H), 2.12–2.31 (m, 2 H), 2.91 (spt, <i>J</i> = 3.50 Hz, 1 H), 4.38–4.54 (m, 2 H), 5.38 (s, 2 H), 7.13 (dd, <i>J</i> = 5.27, 0.50 Hz, 1 H), 7.27 (d, <i>J</i> = 8.28 Hz, 1 H), 7.61 (d, <i>J</i> = 8.53 Hz, 1 H), 8.36 (d, <i>J</i> = 5.27 Hz, 1 H), 8.77 (s, 1 H). HPLC method J, Rt = 0.86, purity 99%, <i>m</i>/<i>z</i> = 451 (M + H)<sup>+</sup>.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 1-Cyclopropyl-3-((1-(3-(methylsulfonyl)propyl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-2-yl)methyl)-1,3-dihydro-2<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-one (<b>41</b>)</h3><div class="NLM_p last">A solution of (3-bromo-1-(3-(methylsulfonyl)propyl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-2-yl)methanol (200 mg, 0.57 mmol) and 1-cyclopropyl-3<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-one (101 mg, 0.57 mmol) in THF (10 mL) was stirred at room temperature. Triphenylphosphine (151 mg, 0.57 mmol) was added followed with DIAD (113 μL, 0.57 mmol) dropwise under a nitrogen atmosphere. The resulting mixture was stirred overnight. The mixture was evaporated and diluted with diisopropyl ether. The precipitate was collected by filtration (83 mg, 27% yield). This was dissolved in methanol (15 mL) and stirred in the presence of a catalytic amount of palladium on carbon under hydrogen atmosphere to get the title compound after column chromatography using dichloromethane and methanol 9/1 as eluent (26.6 mg, 40% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.90–0.97 (m, 2 H), 1.03–1.11 (m, 2 H), 1.97 (m, <i>J</i> = 15.06, 7.78, 7.78 Hz, 2 H), 2.94–3.05 (m, 4 H), 3.16 (t, <i>J</i> = 8.00 Hz, 2 H), 4.43 (t, <i>J</i> = 7.65 Hz, 2 H), 5.36 (s, 2 H), 6.73 (s, 1 H), 7.29 (d, <i>J</i> = 5.27 Hz, 1 H), 7.62 (d, <i>J</i> = 5.52 Hz, 1 H), 8.25 (d, <i>J</i> = 5.27 Hz, 1 H), 8.26 (d, <i>J</i> = 6.02 Hz, 1 H), 8.42 (s, 1 H), 8.83 (s, 1 H). HPLC method A, Rt = 1.15, purity 96%, <i>m</i>/<i>z</i> = 426 (M + H)<sup>+</sup>.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 3-((5-Chloro-1-(3-(methylsulfonyl)propyl)-1<i>H</i>-indol-2-yl)methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-one (<b>53</b>)</h3><div class="NLM_p last">To a stirred solution of (5-chloro-1-(3-(methylsulfonyl)propyl)-1<i>H</i>-indol-2-yl)methanol (40 g, 132.5 mmol), 1-(2,2,2-trifluoroethyl)-1,3-dihydro-2<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-one (28.8 g, 132.5 mmol), and tributylphosphine (49.7 mL, 199 mmol) in dry THF (400 mL) was added DIAD (38.7 mL, 199 mmol) dropwise at room temperature. The resulting mixture was stirred at room temperature for 1 h. The mixture was concentrated to dryness, and the residue was crystallized in ethanol/acetonitrile mixture (10/1) (1200 mL) and stirred overnight. The white crystals were collected by filtration (36.5 g, 55% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.88–2.02 (m, 2 H), 2.97 (s, 3 H), 3.15 (t, <i>J</i> = 8.00 Hz, 2 H), 4.38 (t, <i>J</i> = 7.50 Hz, 2 H), 4.89 (q, <i>J</i> = 9.00 Hz, 2 H), 5.40 (s, 2 H), 6.48 (s, 1 H), 7.17 (dd, <i>J</i> = 8.78, 2.01 Hz, 1 H), 7.44 (d, <i>J</i> = 5.27 Hz, 1 H), 7.54 (d, <i>J</i> = 8.78 Hz, 1 H), 7.57 (d, <i>J</i> = 2.01 Hz, 1 H), 8.31 (d, <i>J</i> = 5.27 Hz, 1 H), 8.49 (s, 1 H). HPLC method D, Rt = 1.68, purity 100%, <i>m</i>/<i>z</i> = 501 (M + H)<sup>+</sup>.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 4-(5-Chloro-2-((1-(3,4-dimethoxyphenyl)-2-oxo-1,2-dihydro-3<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-3-yl)methyl)-1<i>H</i>-indol-1-yl)butanenitrile (<b>64</b>)</h3><div class="NLM_p last">To a stirred solution of 4-(5-chloro-2-(hydroxymethyl)-1<i>H</i>-indol-1-yl)butanenitrile (3.34 g, 13.43 mmol), 1-(3,4-dimethoxyphenyl)-1,3-dihydro-2<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-one (3.31 g, 12.21 mmol), and tributylphosphine (4.6 mL, 18.32 mmol) in dry THF (300 mL) was added DIAD (3.56 mL, 18.32 mmol) dropwise at room temperature. The resulting mixture was stirred at room temperature overnight. The mixture was concentrated to dryness, and the residue was triturated in DIPE. The formed solid was filtered and then crystallized in ethanol. The white crystals were collected by filtration (3.89 g, 63% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.94 (quin, <i>J</i> = 7.48 Hz, 2 H), 2.52–2.58 (m, 2 H), 3.79 (s, 3 H), 3.84 (s, 3 H), 4.32–4.40 (m, 2 H), 5.42 (s, 2 H), 6.56 (s, 1 H), 7.05–7.20 (m, 5 H), 7.55 (d, <i>J</i> = 8.80 Hz, 1 H), 7.57 (d, <i>J</i> = 1.98 Hz, 1 H), 8.23 (d, <i>J</i> = 5.28 Hz, 1 H), 8.51 (s, 1 H). HPLC method J, Rt = 1.03 min, purity 100%, <i>m</i>/<i>z</i> = 502 (M + H)<sup>+</sup>.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> RSV Assay</h3><div class="NLM_p last">Antiviral activity of the compounds against rgRSV224 was determined using a phenotypic cell-based infection assay with fluorescence readout.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Briefly, black 384-well clear-bottom microtiter plates were filled in quadruplicate using a customized robot system with serial 4-fold dilutions of compound in a final volume of 200 nL DMSO. Then, 20 μL of a HeLa cell suspension (5 × 10<sup>4</sup> cells mL<sup>–1</sup>) in culture medium was added to each well followed by the addition of 20 μL of RSV (MOI = 0.02) in culture medium, or 20 μL culture medium for cell controls, using a multidrop dispenser. Three days after virus exposure, viral replication was quantified by measuring eGFP expression in the cells with a laser microscope. In parallel, compounds were incubated for 3 days in a set of white 384-well microtiter plates and the cytotoxicity of compounds in HeLa cells (CC<sub>50</sub>) was determined by measuring the adenosine triphosphate (ATP) content of the cells using the ATPlite kit (PerkinElmer, Waltham, MA) according to the manufacturer’s instructions.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00226" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76016" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76016" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00226?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00226</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00226/suppl_file/jm0c00226_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline"><sup>1</sup>H NMR data, HPLC–MS details, purity determination of all final compounds <b>4</b>–<b>74</b> (except <b>39</b>, <b>41</b>, <b>53</b>, and <b>64</b>); protein crystallization and structure determination protocols; <i>in vivo</i> efficacy results; dose–response data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00226/suppl_file/jm0c00226_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00226/suppl_file/jm0c00226_si_001.csv">jm0c00226_si_001.csv (4.01 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00226/suppl_file/jm0c00226_si_002.pdf">jm0c00226_si_002.pdf (361.95 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Compound <b>39</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VKC">6VKC</a>. Compound <b>41</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VKD">6VKD</a>. Compound <b>64</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VKE">6VKE</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c00226" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35814" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35814" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tim H. M. Jonckers</span> - <span class="hlFld-Affiliation affiliation">Janssen Pharmaceutica
NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3974-822X" title="Orcid link">http://orcid.org/0000-0003-3974-822X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#cbbfa1a4a5a8a0aeb98ba2bfb8e5a1a5a1e5a8a4a6"><span class="__cf_email__" data-cfemail="5d293732333e36382f1d34292e73373337733e3230">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandrine Vendeville</span> - <span class="hlFld-Affiliation affiliation">Janssen Pharmaceutica
NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</span>; 
    <span>Present Address:
                        S.V.: Aligos Belgium BVBA, Gaston Geenslaan 1, bus (gebouw 3), 3001 Heverlee, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Abdellah Tahri</span> - <span class="hlFld-Affiliation affiliation">Janssen Pharmaceutica
NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lili Hu</span> - <span class="hlFld-Affiliation affiliation">Janssen Pharmaceutica
NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Samuel Demin</span> - <span class="hlFld-Affiliation affiliation">Janssen Pharmaceutica
NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ludwig Cooymans</span> - <span class="hlFld-Affiliation affiliation">Janssen Pharmaceutica
NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ann Vos</span> - <span class="hlFld-Affiliation affiliation">Janssen Pharmaceutica
NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leen Kwanten</span> - <span class="hlFld-Affiliation affiliation">Janssen Pharmaceutica
NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joke Van den Berg</span> - <span class="hlFld-Affiliation affiliation">Janssen Pharmaceutica
NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael B. Battles</span> - <span class="hlFld-Affiliation affiliation">Department of Biochemistry and Cell Biology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire 03755, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason S. McLellan</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Biosciences, The University
of Texas at Austin, Austin, Texas 78712, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anil Koul</span> - <span class="hlFld-Affiliation affiliation">Janssen Pharmaceutica
NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pierre Raboisson</span> - <span class="hlFld-Affiliation affiliation">Janssen Pharmaceutica
NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</span>; 
    <span>Present Address:
                        S.V.: Aligos Belgium BVBA, Gaston Geenslaan 1, bus (gebouw 3), 3001 Heverlee, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dirk Roymans</span> - <span class="hlFld-Affiliation affiliation">Janssen Pharmaceutica
NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47702" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47702" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Nigel Austin, Miek Desmidt, Brigitte Loenders, Filip Vanhoutte, and Kenny Simmen for their support in the pharmaceutical profiling of the RSV fusion inhibitors. Results shown in this report are derived from work performed at Argonne National Laboratory, Structural Biology Center at the Advanced Photon Source. SBC is operated by the U.S. Department of Energy, Office of Biological and Environmental Research under Contract DE-AC02-06CH11357.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">RSV</td><td class="NLM_def"><p class="first last">respiratory syncytial virus</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, elimination</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">RNA</td><td class="NLM_def"><p class="first last">ribonucleic acid</p></td></tr><tr><td class="NLM_term">LRTI</td><td class="NLM_def"><p class="first last">lower respiratory tract infection</p></td></tr><tr><td class="NLM_term">SI</td><td class="NLM_def"><p class="first last">selectivity index</p></td></tr><tr><td class="NLM_term">TDI</td><td class="NLM_def"><p class="first last">time-dependent inhibition</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">Sprague-Dawley</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under curve</p></td></tr><tr><td class="NLM_term">PFU</td><td class="NLM_def"><p class="first last">plaque forming units</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamic</p></td></tr><tr><td class="NLM_term">BALF</td><td class="NLM_def"><p class="first last">Broncho alveolar lavage fluid</p></td></tr><tr><td class="NLM_term">LiOH</td><td class="NLM_def"><p class="first last">lithium hydroxide</p></td></tr><tr><td class="NLM_term">DIAD</td><td class="NLM_def"><p class="first last">diisopropyl (<i>E</i>)-diazene-1 2-dicarboxylate</p></td></tr><tr><td class="NLM_term">DIPE</td><td class="NLM_def"><p class="first last">diisopropyl ether</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21847" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21847" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 48 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nair, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nokes, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessner, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dherani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhi, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theodoratou, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutanto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedyaningsih, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munywoki, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kartasasmita, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simões, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, H.</span></span> <span> </span><span class="NLM_article-title">Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>375</i></span> (<span class="NLM_issue">9725</span>),  <span class="NLM_fpage">1545</span>– <span class="NLM_lpage">1555</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(10)60206-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1016%2FS0140-6736%2810%2960206-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=20399493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A280%3ADC%252BC3czgtlaqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2010&pages=1545-1555&issue=9725&author=H.+Nairauthor=J.+D.+Nokesauthor=B.+D.+Gessnerauthor=M.+Dheraniauthor=S.+A.+Madhiauthor=R.+J.+Singletonauthor=K.+L.+O%E2%80%99Brienauthor=A.+Rocaauthor=P.+F.+Wrightauthor=N.+Bruceauthor=A.+Chandranauthor=E.+Theodoratouauthor=A.+Sutantoauthor=E.+R.+Sedyaningsihauthor=M.+Ngamaauthor=P.+K.+Munywokiauthor=C.+Kartasasmitaauthor=E.+A.+Sim%C3%B5esauthor=I.+Rudanauthor=M.+W.+Weberauthor=H.+Campbell&title=Global+burden+of+acute+lower+respiratory+infections+due+to+respiratory+syncytial+virus+in+young+children%3A+a+systematic+review+and+meta-analysis&doi=10.1016%2FS0140-6736%2810%2960206-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis</span></div><div class="casAuthors">Nair Harish; Nokes D James; Gessner Bradford D; Dherani Mukesh; Madhi Shabir A; Singleton Rosalyn J; O'Brien Katherine L; Roca Anna; Wright Peter F; Bruce Nigel; Chandran Aruna; Theodoratou Evropi; Sutanto Agustinus; Sedyaningsih Endang R; Ngama Mwanajuma; Munywoki Patrick K; Kartasasmita Cissy; Simoes Eric A F; Rudan Igor; Weber Martin W; Campbell Harry</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">9725</span>),
    <span class="NLM_cas:pages">1545-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The global burden of disease attributable to respiratory syncytial virus (RSV) remains unknown.  We aimed to estimate the global incidence of and mortality from episodes of acute lower respiratory infection (ALRI) due to RSV in children younger than 5 years in 2005.  METHODS:  We estimated the incidence of RSV-associated ALRI in children younger than 5 years, stratified by age, using data from a systematic review of studies published between January, 1995, and June, 2009, and ten unpublished population-based studies.  We estimated possible boundaries for RSV-associated ALRI mortality by combining case fatality ratios with incidence estimates from hospital-based reports from published and unpublished studies and identifying studies with population-based data for RSV seasonality and monthly ALRI mortality.  FINDINGS:  In 2005, an estimated 33.8 (95% CI 19.3-46.2) million new episodes of RSV-associated ALRI occurred worldwide in children younger than 5 years (22% of ALRI episodes), with at least 3.4 (2.8-4.3) million episodes representing severe RSV-associated ALRI necessitating hospital admission.  We estimated that 66 000-199 000 children younger than 5 years died from RSV-associated ALRI in 2005, with 99% of these deaths occurring in developing countries.  Incidence and mortality can vary substantially from year to year in any one setting.  INTERPRETATION:  Globally, RSV is the most common cause of childhood ALRI and a major cause of admission to hospital as a result of severe ALRI.  Mortality data suggest that RSV is an important cause of death in childhood from ALRI, after pneumococcal pneumonia and Haemophilus influenzae type b.  The development of novel prevention and treatment strategies should be accelerated as a priority.  FUNDING:  WHO; Bill & Melinda Gates Foundation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSnFoanGZgE-0EksK8CslK8fW6udTcc2eYk74rqlnCzU7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czgtlaqug%253D%253D&md5=6f2c5f53dae65be05c020454d010f32c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2810%2960206-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252810%252960206-1%26sid%3Dliteratum%253Aachs%26aulast%3DNair%26aufirst%3DH.%26aulast%3DNokes%26aufirst%3DJ.%2BD.%26aulast%3DGessner%26aufirst%3DB.%2BD.%26aulast%3DDherani%26aufirst%3DM.%26aulast%3DMadhi%26aufirst%3DS.%2BA.%26aulast%3DSingleton%26aufirst%3DR.%2BJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DK.%2BL.%26aulast%3DRoca%26aufirst%3DA.%26aulast%3DWright%26aufirst%3DP.%2BF.%26aulast%3DBruce%26aufirst%3DN.%26aulast%3DChandran%26aufirst%3DA.%26aulast%3DTheodoratou%26aufirst%3DE.%26aulast%3DSutanto%26aufirst%3DA.%26aulast%3DSedyaningsih%26aufirst%3DE.%2BR.%26aulast%3DNgama%26aufirst%3DM.%26aulast%3DMunywoki%26aufirst%3DP.%2BK.%26aulast%3DKartasasmita%26aufirst%3DC.%26aulast%3DSim%25C3%25B5es%26aufirst%3DE.%2BA.%26aulast%3DRudan%26aufirst%3DI.%26aulast%3DWeber%26aufirst%3DM.%2BW.%26aulast%3DCampbell%26aufirst%3DH.%26atitle%3DGlobal%2520burden%2520of%2520acute%2520lower%2520respiratory%2520infections%2520due%2520to%2520respiratory%2520syncytial%2520virus%2520in%2520young%2520children%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DLancet%26date%3D2010%26volume%3D375%26issue%3D9725%26spage%3D1545%26epage%3D1555%26doi%3D10.1016%2FS0140-6736%2810%2960206-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boschi-Pinto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biloglav, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulholland, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, H.</span></span> <span> </span><span class="NLM_article-title">Epidemiology and etiology of childhood pneumonia</span>. <i>Bull. World Health Organ.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>86</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">408</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.2471/BLT.07.048769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.2471%2FBLT.07.048769" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=18545744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A280%3ADC%252BD1cznsleqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2008&pages=408-416&issue=5&author=I.+Rudanauthor=C.+Boschi-Pintoauthor=Z.+Biloglavauthor=K.+Mulhollandauthor=H.+Campbell&title=Epidemiology+and+etiology+of+childhood+pneumonia&doi=10.2471%2FBLT.07.048769"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology and etiology of childhood pneumonia</span></div><div class="casAuthors">Rudan Igor; Boschi-Pinto Cynthia; Biloglav Zrinka; Mulholland Kim; Campbell Harry</div><div class="citationInfo"><span class="NLM_cas:title">Bulletin of the World Health Organization</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">408-16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Childhood pneumonia is the leading single cause of mortality in children aged less than 5 years.  The incidence in this age group is estimated to be 0.29 episodes per child-year in developing and 0.05 episodes per child-year in developed countries.  This translates into about 156 million new episodes each year worldwide, of which 151 million episodes are in the developing world.  Most cases occur in India (43 million), China (21 million) and Pakistan (10 million), with additional high numbers in Bangladesh, Indonesia and Nigeria (6 million each).  Of all community cases, 7-13% are severe enough to be life-threatening and require hospitalization.  Substantial evidence revealed that the leading risk factors contributing to pneumonia incidence are lack of exclusive breastfeeding, undernutrition, indoor air pollution, low birth weight, crowding and lack of measles immunization.  Pneumonia is responsible for about 19% of all deaths in children aged less than 5 years, of which more than 70% take place in sub-Saharan Africa and south-east Asia.  Although based on limited available evidence, recent studies have identified Streptococcus pneumoniae, Haemophilus influenzae and respiratory syncytial virus as the main pathogens associated with childhood pneumonia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjSg8oBVMgIcuCWE5mhx1RfW6udTcc2eYk74rqlnCzU7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cznsleqsw%253D%253D&md5=98002bcca488350c6a878fd496bfe4cf</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2471%2FBLT.07.048769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2471%252FBLT.07.048769%26sid%3Dliteratum%253Aachs%26aulast%3DRudan%26aufirst%3DI.%26aulast%3DBoschi-Pinto%26aufirst%3DC.%26aulast%3DBiloglav%26aufirst%3DZ.%26aulast%3DMulholland%26aufirst%3DK.%26aulast%3DCampbell%26aufirst%3DH.%26atitle%3DEpidemiology%2520and%2520etiology%2520of%2520childhood%2520pneumonia%26jtitle%3DBull.%2520World%2520Health%2520Organ.%26date%3D2008%26volume%3D86%26issue%3D5%26spage%3D408%26epage%3D416%26doi%3D10.2471%2FBLT.07.048769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feltes, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondheimer, H. M.</span></span> <span> </span><span class="NLM_article-title">Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease</span>. <i>Expert Opin. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1471</span>– <span class="NLM_lpage">1480</span>, <span class="refDoi"> DOI: 10.1517/14712598.7.9.1471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1517%2F14712598.7.9.1471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=17727335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BD2sXps1Wnsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1471-1480&issue=9&author=T.+F.+Feltesauthor=H.+M.+Sondheimer&title=Palivizumab+and+the+prevention+of+respiratory+syncytial+virus+illness+in+pediatric+patients+with+congenital+heart+disease&doi=10.1517%2F14712598.7.9.1471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease</span></div><div class="casAuthors">Feltes, Timothy F.; Sondheimer, Henry M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1471-1480</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Respiratory syncytial virus (RSV) is a significant pathogen for infants and children with congenital heart disease.  Non-sustained immunity and failure to develop an effective vaccine has steered RSV management toward a passive immunotherapy strategy in at-risk children.  Palivizumab is a humanized murine monoclonal antibody targeting the RSV envelope F glycoprotein.  In a Phase III clin. trial palivizumab significantly reduced RSV hospitalization in children with significant congenital heart disease and was proven to be safe.  Palivizumab is one of the first monoclonal antibodies to significantly impact a pediatric disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYl03zv6kWuLVg90H21EOLACvtfcHk0ljp67nSCvJAXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXps1Wnsb8%253D&md5=48c600df4bf1fbd64e784d794e1af2a3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1517%2F14712598.7.9.1471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.7.9.1471%26sid%3Dliteratum%253Aachs%26aulast%3DFeltes%26aufirst%3DT.%2BF.%26aulast%3DSondheimer%26aufirst%3DH.%2BM.%26atitle%3DPalivizumab%2520and%2520the%2520prevention%2520of%2520respiratory%2520syncytial%2520virus%2520illness%2520in%2520pediatric%2520patients%2520with%2520congenital%2520heart%2520disease%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2007%26volume%3D7%26issue%3D9%26spage%3D1471%26epage%3D1480%26doi%3D10.1517%2F14712598.7.9.1471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falsey, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennessey, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Formica, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, E. E.</span></span> <span> </span><span class="NLM_article-title">Respiratory syncytial virus infection in the elderly and high-risk adults</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">1749</span>– <span class="NLM_lpage">1759</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa043951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1056%2FNEJMoa043951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=15858184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsFyhsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=1749-1759&issue=17&author=A.+R.+Falseyauthor=P.+A.+Hennesseyauthor=M.+A.+Formicaauthor=C.+Coxauthor=E.+E.+Walsh&title=Respiratory+syncytial+virus+infection+in+the+elderly+and+high-risk+adults&doi=10.1056%2FNEJMoa043951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus infection in elderly and high-risk adults</span></div><div class="casAuthors">Falsey, Ann R.; Hennessey, Patricia A.; Formica, Maria A.; Cox, Christopher; Walsh, Edward E.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1749-1759</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Respiratory syncytial virus (RSV) is an increasingly recognized cause of illness in adults.  Data on the epidemiol. and clin. effects in community-dwelling elderly persons and high-risk adults can help in assessing the need for vaccine development.  METHODS During four consecutive winters, we evaluated all respiratory illnesses in prospective cohorts of healthy elderly patients (≥65 years of age) and high-risk adults (those with chronic heart or lung disease) and in patients hospitalized with acute cardiopulmonary conditions.  RSV infection and influenza A were diagnosed on the basis of culture, reverse-transcriptase polymerase chain reaction, and serol. studies.  RESULTS A total of 608 healthy elderly patients and 540 high-risk adults were enrolled in prospective surveillance, and 1388 hospitalized patients were enrolled.  A total of 2514 illnesses were evaluated.  RSV infection was identified in 102 patients in the prospective cohorts and 142 hospitalized patients, and influenza A was diagnosed in 44 patients in the prospective cohorts and 154 hospitalized patients.  RSV infection developed annually in 3 to 7 percent of healthy elderly patients and in 4 to 10 percent of high-risk adults.  Among healthy elderly patients, RSV infection generated fewer office visits than influenza; however, the use of health care services by high-risk adults was similar in the two groups.  In the hospitalized cohort, RSV infection and influenza A resulted in similar lengths of stay, rates of use of intensive care (15 percent and 12 percent, resp.), and mortality (8 percent and 7 percent, resp.).  On the basis of the diagnostic codes of the International Classification of Diseases, 9th Revision, Clin. Modification at discharge, RSV infection accounted for 10.6 percent of hospitalizations for pneumonia, 11.4 percent for chronic obstructive pulmonary disease, 5.4 percent for congestive heart failure, and 7.2 percent for asthma.  CONCLUSIONS RSV infection is an important illness in elderly and high-risk adults, with a disease burden similar to that of nonpandemic influenza A in a population in which the prevalence of vaccination for influenza is high.  An effective RSV vaccine may offer benefits for these adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC4DLnaPCjP7Vg90H21EOLACvtfcHk0ljp67nSCvJAXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsFyhsr8%253D&md5=84051565564c0794974fde0b28a0e887</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa043951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa043951%26sid%3Dliteratum%253Aachs%26aulast%3DFalsey%26aufirst%3DA.%2BR.%26aulast%3DHennessey%26aufirst%3DP.%2BA.%26aulast%3DFormica%26aufirst%3DM.%2BA.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DWalsh%26aufirst%3DE.%2BE.%26atitle%3DRespiratory%2520syncytial%2520virus%2520infection%2520in%2520the%2520elderly%2520and%2520high-risk%2520adults%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26issue%3D17%26spage%3D1749%26epage%3D1759%26doi%3D10.1056%2FNEJMoa043951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wainwright, C.</span></span> <span> </span><span class="NLM_article-title">Acute viral bronchiolitis in children - a very common condition with few therapeutic options</span>. <i>Paediatr. Respir. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/j.prrv.2009.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1016%2Fj.prrv.2009.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=20113991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252Fotlyhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=39-45&issue=1&author=C.+Wainwright&title=Acute+viral+bronchiolitis+in+children+-+a+very+common+condition+with+few+therapeutic+options&doi=10.1016%2Fj.prrv.2009.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Acute viral bronchiolitis in children- a very common condition with few therapeutic options</span></div><div class="casAuthors">Wainwright Claire</div><div class="citationInfo"><span class="NLM_cas:title">Paediatric respiratory reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-45; quiz 45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acute viral bronchiolitis remains a cause of substantial morbidity and health care costs in young infants.  It is the most common lower respiratory tract condition and most common reason for admission to hospital in infants.  Many respiratory viruses have been associated with acute viral bronchiolitis although respiratory syncytial virus (RSV) remains the most frequently identified virus.  Most infants have a mild self limiting illness while others have more severe illness and require hospital admission and some will need ventilatory support.  Differences in innate immune function in response to the respiratory viral insult as well as differences in the geometry of the airways may explain some of the variability in clinical pattern.  Young age and history of prematurity remain the most important risk factors although male gender, indigenous status, exposure to tobacco smoke, poor socioeconomic factors and associated co-morbidities such as chronic lung disease and congenital heart disease increase the risks of more severe illness.  Supportive therapy remains the major treatment option as no specific treatments to date have been shown to provide clinically important benefits except for inhaled hypertonic saline.  Prophylaxis of high risk infants with palivizumab should be considered although the cost effectiveness is still unclear.  Many questions remain regarding optimal management approaches for infants requiring hospitalisation with bronchiolitis including use of nasogastric feeding, the optimal role of supplemental oxygen, optimal use of hypertonic saline and the role of combinations of therapies, the use of heliox or modern physiotherapy approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQjYoMkmkNtP-Lt9HypzAgQfW6udTcc2eb7_T_-Hpc8zbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252Fotlyhsw%253D%253D&md5=ef94d9327375911261d3d3cf730c66bd</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.prrv.2009.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.prrv.2009.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DWainwright%26aufirst%3DC.%26atitle%3DAcute%2520viral%2520bronchiolitis%2520in%2520children%2520-%2520a%2520very%2520common%2520condition%2520with%2520few%2520therapeutic%2520options%26jtitle%3DPaediatr.%2520Respir.%2520Rev.%26date%3D2010%26volume%3D11%26issue%3D1%26spage%3D39%26epage%3D45%26doi%3D10.1016%2Fj.prrv.2009.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Empey, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peebles, R. S.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolls, J. K.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic advances in the treatment and prevention of respiratory syncytial virus</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1258</span>– <span class="NLM_lpage">1267</span>, <span class="refDoi"> DOI: 10.1086/651603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1086%2F651603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=20235830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVehtL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=1258-1267&issue=9&author=K.+M.+Empeyauthor=R.+S.+Peeblesauthor=J.+K.+Kolls&title=Pharmacologic+advances+in+the+treatment+and+prevention+of+respiratory+syncytial+virus&doi=10.1086%2F651603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic advances in the treatment and prevention of respiratory syncytial virus</span></div><div class="casAuthors">Empey, Kerry M.; Peebles, R. Stokes, Jr.; Kolls, Jay K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1258-1267</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">A review.  Currently, only 2 drugs have been approved for the treatment of respiratory syncytial virus (RSV).  Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children.  Ribavirin is approved for treatment of severe RSV disease; however, its effectiveness in improving outcomes is questionable.  During the past 40 years, many obstacles have delayed the development of safe and effective vaccines and treatment regimens.  This article reviews these obstacles and presents the novel development strategies used to overcome many of them.  Also discussed are promising new antiviral treatment candidates and their assocd. mechanism of action, the significant advances made in vaccine development, and exciting, new studies directed at improving outcomes through pharmacol. manipulation of the host response to RSV disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowVNHvx4G3Z7Vg90H21EOLACvtfcHk0ljPSwaYDUPtVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVehtL3N&md5=f5b23cc6db487b8e50ceb7379cdd107f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1086%2F651603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F651603%26sid%3Dliteratum%253Aachs%26aulast%3DEmpey%26aufirst%3DK.%2BM.%26aulast%3DPeebles%26aufirst%3DR.%2BS.%26aulast%3DKolls%26aufirst%3DJ.%2BK.%26atitle%3DPharmacologic%2520advances%2520in%2520the%2520treatment%2520and%2520prevention%2520of%2520respiratory%2520syncytial%2520virus%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2010%26volume%3D50%26issue%3D9%26spage%3D1258%26epage%3D1267%26doi%3D10.1086%2F651603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span> <span> </span><span class="NLM_article-title">Respiratory syncytial virus: a prioritized or neglected target?</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1523</span>– <span class="NLM_lpage">1527</span>, <span class="refDoi"> DOI: 10.4155/fmc.10.235</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.4155%2Ffmc.10.235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=21426146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1yqsbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=1523-1527&issue=10&author=D.+Roymansauthor=A.+Koul&title=Respiratory+syncytial+virus%3A+a+prioritized+or+neglected+target%3F&doi=10.4155%2Ffmc.10.235"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus: a prioritized or neglected target?</span></div><div class="casAuthors">Roymans, Dirk; Koul, Anil</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1523-1527</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5WHK0tco01LVg90H21EOLACvtfcHk0ljPSwaYDUPtVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1yqsbjO&md5=78297af20cb3e9afb2878c2eb70f2be4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.4155%2Ffmc.10.235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.10.235%26sid%3Dliteratum%253Aachs%26aulast%3DRoymans%26aufirst%3DD.%26aulast%3DKoul%26aufirst%3DA.%26atitle%3DRespiratory%2520syncytial%2520virus%253A%2520a%2520prioritized%2520or%2520neglected%2520target%253F%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2010%26volume%3D2%26issue%3D10%26spage%3D1523%26epage%3D1527%26doi%3D10.4155%2Ffmc.10.235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span>; <span class="NLM_string-name">Koul, A.</span></span> <span> </span><span class="NLM_article-title">Treatment of respiratory syncytial virus infection: Past, present and future</span>. In  <i>Human Respiratory Syncytial Virus Infection</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resch, B</span></span>, Ed.; <span class="NLM_publisher-name">InTech</span>: <span class="NLM_publisher-loc">Rijeka, Croatia</span>, <span class="NLM_year">2011</span>; pp  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">215</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.5772%2F26528" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=197-215&author=D.+Roymans&author=A.+Koulauthor=B+Resch&title=Human+Respiratory+Syncytial+Virus+Infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.5772%2F26528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.5772%252F26528%26sid%3Dliteratum%253Aachs%26aulast%3DRoymans%26aufirst%3DD.%26atitle%3DTreatment%2520of%2520respiratory%2520syncytial%2520virus%2520infection%253A%2520Past%252C%2520present%2520and%2520future%26btitle%3DHuman%2520Respiratory%2520Syncytial%2520Virus%2520Infection%26aulast%3DResch%26aufirst%3DB%26pub%3DInTech%26date%3D2011%26spage%3D197%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Saleeby, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, A. J.</span></span> <span> </span><span class="NLM_article-title">Respiratory syncytial virus load predicts disease severity in previously healthy infants</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>191</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1861</span>– <span class="NLM_lpage">1868</span>, <span class="refDoi"> DOI: 10.1086/430008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1086%2F430008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=15871119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A280%3ADC%252BD2Mzitl2ktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2005&pages=1861-1868&issue=11&author=J.+P.+DeVincenzoauthor=C.+M.+El+Saleebyauthor=A.+J.+Bush&title=Respiratory+syncytial+virus+load+predicts+disease+severity+in+previously+healthy+infants&doi=10.1086%2F430008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus load predicts disease severity in previously healthy infants</span></div><div class="casAuthors">DeVincenzo John P; El Saleeby Chadi M; Bush Andrew J</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of infectious diseases</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1861-8</span>
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    </div><div class="casAbstract">BACKGROUND:  Elucidating the relationship between viral load and respiratory syncytial virus (RSV) disease severity is critical to understanding pathogenesis and predicting the utility of antivirals.  METHODS:  Previously healthy, naturally RSV-infected infants <24 months old not treated with ribavirin, passive antibody, or corticosteroids were prospectively studied (n=141).  Viral loads were measured by fresh quantitative culture from nasal washes collected at a single time point shortly after hospitalization.  RESULTS:  The subjects' mean age was 112.1 days, and the mean estimated gestational age at birth was 38.38 weeks.  RSV load decreased with longer durations of symptoms before specimen collection (P=.01).  Male subjects had higher RSV loads than female subjects (P=.036).  Significant independent predictors of longer hospitalization were congenital anomaly (P<.0001), lower weight on admission (P=.028), and higher nasal RSV load (P=.008).  A 1-log higher RSV load predicted a 0.8-day longer hospitalization.  Lower weight and higher RSV load were also independently associated with respiratory failure (P<.0005 and P=.0049, respectively) and requirement for intensive care (P=.0007 and P=.0048, respectively).  CONCLUSIONS:  In previously healthy infants, higher RSV loads measured at capturable time points after symptom onset predict clinically relevant measures of increased disease severity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT2TotJolUTY6Nc3HjJRoFAfW6udTcc2eZhmlL19GSm77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mzitl2ktA%253D%253D&md5=bbc73709fc42da99a8a9d950120972a3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1086%2F430008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F430008%26sid%3Dliteratum%253Aachs%26aulast%3DDeVincenzo%26aufirst%3DJ.%2BP.%26aulast%3DEl%2BSaleeby%26aufirst%3DC.%2BM.%26aulast%3DBush%26aufirst%3DA.%2BJ.%26atitle%3DRespiratory%2520syncytial%2520virus%2520load%2520predicts%2520disease%2520severity%2520in%2520previously%2520healthy%2520infants%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2005%26volume%3D191%26issue%3D11%26spage%3D1861%26epage%3D1868%26doi%3D10.1086%2F430008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cehelsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nochur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeking, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pareek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studholme, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsett, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambkin-Williams, R.</span></span> <span> </span><span class="NLM_article-title">Viral load drives disease in humans experimentally infected with respiratory syncytial virus</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>182</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">1314</span>, <span class="refDoi"> DOI: 10.1164/rccm.201002-0221OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1164%2Frccm.201002-0221OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=20622030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1equg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2010&pages=1305-1314&issue=10&author=J.+P.+DeVincenzoauthor=T.+Wilkinsonauthor=A.+Vaishnawauthor=J.+Cehelskyauthor=R.+Meyersauthor=S.+Nochurauthor=L.+Harrisonauthor=P.+Meekingauthor=A.+Mannauthor=E.+Moaneauthor=J.+Oxfordauthor=R.+Pareekauthor=R.+Mooreauthor=E.+Walshauthor=R.+Studholmeauthor=P.+Dorsettauthor=R.+Alvarezauthor=R.+Lambkin-Williams&title=Viral+load+drives+disease+in+humans+experimentally+infected+with+respiratory+syncytial+virus&doi=10.1164%2Frccm.201002-0221OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Viral load drives disease in humans experimentally infected with respiratory syncytial virus</span></div><div class="casAuthors">DeVincenzo, John P.; Wilkinson, Tom; Vaishnaw, Akshay; Cehelsky, Jeff; Meyers, Rachel; Nochur, Saraswathy; Harrison, Lisa; Meeking, Patricia; Mann, Alex; Moane, Elizabeth; Oxford, John; Pareek, Rajat; Moore, Ryves; Walsh, Ed; Studholme, Robert; Dorsett, Preston; Alvarez, Rene; Lambkin-Williams, Robert</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1305-1314</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) is the leading cause of childhood lower respiratory infection, yet viable therapies are lacking.  Two major challenges have stalled antiviral development: ethical difficulties in performing pediatric proof-of-concept studies and the prevailing concept that the disease is immune-mediated rather than being driven by viral load.  The development of a human exptl. wild-type RSV infection model to address these challenges.  Healthy volunteers (n = 35), in five cohorts, received increasing quantities (3.0-5.4 log plaque-forming units/person) of wild-type RSV-A intranasally.  Overall, 77% of volunteers consistently shed virus.  Infection rate, viral loads, disease severity, and safety were similar between cohorts and were unrelated to quantity of RSV received.  Symptoms began near the time of initial viral detection, peaked in severity near when viral load peaked, and subsided as viral loads (measured by real-time polymerase chain reaction) slowly declined.  Viral loads correlated significantly with intranasal proinflammatory cytokine concns. (IL-6 and IL-8).  Increased viral load correlated consistently with increases in multiple different disease measurements (symptoms, phys. examn., and amt. of nasal mucus).  Viral load appears to drive disease manifestations in humans with RSV infection.  The obsd. parallel viral and disease kinetics support a potential clin. benefit of RSV antivirals.  This reproducible model facilitates the development of future RSV therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-DVpVkrytZ7Vg90H21EOLACvtfcHk0ljPSwaYDUPtVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1equg%253D%253D&md5=baadbf1735812bf00a63b9499a2fe3bd</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1164%2Frccm.201002-0221OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201002-0221OC%26sid%3Dliteratum%253Aachs%26aulast%3DDeVincenzo%26aufirst%3DJ.%2BP.%26aulast%3DWilkinson%26aufirst%3DT.%26aulast%3DVaishnaw%26aufirst%3DA.%26aulast%3DCehelsky%26aufirst%3DJ.%26aulast%3DMeyers%26aufirst%3DR.%26aulast%3DNochur%26aufirst%3DS.%26aulast%3DHarrison%26aufirst%3DL.%26aulast%3DMeeking%26aufirst%3DP.%26aulast%3DMann%26aufirst%3DA.%26aulast%3DMoane%26aufirst%3DE.%26aulast%3DOxford%26aufirst%3DJ.%26aulast%3DPareek%26aufirst%3DR.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DWalsh%26aufirst%3DE.%26aulast%3DStudholme%26aufirst%3DR.%26aulast%3DDorsett%26aufirst%3DP.%26aulast%3DAlvarez%26aufirst%3DR.%26aulast%3DLambkin-Williams%26aufirst%3DR.%26atitle%3DViral%2520load%2520drives%2520disease%2520in%2520humans%2520experimentally%2520infected%2520with%2520respiratory%2520syncytial%2520virus%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2010%26volume%3D182%26issue%3D10%26spage%3D1305%26epage%3D1314%26doi%3D10.1164%2Frccm.201002-0221OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El Saleeby, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aitken, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J. P.</span></span> <span> </span><span class="NLM_article-title">Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>204</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">996</span>– <span class="NLM_lpage">1002</span>, <span class="refDoi"> DOI: 10.1093/infdis/jir494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1093%2Finfdis%2Fjir494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=21881113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A280%3ADC%252BC3Mfgt1GnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2011&pages=996-1002&issue=7&author=C.+M.+El+Saleebyauthor=A.+J.+Bushauthor=L.+M.+Harrisonauthor=J.+A.+Aitkenauthor=J.+P.+DeVincenzo&title=Respiratory+syncytial+virus+load%2C+viral+dynamics%2C+and+disease+severity+in+previously+healthy+naturally+infected+children&doi=10.1093%2Finfdis%2Fjir494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children</span></div><div class="casAuthors">El Saleeby Chadi M; Bush Andy J; Harrison Lisa M; Aitken Jody A; Devincenzo John P</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of infectious diseases</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">996-1002</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Respiratory syncytial virus (RSV) disease severity was thought to be a result of host immunopathology but alternatively may be driven by high-level viral replication.  The relationships between RSV load, viral clearance dynamics, and disease severity have not been carefully evaluated.  METHODS:  Previously healthy RSV-infected children <2 years old were recruited.  RSV load was measured in respiratory secretions by fresh quantitative culture over 3 hospital days.  Measures of disease severity were hospital admission, duration of hospitalization, requirement for intensive care, and respiratory failure.  RESULTS:  Multivariate logistic regression models revealed independent predictors of increased duration of hospitalization: male sex, lower weight, and higher viral load on any day.  Viral loads at day 3 were more significantly associated with requirement for intensive care and respiratory failure than were viral loads at earlier time points.  Faster RSV clearance was independently associated with shorter hospitalization.  DISCUSSION:  These observations challenge the immunopathology-based pathogenesis paradigm.  They also have major therapeutic implications, suggesting that application of antiviral agents early in the disease course, even at a time when viral replication is at its highest, might improve subsequent morbidity by significantly lowering viral load and direct viral cytopathic effects, and aborting the potential downstream immunopathology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmIt942YeXHUPI-fCgwosgfW6udTcc2eaX20TzHYyvJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mfgt1GnsQ%253D%253D&md5=df2aee4217ba4325199646ac70599049</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjir494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjir494%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BSaleeby%26aufirst%3DC.%2BM.%26aulast%3DBush%26aufirst%3DA.%2BJ.%26aulast%3DHarrison%26aufirst%3DL.%2BM.%26aulast%3DAitken%26aufirst%3DJ.%2BA.%26aulast%3DDeVincenzo%26aufirst%3DJ.%2BP.%26atitle%3DRespiratory%2520syncytial%2520virus%2520load%252C%2520viral%2520dynamics%252C%2520and%2520disease%2520severity%2520in%2520previously%2520healthy%2520naturally%2520infected%2520children%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2011%26volume%3D204%26issue%3D7%26spage%3D996%26epage%3D1002%26doi%3D10.1093%2Finfdis%2Fjir494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperandio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrish, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boojamra, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babaoglu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piedra, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stray, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinkade, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theodore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human rsv challenge Study</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1630</span>– <span class="NLM_lpage">1643</span>, <span class="refDoi"> DOI: 10.1021/jm5017768</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5017768" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1yltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1630-1643&issue=4&author=R.+L.+Mackmanauthor=M.+Sangiauthor=D.+Sperandioauthor=J.+P.+Parrishauthor=E.+Eisenbergauthor=M.+Perronauthor=H.+Huiauthor=L.+Zhangauthor=D.+Siegelauthor=H.+Yangauthor=O.+Saundersauthor=O.+Boojamraauthor=G.+Leeauthor=D.+Samuelauthor=K.+Babaogluauthor=A.+Careyauthor=B.+E.+Gilbertauthor=P.+A.+Piedraauthor=R.+Strickleyauthor=Q.+Iwataauthor=J.+Hayesauthor=K.+Strayauthor=A.+Kinkadeauthor=D.+Theodoreauthor=R.+Jordanauthor=M.+Desaiauthor=T.+Cihlar&title=Discovery+of+an+oral+respiratory+syncytial+virus+%28RSV%29+fusion+inhibitor+%28GS-5806%29+and+clinical+proof+of+concept+in+a+human+rsv+challenge+Study&doi=10.1021%2Fjm5017768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Oral Respiratory Syncytial Virus (RSV) Fusion Inhibitor (GS-5806) and Clinical Proof of Concept in a Human RSV Challenge Study</span></div><div class="casAuthors">Mackman, Richard L.; Sangi, Michael; Sperandio, David; Parrish, Jay P.; Eisenberg, Eugene; Perron, Michel; Hui, Hon; Zhang, Lijun; Siegel, Dustin; Yang, Hai; Saunders, Oliver; Boojamra, Constantine; Lee, Gary; Samuel, Dharmaraj; Babaoglu, Kerim; Carey, Anne; Gilbert, Brian E.; Piedra, Pedro A.; Strickley, Robert; Iwata, Quynh; Hayes, Jaclyn; Stray, Kirsten; Kinkade, April; Theodore, Dorothy; Jordan, Robert; Desai, Manoj; Cihlar, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1630-1643</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">GS-5806 I is a novel, orally bioavailable RSV fusion inhibitor discovered following a lead optimization campaign on a screening hit.  The oral absorption properties were optimized by converting to the pyrazolo[1,5-a]-pyrimidine heterocycle, while potency, metabolic, and physicochem. properties were optimized by introducing the para-chloro and aminopyrrolidine groups.  A mean EC50 = 0.43 nM was found toward a panel of 75 RSV A and B clin. isolates and dose-dependent antiviral efficacy in the cotton rat model of RSV infection.  Oral bioavailability in preclin. species ranged from 46 to 100%, with evidence of efficient penetration into lung tissue.  In healthy human volunteers exptl. infected with RSV, a potent antiviral effect was obsd. with a mean 4.2 log10 redn. in peak viral load and a significant redn. in disease severity compared to placebo.  In conclusion, a potent, once daily, oral RSV fusion inhibitor with the potential to treat RSV infection in infants and adults is reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL4lY74Xv7GbVg90H21EOLACvtfcHk0ljPKPOL8ovMtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1yltw%253D%253D&md5=5a723ce1defe717da8cb7985ee297811</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm5017768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5017768%26sid%3Dliteratum%253Aachs%26aulast%3DMackman%26aufirst%3DR.%2BL.%26aulast%3DSangi%26aufirst%3DM.%26aulast%3DSperandio%26aufirst%3DD.%26aulast%3DParrish%26aufirst%3DJ.%2BP.%26aulast%3DEisenberg%26aufirst%3DE.%26aulast%3DPerron%26aufirst%3DM.%26aulast%3DHui%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DSaunders%26aufirst%3DO.%26aulast%3DBoojamra%26aufirst%3DO.%26aulast%3DLee%26aufirst%3DG.%26aulast%3DSamuel%26aufirst%3DD.%26aulast%3DBabaoglu%26aufirst%3DK.%26aulast%3DCarey%26aufirst%3DA.%26aulast%3DGilbert%26aufirst%3DB.%2BE.%26aulast%3DPiedra%26aufirst%3DP.%2BA.%26aulast%3DStrickley%26aufirst%3DR.%26aulast%3DIwata%26aufirst%3DQ.%26aulast%3DHayes%26aufirst%3DJ.%26aulast%3DStray%26aufirst%3DK.%26aulast%3DKinkade%26aufirst%3DA.%26aulast%3DTheodore%26aufirst%3DD.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DDesai%26aufirst%3DM.%26aulast%3DCihlar%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520an%2520oral%2520respiratory%2520syncytial%2520virus%2520%2528RSV%2529%2520fusion%2520inhibitor%2520%2528GS-5806%2529%2520and%2520clinical%2520proof%2520of%2520concept%2520in%2520a%2520human%2520rsv%2520challenge%2520Study%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D4%26spage%3D1630%26epage%3D1643%26doi%3D10.1021%2Fjm5017768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deval, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyatkina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prhavc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serebryany, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symons, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4′-Chloromethyl-2′-deoxy-3′,5′-di-O-isobutyryl-2′-fluorocytidine (ALS-8176), A first-in-class rsv polymerase inhibitor for treatment of human respiratory syncytial virus infection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1862</span>– <span class="NLM_lpage">1878</span>, <span class="refDoi"> DOI: 10.1021/jm5017279</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5017279" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisF2jsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1862-1878&issue=4&author=G.+Wangauthor=J.+Devalauthor=J.+Hongauthor=N.+Dyatkinaauthor=M.+Prhavcauthor=J.+Taylorauthor=A.+Fungauthor=Z.+Jinauthor=S.+K.+Stevensauthor=V.+Serebryanyauthor=J.+Liuauthor=Q.+Zhangauthor=Y.+Tamauthor=S.+M.+Chandaauthor=D.+B.+Smithauthor=J.+A.+Symonsauthor=L.+M.+Blattauthor=L.+Beigelman&title=Discovery+of+4%E2%80%B2-Chloromethyl-2%E2%80%B2-deoxy-3%E2%80%B2%2C5%E2%80%B2-di-O-isobutyryl-2%E2%80%B2-fluorocytidine+%28ALS-8176%29%2C+A+first-in-class+rsv+polymerase+inhibitor+for+treatment+of+human+respiratory+syncytial+virus+infection&doi=10.1021%2Fjm5017279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4'-Chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), A First-in-Class RSV Polymerase Inhibitor for Treatment of Human Respiratory Syncytial Virus Infection</span></div><div class="casAuthors">Wang, Guangyi; Deval, Jerome; Hong, Jin; Dyatkina, Natalia; Prhavc, Marija; Taylor, Joshua; Fung, Amy; Jin, Zhinan; Stevens, Sarah K.; Serebryany, Vladimir; Liu, Jyanwei; Zhang, Qingling; Tam, Yuen; Chanda, Sushmita M.; Smith, David B.; Symons, Julian A.; Blatt, Lawrence M.; Beigelman, Leo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1862-1878</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) is a leading pathogen of childhood and is assocd. with significant morbidity and mortality.  To date, ribavirin is the only approved small mol. drug, which has limited use.  The only other RSV drug is palivizumab, a monoclonal antibody, which is used for RSV prophylaxis.  Clearly, there is an urgent need for small mol. RSV drugs.  This article reports the design, synthesis, anti-RSV activity, metab., and pharmacokinetics of a series of 4'-substituted cytidine nucleosides.  Among tested compds. 4'-chloromethyl-2'-deoxy-2'-fluorocytidine I exhibited the most promising activity in the RSV replicon assay with an EC50 of 0.15 μM.  The 5'-triphosphate of I (I-TP)inhibited RSV polymerase with an IC50 of 0.02 μM without appreciable inhibition of human DNA and RNA polymerases at 100 μM.  ALS-8176 II, the 3',5'-di-O-isobutyryl prodrug of I, demonstrated good oral bioavailability and a high level of I-TP in vivo.  Compd. II is a first-in-class nucleoside RSV polymerase inhibitor that demonstrated excellent anti-RSV efficacy and safety in a phase 2 clin. RSV challenge study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaKHh4AhV9drVg90H21EOLACvtfcHk0lj_18B51L2zwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisF2jsL4%253D&md5=da9e883eb67f20ca259dec06a6a05367</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm5017279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5017279%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DG.%26aulast%3DDeval%26aufirst%3DJ.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DDyatkina%26aufirst%3DN.%26aulast%3DPrhavc%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DJ.%26aulast%3DFung%26aufirst%3DA.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DStevens%26aufirst%3DS.%2BK.%26aulast%3DSerebryany%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DTam%26aufirst%3DY.%26aulast%3DChanda%26aufirst%3DS.%2BM.%26aulast%3DSmith%26aufirst%3DD.%2BB.%26aulast%3DSymons%26aufirst%3DJ.%2BA.%26aulast%3DBlatt%26aufirst%3DL.%2BM.%26aulast%3DBeigelman%26aufirst%3DL.%26atitle%3DDiscovery%2520of%25204%25E2%2580%25B2-Chloromethyl-2%25E2%2580%25B2-deoxy-3%25E2%2580%25B2%252C5%25E2%2580%25B2-di-O-isobutyryl-2%25E2%2580%25B2-fluorocytidine%2520%2528ALS-8176%2529%252C%2520A%2520first-in-class%2520rsv%2520polymerase%2520inhibitor%2520for%2520treatment%2520of%2520human%2520respiratory%2520syncytial%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D4%26spage%3D1862%26epage%3D1878%26doi%3D10.1021%2Fjm5017279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaglioni-Weinlich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambkin-Williams, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Riordan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toback, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, J. W.</span></span> <span> </span><span class="NLM_article-title">Oral GS-5806 activity in a respiratory syncytial virus challenge study</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">722</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1401184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1056%2FNEJMoa1401184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=25140957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Cjsb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=711-722&author=J.+P.+DeVincenzoauthor=R.+J.+Whitleyauthor=R.+L.+Mackmanauthor=C.+Scaglioni-Weinlichauthor=L.+Harrisonauthor=E.+Farrellauthor=S.+McBrideauthor=R.+Lambkin-Williamsauthor=R.+Jordanauthor=Y.+Xinauthor=S.+Ramanathanauthor=T.+O%E2%80%99Riordanauthor=S.+A.+Lewisauthor=X.+Liauthor=S.+L.+Tobackauthor=S.+Linauthor=J.+W.+Chien&title=Oral+GS-5806+activity+in+a+respiratory+syncytial+virus+challenge+study&doi=10.1056%2FNEJMoa1401184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Oral GS-5806 activity in a respiratory syncytial virus challenge study</span></div><div class="casAuthors">DeVincenzo, John P.; Whitley, Richard J.; Mackman, Richard L.; Scaglioni-Weinlich, Cecilia; Harrison, Lisa; Farrell, Eric; McBride, Stephen; Lambkin-Williams, Robert; Jordan, Robert; Xin, Yan; Ramanathan, Srini; O'Riordan, Thomas; Lewis, Sandra A.; Li, Xiaoming; Toback, Seth L.; Lin, Shao-Lee; Chien, Jason W.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">711-722, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Respiratory syncytial virus (RSV) is a common cause of infant hospitalizations and is increasingly recognized as a cause of considerable morbidity and mortality.  No accepted antiviral treatment exists.  Methods: We conducted a double-blind, placebo-controlled study of GS-5806, an oral RSV-entry inhibitor, in healthy adults who received a clin. challenge strain of RSV intranasally.  Participants were monitored for 12 days.  At the time of a pos. test for RSV infection or 5 days after inoculation, whichever occurred first, participants were randomly assigned to receive GS-5806 or placebo in one of seven sequential cohorts.  Cohorts 1 to 4 received a first dose of 50 mg of GS-5806 and then 25 mg daily for the next 4 days, cohort 5 received a first dose of 50 mg and then 25 mg daily for the next 2 days, cohort 6 received one 100-mg dose, and cohort 7 received a first dose of 10 mg and then 5 mg daily for the next 4 days.  Dose selection for cohorts 5, 6, and 7 occurred after an interim anal. of data for cohorts 1 to 4.  The primary end point was the area under the curve (AUC) for the viral load, which was assessed after administration of the first dose through the 12th day after inoculation.  Secondary end points were mucus wt. and symptom scores.  Results: Among the 54 participants in cohorts 1 to 4 who were infected with RSV, active treatment was assocd. with a lower viral load (adjusted mean, 250.7 vs. 757.7 log10 plaque-forming-unit equiv. [PFUe] × hours per mL; P<0.001), lower total mucus wt. (mean, 6.9 g vs. 15.1 g; P = 0.03), and a lower AUC for the change from baseline in symptom scores (adjusted mean, -20.2 vs. 204.9 × hours; P = 0.005).  The results were similar in cohorts 5, 6, and 7.  Adverse events, including low neutrophil counts and increased levels of alanine aminotransferase, were more common among participants receiving GS-5806.  Conclusions: Treatment with GS-5806 reduced the viral load and the severity of clin. disease in a challenge study of healthy adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqxDrIVO5aQLVg90H21EOLACvtfcHk0lj_18B51L2zwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Cjsb7O&md5=72276739a80d55a732269359e338fb95</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1401184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1401184%26sid%3Dliteratum%253Aachs%26aulast%3DDeVincenzo%26aufirst%3DJ.%2BP.%26aulast%3DWhitley%26aufirst%3DR.%2BJ.%26aulast%3DMackman%26aufirst%3DR.%2BL.%26aulast%3DScaglioni-Weinlich%26aufirst%3DC.%26aulast%3DHarrison%26aufirst%3DL.%26aulast%3DFarrell%26aufirst%3DE.%26aulast%3DMcBride%26aufirst%3DS.%26aulast%3DLambkin-Williams%26aufirst%3DR.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DXin%26aufirst%3DY.%26aulast%3DRamanathan%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Riordan%26aufirst%3DT.%26aulast%3DLewis%26aufirst%3DS.%2BA.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DToback%26aufirst%3DS.%2BL.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DChien%26aufirst%3DJ.%2BW.%26atitle%3DOral%2520GS-5806%2520activity%2520in%2520a%2520respiratory%2520syncytial%2520virus%2520challenge%2520study%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D711%26epage%3D722%26doi%3D10.1056%2FNEJMoa1401184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClure, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symons, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fathi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westland, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambkin-Williams, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, J.</span></span> <span> </span><span class="NLM_article-title">Activity of oral ALS-008176 in a respiratory syncytial virus challenge study</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">2048</span>– <span class="NLM_lpage">2058</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1413275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1056%2FNEJMoa1413275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=26580997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC28XntVSrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=2048-2058&author=J.+P.+DeVincenzoauthor=M.+W.+McClureauthor=J.+A.+Symonsauthor=H.+Fathiauthor=C.+Westlandauthor=S.+Chandaauthor=R.+Lambkin-Williamsauthor=P.+Smithauthor=Q.+Zhangauthor=L.+Beigelmanauthor=L.+M.+Blattauthor=J.+Fry&title=Activity+of+oral+ALS-008176+in+a+respiratory+syncytial+virus+challenge+study&doi=10.1056%2FNEJMoa1413275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of oral ALS-008176 in a respiratory syncytial virus challenge study</span></div><div class="casAuthors">DeVincenzo, John P.; McClure, Matthew W.; Symons, Julian A.; Fathi, Hosnieh; Westland, Christopher; Chanda, Sushmita; Lambkin-Williams, Rob; Smith, Patrick; Zhang, Qingling; Beigelman, Leo; Blatt, Lawrence M.; Fry, John</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2048-2058</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) infection is a cause of substantial morbidity and mortality.  There is no known effective therapy.  We conducted a randomized, double-blind, clin. trial in healthy adults inoculated with RSV.  Participants received the oral nucleoside analog ALS-008176 or placebo 12 h after confirmation of RSV infection or 6 days after inoculation.  Treatment was administered every 12 h for 5 days.  Viral load, disease severity, resistance, and safety were measured throughout the 28-day study period, with measurement beginning before inoculation.  The primary end point was the area under the curve (AUC) for viral load, which was assessed immediately before administration of the first dose through the 12th day after inoculation in participants infected with RSV.  A total of 62 participants received placebo or one of three ALS-008176 dosing regimens: 1 loading dose of 750 mg followed by 9 maintenance doses of 500 mg (group 1), 1 loading dose of 750 mg followed by 9 maintenance doses of 150 mg (group 2), or 10 doses of 375 mg (group 3).  In the 35 infected participants (23 of whom were treated with ALS-008176), the AUCs for viral load for groups 1, 2, and 3 and the placebo group were 59.9, 73.7, 133.4, and 500.9 log10 plaque-forming-unit equiv. × hours per mL, resp. (P≤0.001).  The time to nondetectability on polymerase-chain-reaction assay (P<0.001), the peak viral load (P≤0.001), the AUC for symptom score (P<0.05), and the AUC for mucus wt. were lower in all groups receiving ALS-008176 than in the placebo group.  Antiviral activity was greatest in the two groups that received a loading dose - viral clearance was accelerated (P≤0.05), and the AUC for viral load decreased by 85 to 88% as compared with the placebo group.  Within this small trial, no viral rebound or resistance was identified.  There were no serious adverse events, and there was no need for premature discontinuation of the study drug.  In this RSV challenge study, more rapid RSV clearance and a greater redn. of viral load, with accompanying improvements in the severity of clin. disease, were obsd. in the groups treated with ALS-008176 than in the placebo group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVhsAaDKW-4bVg90H21EOLACvtfcHk0lgfSid14VaqvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntVSrsro%253D&md5=e1cac2ef1b91f47abf768403cb072ec0</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1413275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1413275%26sid%3Dliteratum%253Aachs%26aulast%3DDeVincenzo%26aufirst%3DJ.%2BP.%26aulast%3DMcClure%26aufirst%3DM.%2BW.%26aulast%3DSymons%26aufirst%3DJ.%2BA.%26aulast%3DFathi%26aufirst%3DH.%26aulast%3DWestland%26aufirst%3DC.%26aulast%3DChanda%26aufirst%3DS.%26aulast%3DLambkin-Williams%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DBeigelman%26aufirst%3DL.%26aulast%3DBlatt%26aufirst%3DL.%2BM.%26aulast%3DFry%26aufirst%3DJ.%26atitle%3DActivity%2520of%2520oral%2520ALS-008176%2520in%2520a%2520respiratory%2520syncytial%2520virus%2520challenge%2520study%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D2048%26epage%3D2058%26doi%3D10.1056%2FNEJMoa1413275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagga, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veldman, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaratnam, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambkin-Williams, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxford, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClain, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsburg, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devincenzo, J. P.</span></span> <span> </span><span class="NLM_article-title">Comparing influenza and rsvviral and disease dynamics in experimentally infected adults predicts clinical effectiveness of rsv antivirals</span>. <i>Antiviral Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">785</span>– <span class="NLM_lpage">791</span>, <span class="refDoi"> DOI: 10.3851/IMP2629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.3851%2FIMP2629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=23714753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjsVentbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=785-791&author=B.+Baggaauthor=C.+W.+Woodsauthor=T.+H.+Veldmanauthor=A.+Gilbertauthor=A.+Mannauthor=G.+Balaratnamauthor=R.+Lambkin-Williamsauthor=J.+S.+Oxfordauthor=M.+T.+McClainauthor=T.+Wilkinsonauthor=B.+P.+Nicholsonauthor=G.+S.+Ginsburgauthor=J.+P.+Devincenzo&title=Comparing+influenza+and+rsvviral+and+disease+dynamics+in+experimentally+infected+adults+predicts+clinical+effectiveness+of+rsv+antivirals&doi=10.3851%2FIMP2629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals</span></div><div class="casAuthors">Bagga, Bindiya; Woods, Christopher W.; Veldman, Timothy H.; Gilbert, Anthony; Mann, Alex; Balaratnam, Ganesh; Lambkin-Williams, Robert; Oxford, John S.; McClain, Micah T.; Wilkinson, Tom; Nicholson, Brad P.; Ginsburg, Geoffrey S.; DeVincenzo, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">785-791</span>CODEN:
                <span class="NLM_cas:coden">ANTHFA</span>;
        ISSN:<span class="NLM_cas:issn">1359-6535</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press</span>)
        </div><div class="casAbstract">Background: Antivirals reduce influenza viral replication and illness measures, particularly if initiated early, within 48 h of symptom onset.  Whether exptl. antivirals that reduce respiratory syncytial virus (RSV) load would also reduce disease is unknown.  This study compares viral and disease dynamics in humans exptl. infected with influenza or RSV.  Methods: Clin. strains of RSV-A and influenza A were inoculated intranasally into 20 and 17 healthy volunteers, resp., on day 0.  Symptom scores and nasal washes were performed twice daily, and daily mucus wts. were collected.  Viral loads in nasal washes were quantified by culture (plaque assay in HEp-2 cells for RSV and by end point diln. in Madin-Darby canine kidney cells for influenza).  Results: After influenza inoculation, influenza viral load and illness markers increased simultaneously until day 2.  Within individual subjects, peak influenza load occurred 0.4 days (95% CI -0.4, 1.3) before peak symptoms.  Influenza viral load and disease declined thereafter.  After RSV inoculation, a longer incubation period occurred prior to viral detection and symptom onset.  RSV load and disease increased together until day 5.  Within individual subjects, peak RSV loads occurred 0.2 days (95% CI -0.7, 1.05) before peak symptoms, after which both illness measures and viral load declined together.  Conclusions: Viral and disease dynamics in exptl. human infections suggest that reducing RSV load, if timed similarly to clin.-effective influenza antivirals, might be expected to have a similar or greater window of opportunity for reducing clin. RSV disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIQJMu3gqtHLVg90H21EOLACvtfcHk0lgfSid14VaqvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjsVentbY%253D&md5=4c7a76da9b4a9c760292886ae3326b84</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.3851%2FIMP2629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3851%252FIMP2629%26sid%3Dliteratum%253Aachs%26aulast%3DBagga%26aufirst%3DB.%26aulast%3DWoods%26aufirst%3DC.%2BW.%26aulast%3DVeldman%26aufirst%3DT.%2BH.%26aulast%3DGilbert%26aufirst%3DA.%26aulast%3DMann%26aufirst%3DA.%26aulast%3DBalaratnam%26aufirst%3DG.%26aulast%3DLambkin-Williams%26aufirst%3DR.%26aulast%3DOxford%26aufirst%3DJ.%2BS.%26aulast%3DMcClain%26aufirst%3DM.%2BT.%26aulast%3DWilkinson%26aufirst%3DT.%26aulast%3DNicholson%26aufirst%3DB.%2BP.%26aulast%3DGinsburg%26aufirst%3DG.%2BS.%26aulast%3DDevincenzo%26aufirst%3DJ.%2BP.%26atitle%3DComparing%2520influenza%2520and%2520rsvviral%2520and%2520disease%2520dynamics%2520in%2520experimentally%2520infected%2520adults%2520predicts%2520clinical%2520effectiveness%2520of%2520rsv%2520antivirals%26jtitle%3DAntiviral%2520Ther.%26date%3D2013%26volume%3D18%26spage%3D785%26epage%3D791%26doi%3D10.3851%2FIMP2629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beigel, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krafft, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ince, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kamary, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, A. C.</span></span> <span> </span><span class="NLM_article-title">Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2019.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1016%2Fj.antiviral.2019.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=30974127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsVCjsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2019&pages=45-67&author=J.+H.+Beigelauthor=H.+H.+Namauthor=P.+L.+Adamsauthor=A.+Krafftauthor=W.+L.+Inceauthor=S.+S.+El-Kamaryauthor=A.+C.+Sims&title=Advances+in+respiratory+virus+therapeutics+-+A+meeting+report+from+the+6th+isirv+Antiviral+Group+conference&doi=10.1016%2Fj.antiviral.2019.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference</span></div><div class="casAuthors">Beigel, John H.; Nam, Hannah H.; Adams, Peter L.; Krafft, Amy; Ince, William L.; El-Kamary, Samer S.; Sims, Amy C.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">45-67</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The International Society for Influenza and other Respiratory Virus Diseases held its 6th Antiviral Group (isirv-AVG) conference in Rockville, Maryland, Nov. 13-15, 2018.  The three-day program was focused on therapeutics towards seasonal and pandemic influenza, respiratory syncytial virus, coronaviruses including MERS-CoV and SARS-CoV, human rhinovirus, and other respiratory viruses.  Updates were presented on several influenza antivirals including baloxavir, CC-42344, VIS410, Ig, immune plasma, MHAA4549A, pimodivir (JNJ-63623872), umifenovir, and HA minibinders; RSV antivirals including presatovir (GS-5806), ziresovir (AK0529), lumicitabine (ALS-008176), JNJ-53718678, JNJ-64417184, and EDP-938; broad spectrum antivirals such as favipiravir, VH244, remdesivir, and EIDD-1931/EIDD-2801; and host directed strategies including nitazoxanide, eritoran, and diltiazem.  Other topics included considerations of novel endpoints such as ordinal scales and patient reported outcomes (PRO), and study design issues, and other regulatory considerations for antiviral drug development.  The aim of this report is to provide a summary of the presentations given at this meeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1dbwsivcYWLVg90H21EOLACvtfcHk0lgfSid14VaqvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsVCjsLw%253D&md5=2c6ccc83bc1a3677ca70191a3bbc4e06</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2019.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2019.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DBeigel%26aufirst%3DJ.%2BH.%26aulast%3DNam%26aufirst%3DH.%2BH.%26aulast%3DAdams%26aufirst%3DP.%2BL.%26aulast%3DKrafft%26aufirst%3DA.%26aulast%3DInce%26aufirst%3DW.%2BL.%26aulast%3DEl-Kamary%26aufirst%3DS.%2BS.%26aulast%3DSims%26aufirst%3DA.%2BC.%26atitle%3DAdvances%2520in%2520respiratory%2520virus%2520therapeutics%2520-%2520A%2520meeting%2520report%2520from%2520the%25206th%2520isirv%2520Antiviral%2520Group%2520conference%26jtitle%3DAntiviral%2520Res.%26date%3D2019%26volume%3D167%26spage%3D45%26epage%3D67%26doi%3D10.1016%2Fj.antiviral.2019.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jardetzky, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, R. A.</span></span> <span> </span><span class="NLM_article-title">Activation of paramyxovirus membrane fusion and virus entry</span>. <i>Curr. Opin. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1016/j.coviro.2014.01.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1016%2Fj.coviro.2014.01.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=24530984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVWhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=24-33&author=T.+S.+Jardetzkyauthor=R.+A.+Lamb&title=Activation+of+paramyxovirus+membrane+fusion+and+virus+entry&doi=10.1016%2Fj.coviro.2014.01.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of paramyxovirus membrane fusion and virus entry</span></div><div class="casAuthors">Jardetzky, Theodore S.; Lamb, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Virology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">24-33</span>CODEN:
                <span class="NLM_cas:coden">COVUAF</span>;
        ISSN:<span class="NLM_cas:issn">1879-6257</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  The paramyxoviruses represent a diverse virus family responsible for a wide range of human and animal diseases.  In contrast to other viruses, such as HIV and influenza virus, which use a single glycoprotein to mediate host receptor binding and virus entry, the paramyxoviruses require two distinct proteins.  One of these is an attachment glycoprotein that binds receptor, while the second is a fusion glycoprotein, which undergoes conformational changes that drive virus-cell membrane fusion and virus entry.  The details of how receptor binding by one protein activates the second to undergo conformational changes have been poorly understood until recently.  Over the past couple of years, structural and functional data have accumulated on representative members of this family, including parainfluenza virus 5, Newcastle disease virus, measles virus, Nipah virus and others, which suggest a mechanistic convergence of activation models.  Here we review the data indicating that paramyxovirus attachment glycoproteins shield activating residues within their N-terminal stalk domains, which are then exposed upon receptor binding, leading to the activation of the fusion protein by a 'provocateur' mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6zT4qEZFqp7Vg90H21EOLACvtfcHk0lgJVFLTJjjMGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVWhtrY%253D&md5=1b7c091182b48ab98d452c6edcaaabef</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.coviro.2014.01.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coviro.2014.01.005%26sid%3Dliteratum%253Aachs%26aulast%3DJardetzky%26aufirst%3DT.%2BS.%26aulast%3DLamb%26aufirst%3DR.%2BA.%26atitle%3DActivation%2520of%2520paramyxovirus%2520membrane%2520fusion%2520and%2520virus%2520entry%26jtitle%3DCurr.%2520Opin.%2520Virol.%26date%3D2014%26volume%3D5%26spage%3D24%26epage%3D33%26doi%3D10.1016%2Fj.coviro.2014.01.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeples, M. E.</span></span> <span> </span><span class="NLM_article-title">Structure and function of rsv surface glycoproteins</span>. <i>Curr. Top. Microbiol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1007/978-3-642-38919-1_4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1007%2F978-3-642-38919-1_4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=24362685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsl2qtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2013&pages=83-104&author=J.+S.+McLellanauthor=W.+C.+Rayauthor=M.+E.+Peeples&title=Structure+and+function+of+rsv+surface+glycoproteins&doi=10.1007%2F978-3-642-38919-1_4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Function of Respiratory Syncytial Virus Surface Glycoproteins</span></div><div class="casAuthors">McLellan, Jason S.; Ray, William C.; Peeples, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Microbiology and Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">Challenges and Opportunities for Respiratory Syncytial Virus Vaccines</span>),
    <span class="NLM_cas:pages">83-104</span>CODEN:
                <span class="NLM_cas:coden">CTMIA3</span>;
        ISSN:<span class="NLM_cas:issn">2196-9965</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">The two major glycoproteins on the surface of the respiratory syncytial virus (RSV) virion, the attachment glycoprotein (G) and the fusion glycoprotein (F), control the initial phases of infection.  G targets the ciliated cells of the airways, and F causes the virion membrane to fuse with the target cell membrane.  The F protein is the major target for antiviral drug development, and both G and F glycoproteins are the antigens targeted by neutralizing antibodies induced by infection.  In this chapter, we review the structure and function of the RSV surface glycoproteins, including recent X-ray crystallog. data of the F glycoprotein in its pre- and postfusion conformations, and discuss how this information informs antigen selection and vaccine development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLjhvYg5ZfUrVg90H21EOLACvtfcHk0lgJVFLTJjjMGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsl2qtrk%253D&md5=4b6fe29a55e09542541be00f7f30ab67</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-38919-1_4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-38919-1_4%26sid%3Dliteratum%253Aachs%26aulast%3DMcLellan%26aufirst%3DJ.%2BS.%26aulast%3DRay%26aufirst%3DW.%2BC.%26aulast%3DPeeples%26aufirst%3DM.%2BE.%26atitle%3DStructure%2520and%2520function%2520of%2520rsv%2520surface%2520glycoproteins%26jtitle%3DCurr.%2520Top.%2520Microbiol.%2520Immunol.%26date%3D2013%26volume%3D372%26spage%3D83%26epage%3D104%26doi%3D10.1007%2F978-3-642-38919-1_4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Battles, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langedijk, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furmanova-Hollenstein, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaiwatpongsakorn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costello, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwanten, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vranckx, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vink, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaensch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonckers, T. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnoult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeples, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, J. S.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of respiratory syncytial virus fusion inhibitors</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1038%2Fnchembio.1982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=26641933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFemsbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=87-93&author=M.+B.+Battlesauthor=J.+P.+Langedijkauthor=P.+Furmanova-Hollensteinauthor=S.+Chaiwatpongsakornauthor=H.+M.+Costelloauthor=L.+Kwantenauthor=L.+Vranckxauthor=P.+Vinkauthor=S.+Jaenschauthor=T.+H.+M.+Jonckersauthor=A.+Koulauthor=E.+Arnoultauthor=M.+E.+Peeplesauthor=D.+Roymansauthor=J.+S.+McLellan&title=Molecular+mechanism+of+respiratory+syncytial+virus+fusion+inhibitors&doi=10.1038%2Fnchembio.1982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of respiratory syncytial virus fusion inhibitors</span></div><div class="casAuthors">Battles, Michael B.; Langedijk, Johannes P.; Furmanova-Hollenstein, Polina; Chaiwatpongsakorn, Supranee; Costello, Heather M.; Kwanten, Leen; Vranckx, Luc; Vink, Paul; Jaensch, Steffen; Jonckers, Tim H. M.; Koul, Anil; Arnoult, Eric; Peeples, Mark E.; Roymans, Dirk; McLellan, Jason S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-93</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) is a leading cause of pneumonia and bronchiolitis in young children and the elderly.  Therapeutic small mols. have been developed that bind the RSV F glycoprotein and inhibit membrane fusion, yet their binding sites and mol. mechanisms of action remain largely unknown.  Here we show that these inhibitors bind to a three-fold-sym. pocket within the central cavity of the metastable prefusion conformation of RSV F.  Inhibitor binding stabilizes this conformation by tethering two regions that must undergo a structural rearrangement to facilitate membrane fusion.  Inhibitor-escape mutations occur in residues that directly contact the inhibitors or are involved in the conformational rearrangements required to accommodate inhibitor binding.  Resistant viruses do not propagate as well as wild-type RSV in vitro, indicating a fitness cost for inhibitor escape.  Collectively, these findings provide new insight into class I viral fusion proteins and should facilitate development of optimal RSV fusion inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowEnQ0xJnoFLVg90H21EOLACvtfcHk0lgJVFLTJjjMGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFemsbrK&md5=c126990069d3f23d95d06693fe90a061</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1982%26sid%3Dliteratum%253Aachs%26aulast%3DBattles%26aufirst%3DM.%2BB.%26aulast%3DLangedijk%26aufirst%3DJ.%2BP.%26aulast%3DFurmanova-Hollenstein%26aufirst%3DP.%26aulast%3DChaiwatpongsakorn%26aufirst%3DS.%26aulast%3DCostello%26aufirst%3DH.%2BM.%26aulast%3DKwanten%26aufirst%3DL.%26aulast%3DVranckx%26aufirst%3DL.%26aulast%3DVink%26aufirst%3DP.%26aulast%3DJaensch%26aufirst%3DS.%26aulast%3DJonckers%26aufirst%3DT.%2BH.%2BM.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DArnoult%26aufirst%3DE.%26aulast%3DPeeples%26aufirst%3DM.%2BE.%26aulast%3DRoymans%26aufirst%3DD.%26aulast%3DMcLellan%26aufirst%3DJ.%2BS.%26atitle%3DMolecular%2520mechanism%2520of%2520respiratory%2520syncytial%2520virus%2520fusion%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26spage%3D87%26epage%3D93%26doi%3D10.1038%2Fnchembio.1982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span> <span> </span><span class="NLM_article-title">Respiratory syncytial virus entry inhibitors targeting the F protein</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.3390/v5010211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.3390%2Fv5010211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=23325327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1yqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=211-225&author=Z.+Sunauthor=Y.+Panauthor=S.+Jiangauthor=L.+Lu&title=Respiratory+syncytial+virus+entry+inhibitors+targeting+the+F+protein&doi=10.3390%2Fv5010211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus entry inhibitors targeting the F protein</span></div><div class="casAuthors">Sun, Zhiwu; Pan, Yanbin; Jiang, Shibo; Lu, Lu</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">211-225</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Human respiratory syncytial virus (RSV) is the main viral cause of respiratory tract infection in infants as well as some elderly and high-risk adults with chronic pulmonary disease and the severely immunocompromised.  So far, no specific anti-R SV therapeutics or effective anti-RSV vaccines have been reported.  Only one humanized monoclonal antibody, Palivizumab, has been approved for use in high-risk infants to prevent RSV infection.  Ribavirin is the only drug licensed for therapy of RSV infection, but its clin. use is limited by its nonspecific anti-RSV activity, toxic effect, and relatively high cost.  Therefore, development of novel effective anti-RSV therapeutics is urgently needed.  The RSV envelope glycoprotein F plays an important role in RSV fusion with, and entry into, the host cell and, consequently, serves as an attractive target for developing RSV entry inhibitors.  This article reviews advances made in studies of the structure and function of the F protein and the development of RSV entry inhibitors targeting it.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPOeEk3HJ9DbVg90H21EOLACvtfcHk0lhKUUa94hfkMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1yqtLY%253D&md5=845867182964c18a459de59ed022f6d1</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.3390%2Fv5010211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv5010211%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DZ.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DL.%26atitle%3DRespiratory%2520syncytial%2520virus%2520entry%2520inhibitors%2520targeting%2520the%2520F%2520protein%26jtitle%3DViruses%26date%3D2013%26volume%3D5%26spage%3D211%26epage%3D225%26doi%3D10.3390%2Fv5010211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of piperazinylquinoline derivatives as novel respiratory syncytial virus fusion inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00234</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00234" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsVamsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=558-562&author=X.+Zhengauthor=L.+Wangauthor=B.+Wangauthor=K.+Miaoauthor=K.+Xiangauthor=S.+Fengauthor=L.+Gaoauthor=H.+C.+Shenauthor=H.+Yun&title=Discovery+of+piperazinylquinoline+derivatives+as+novel+respiratory+syncytial+virus+fusion+inhibitors&doi=10.1021%2Facsmedchemlett.5b00234"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Piperazinylquinoline Derivatives as Novel Respiratory Syncytial Virus Fusion Inhibitors</span></div><div class="casAuthors">Zheng, Xiufang; Wang, Lisha; Wang, Baoxia; Miao, Kun; Xiang, Kunlun; Feng, Song; Gao, Lu; Shen, Hong C.; Yun, Hongying</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">558-562</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of piperazinylquinoline derivs. were discovered as respiratory syncytial virus (RSV) fusion inhibitors by the ligand-based screening approach.  Among 3000 hits, 1-amino-3-[[2-(4-phenyl-1-piperidyl)-4-quinolyl]amino]propan-2-ol was proven to be active against the RSV long (A) strain.  The anti-RSV activity was improved by converting piperidine to benzylcarbonyl substituted piperazine.  The basic side chain was also found to be crucial for anti-RSV activity.  The selected analogs, I and II, demonstrated anti-RSV activities up to EC50 = 0.028 μM and 0.033 μM, resp.  A direct anti-RSV effect was confirmed by a plaque redn. assay and a fusion inhibition assay.  Both I and II showed promising DMPK properties with good oral bioavailability, and could potentially lead to novel therapeutic agents targeting the RSV fusion process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr98VDNFO7a27Vg90H21EOLACvtfcHk0lhKUUa94hfkMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsVamsb8%253D&md5=086def8b4fdde5bad248aa1f65106c9e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00234%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DMiao%26aufirst%3DK.%26aulast%3DXiang%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DYun%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520piperazinylquinoline%2520derivatives%2520as%2520novel%2520respiratory%2520syncytial%2520virus%2520fusion%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D558%26epage%3D562%26doi%3D10.1021%2Facsmedchemlett.5b00234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bond, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Draffan, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luttick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nearn, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanford, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayes, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, S. P.</span></span> <span> </span><span class="NLM_article-title">1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (rsv) fusion inhibitors. part 2: identification of BTA9881 as a preclinical candidate</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">976</span>– <span class="NLM_lpage">981</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.11.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1016%2Fj.bmcl.2014.11.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=25595685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGis7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=976-981&author=S.+Bondauthor=A.+G.+Draffanauthor=J.+E.+Fennerauthor=J.+Lambertauthor=C.+Y.+Limauthor=B.+Linauthor=A.+Luttickauthor=J.+P.+Mitchellauthor=C.+J.+Mortonauthor=R.+H.+Nearnauthor=V.+Sanfordauthor=K.+H.+Andersonauthor=P.+A.+Mayesauthor=S.+P.+Tucker&title=1%2C2%2C3%2C9b-Tetrahydro-5H-imidazo%5B2%2C1-a%5Disoindol-5-ones+as+a+new+class+of+respiratory+syncytial+virus+%28rsv%29+fusion+inhibitors.+part+2%3A+identification+of+BTA9881+as+a+preclinical+candidate&doi=10.1016%2Fj.bmcl.2014.11.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: Identification of BTA9881 as a preclinical candidate</span></div><div class="casAuthors">Bond, Silas; Draffan, Alistair G.; Fenner, Jennifer E.; Lambert, John; Lim, Chin Yu; Lin, Bo; Luttick, Angela; Mitchell, Jeffrey P.; Morton, Craig J.; Nearn, Roland H.; Sanford, Vanessa; Anderson, Kelly H.; Mayes, Penelope A.; Tucker, Simon P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">976-981</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections in infants, young children and adults. 1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones with general structure 1 were previously identified as promising inhibitors of RSV targeting the fusion glycoprotein.  In particular, the introduction of a nitrogen at the 8-position of the tricyclic core yielded lead compds.  Extensive exploration of the R2 group established that certain heterocyclic amides conferred potent RSV A&B activity and a good balance of physicochem. and pharmacokinetic properties.  The antiviral activity was found to reside in a single enantiomer and BTA9881 (I) was identified as a candidate for preclin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozl2YGFANzObVg90H21EOLACvtfcHk0lhKUUa94hfkMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGis7rN&md5=6a0df66bad0f8c19627d2cf31bccca61</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.11.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.11.024%26sid%3Dliteratum%253Aachs%26aulast%3DBond%26aufirst%3DS.%26aulast%3DDraffan%26aufirst%3DA.%2BG.%26aulast%3DFenner%26aufirst%3DJ.%2BE.%26aulast%3DLambert%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DC.%2BY.%26aulast%3DLin%26aufirst%3DB.%26aulast%3DLuttick%26aufirst%3DA.%26aulast%3DMitchell%26aufirst%3DJ.%2BP.%26aulast%3DMorton%26aufirst%3DC.%2BJ.%26aulast%3DNearn%26aufirst%3DR.%2BH.%26aulast%3DSanford%26aufirst%3DV.%26aulast%3DAnderson%26aufirst%3DK.%2BH.%26aulast%3DMayes%26aufirst%3DP.%2BA.%26aulast%3DTucker%26aufirst%3DS.%2BP.%26atitle%3D1%252C2%252C3%252C9b-Tetrahydro-5H-imidazo%255B2%252C1-a%255Disoindol-5-ones%2520as%2520a%2520new%2520class%2520of%2520respiratory%2520syncytial%2520virus%2520%2528rsv%2529%2520fusion%2520inhibitors.%2520part%25202%253A%2520identification%2520of%2520BTA9881%2520as%2520a%2520preclinical%2520candidate%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D976%26epage%3D981%26doi%3D10.1016%2Fj.bmcl.2014.11.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">359</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00008</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVWgtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=359-362&author=S.+Fengauthor=D.+Hongauthor=B.+Wangauthor=X.+Zhengauthor=K.+Miaoauthor=L.+Wangauthor=H.+Yunauthor=L.+Gaoauthor=S.+Zhaoauthor=H.+C.+Shen&title=Discovery+of+imidazopyridine+derivatives+as+highly+potent+respiratory+syncytial+virus+fusion+inhibitors&doi=10.1021%2Facsmedchemlett.5b00008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Imidazopyridine Derivatives as Highly Potent Respiratory Syncytial Virus Fusion Inhibitors</span></div><div class="casAuthors">Feng, Song; Hong, Di; Wang, Baoxia; Zheng, Xiufang; Miao, Kun; Wang, Lisha; Yun, Hongying; Gao, Lu; Zhao, Shuhai; Shen, Hong C.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">359-362</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of imidazolepyridine derivs. were designed and synthesized according to the established docking studies.  The imidazopyridine derivs. were found to have good potency and phys.-chem. properties.  Several highly potent compds. such as I (R = CONH2, SO2Me, SO2Et) were identified with single nanomolar activities.  The most potent compd. I (R = SO2Et) showed an IC50 of 3 nM, lower microsome clearance and no CYP inhibition.  The profile of I (R = SO2Et) appeared to be superior to BMS433771, and supported further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI1B0vZ3s1JbVg90H21EOLACvtfcHk0ljeklSzJnBqWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVWgtL8%253D&md5=308e4626c4162c04d89ed4d9afc7e3b3</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00008%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DMiao%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DH.%2BC.%26atitle%3DDiscovery%2520of%2520imidazopyridine%2520derivatives%2520as%2520highly%2520potent%2520respiratory%2520syncytial%2520virus%2520fusion%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D359%26epage%3D362%26doi%3D10.1021%2Facsmedchemlett.5b00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonfanti, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doublet, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacrampe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queguiner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnoult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gevers, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willebrords, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmerman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuyts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigerinck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span> <span> </span><span class="NLM_article-title">Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">4572</span>– <span class="NLM_lpage">4584</span>, <span class="refDoi"> DOI: 10.1021/jm070143x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070143x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFCisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=4572-4584&author=J.-F.+Bonfantiauthor=F.+Doubletauthor=J.+Fortinauthor=J.+Lacrampeauthor=J.+Guillemontauthor=P.+Mullerauthor=L.+Queguinerauthor=E.+Arnoultauthor=T.+Geversauthor=P.+Janssensauthor=H.+Szelauthor=R.+Willebrordsauthor=P.+Timmermanauthor=K.+Wuytsauthor=F.+Janssensauthor=C.+Sommenauthor=P.+Wigerinckauthor=K.+Andries&title=Selection+of+a+respiratory+syncytial+virus+fusion+inhibitor+clinical+candidate%2C+part+1%3A+improving+the+pharmacokinetic+profile+using+the+structure-property+relationship&doi=10.1021%2Fjm070143x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate. Improving the Pharmacokinetic Profile Using the Structure-Property Relationship</span></div><div class="casAuthors">Bonfanti, Jean-Francois; Doublet, Frederic; Fortin, Jerome; Lacrampe, Jean; Guillemont, Jerome; Muller, Philippe; Queguiner, Laurence; Arnoult, Eric; Gevers, Tom; Janssens, Peggy; Szel, Heidi; Willebrords, Rudy; Timmerman, Philip; Wuyts, Koen; Janssens, Frans; Sommen, Cois; Wigerinck, Piet; Andries, Koen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4572-4584</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors previously reported the discovery of substituted benzimidazole fusion inhibitors with nanomolar activity against respiratory syncytial virus.  A lead compd. of the series was selected for preclin. evaluation.  This drug candidate, JNJ-2408068 (formerly R170591, 1), showed long tissue retention times in several species (rat, dog, and monkey), creating cause for concern.  The authors herein describe the optimization program to develop compds. with improved properties in terms of tissue retention.  The authors have identified the aminoethyl-piperidine moiety as being responsible for the long tissue retention time of 1.  The authors have investigated the replacement or the modification of this group, and suggest that the pKa of this part of the mols. influences both the antiviral activity and the pharmacokinetic profile.  The authors were able to identify new respiratory syncytial virus inhibitors with shorter half-lives in lung tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx3B5eDxxv-rVg90H21EOLACvtfcHk0ljeklSzJnBqWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFCisr8%253D&md5=9f1f68c5c62f0179098fdebe25612a1a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm070143x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070143x%26sid%3Dliteratum%253Aachs%26aulast%3DBonfanti%26aufirst%3DJ.-F.%26aulast%3DDoublet%26aufirst%3DF.%26aulast%3DFortin%26aufirst%3DJ.%26aulast%3DLacrampe%26aufirst%3DJ.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DMuller%26aufirst%3DP.%26aulast%3DQueguiner%26aufirst%3DL.%26aulast%3DArnoult%26aufirst%3DE.%26aulast%3DGevers%26aufirst%3DT.%26aulast%3DJanssens%26aufirst%3DP.%26aulast%3DSzel%26aufirst%3DH.%26aulast%3DWillebrords%26aufirst%3DR.%26aulast%3DTimmerman%26aufirst%3DP.%26aulast%3DWuyts%26aufirst%3DK.%26aulast%3DJanssens%26aufirst%3DF.%26aulast%3DSommen%26aufirst%3DC.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3DAndries%26aufirst%3DK.%26atitle%3DSelection%2520of%2520a%2520respiratory%2520syncytial%2520virus%2520fusion%2520inhibitor%2520clinical%2520candidate%252C%2520part%25201%253A%2520improving%2520the%2520pharmacokinetic%2520profile%2520using%2520the%2520structure-property%2520relationship%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D4572%26epage%3D4584%26doi%3D10.1021%2Fjm070143x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3,3′-spiro[azetidine]-2-oxo-indoline derivatives as fusion inhibitors for treatment of rsv infection</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00418</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00418" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVOrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=94-97&author=W.+Shiauthor=Z.+Jiangauthor=H.+Heauthor=F.+Xiaoauthor=F.+Linauthor=Y.+Sunauthor=L.+Houauthor=L.+Shenauthor=L.+Hanauthor=M.+Zengauthor=K.+Laiauthor=Z.+Guauthor=X.+Chenauthor=T.+Zhaoauthor=L.+Guoauthor=C.+Yangauthor=J.+Liauthor=S.+Chen&title=Discovery+of+3%2C3%E2%80%B2-spiro%5Bazetidine%5D-2-oxo-indoline+derivatives+as+fusion+inhibitors+for+treatment+of+rsv+infection&doi=10.1021%2Facsmedchemlett.7b00418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3,3'-Spiro[Azetidine]-2-oxo-indoline Derivatives as Fusion Inhibitors for Treatment of RSV Infection</span></div><div class="casAuthors">Shi, Weihua; Jiang, Zhigan; He, Haiying; Xiao, Fubiao; Lin, Fusen; Sun, Ya; Hou, Lijuan; Shen, Liang; Han, Lixia; Zeng, Minggao; Lai, Kunmin; Gu, Zhengxian; Chen, Xinsheng; Zhao, Tao; Guo, Li; Yang, Chun; Li, Jian; Chen, Shuhui</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">94-97</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new series of 3,3'-spirocyclic 2-oxo-indoline derivs. was synthesized and evaluated against respiratory syncytial virus (RSV) in a cell-based assay and animal model.  Extensive structure-activity relationship study led to a lead compd. 14h, which exhibited excellent in vitro potency with an EC50 value of 0.8 nM and demonstrated 71% oral bioavailability in mice.  In a mouse challenge model of RVS infection, 14h demonstrated superior efficacy with a 3.9log RSV virus load redn. in the lung following an oral dose of 50 mg/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruT_jDJyP0T7Vg90H21EOLACvtfcHk0lgB01kW2kJOSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVOrsw%253D%253D&md5=86701de4a59fb764fe1eea6a79d1cac4</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00418%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DW.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DLin%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DZeng%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DK.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26atitle%3DDiscovery%2520of%25203%252C3%25E2%2580%25B2-spiro%255Bazetidine%255D-2-oxo-indoline%2520derivatives%2520as%2520fusion%2520inhibitors%2520for%2520treatment%2520of%2520rsv%2520infection%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D94%26epage%3D97%26doi%3D10.1021%2Facsmedchemlett.7b00418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ispas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbeeck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders-Beer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouan, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonfanti, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanstockem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verloes, R.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of TMC353121, a respiratory syncytial virus (rsv) fusion inhibitor, in a non-human primate model</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">5</span>), <span class="NLM_elocation-id">e0126959</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0126959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1371%2Fjournal.pone.0126959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=26010881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOqurzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&issue=5&author=G.+Ispasauthor=A.+Koulauthor=J.+Verbeeckauthor=J.+Sheehanauthor=B.+Sanders-Beerauthor=D.+Roymansauthor=K.+Andriesauthor=M.-C.+Rouanauthor=S.+De+Jongheauthor=J.-F.+Bonfantiauthor=M.+Vanstockemauthor=K.+Simmenauthor=R.+Verloes&title=Antiviral+activity+of+TMC353121%2C+a+respiratory+syncytial+virus+%28rsv%29+fusion+inhibitor%2C+in+a+non-human+primate+model&doi=10.1371%2Fjournal.pone.0126959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of TMC353121, a respiratory syncytial virus (RSV) fusion inhibitor, in a non-human primate model</span></div><div class="casAuthors">Ispas, Gabriela; Koul, Anil; Verbeeck, Johan; Sheehan, Jennifer; Sanders-Beer, Brigitte; Roymans, Dirk; Andries, Koen; Rouan, Marie-Claude; De Jonghe, Sandra; Bonfanti, Jean-Francois; Vanstockem, Marc; Simmen, Kenneth; Verloes, Rene</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e0126959/1-e0126959/16</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background The study assessed the antiviral activity of TMC353121, a respiratory syncytial virus (RSV) fusion inhibitor, in a preclin. non-human primate challenge model with a viral shedding pattern similar to that seen in humans, following continuous infusion (CI).  Methods African green monkeys were administered TMC353121 through CI, in 2 studies.  Study 1 evaluated the prophylactic and therapeutic efficacy of TMC353121 at a target plasma level of 50 ng/mL (n =15; Group 1: prophylactic arm [P×50], 0.033 mg/mL TMC353121, flow rate 2.5 mL/kg/h from 24 h pre-infection to 10 days; Group 2: therapeutic arm [T×50], 0.033mg/mL TMC353121 from 24 h postinfection to 8 days; Group 3: control [Vh1] vehicle, 24 h post-infection to 8 days).  Study 2 evaluated the prophylactic efficacy of TMC353121 at target plasma levels of 5 and 500 ng/mL (n = 12; Group 1: prophylactic 5 arm [P×5], 0.0033 mg/mL TMC353121, flow rate 2.5 mL/kg/h from 72 h pre-infection to 14 days; Group 2: prophylactic 500 arm [P×500], 0.33 mg/mL TMC353121; Group 3:control [Vh2] vehicle, 14 days).  Bronchoalveolar lavage fluid and plasma were collected every 2 days from day 1 postinfection for pharmacokinetics and safety anal.  Findings TMC353121 showed a dose-dependent antiviral activity, varying from 1log10 redn. of peak viral load to complete inhibition of the RSV replication.  Complete inhibition of RSV shedding was obsd. for a relatively low plasma exposure (0.39 μg/mL) and was assocd. with a dose-dependent redn. in INFγ, IL6 and MIP1α.  TMC353121 administered as CI for 16 days was generally well-tolerated.  Conclusion TMC353121 exerted dose-dependent antiviral effect ranging from full inhibition to absence of antiviral activity, in a preclin. model highly permissive for RSV replication.  No new safety findings emerged from the study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_bXyz9PIFS7Vg90H21EOLACvtfcHk0lgB01kW2kJOSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOqurzP&md5=94a5819dad3fa1b836ad2c08f667345b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0126959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0126959%26sid%3Dliteratum%253Aachs%26aulast%3DIspas%26aufirst%3DG.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DVerbeeck%26aufirst%3DJ.%26aulast%3DSheehan%26aufirst%3DJ.%26aulast%3DSanders-Beer%26aufirst%3DB.%26aulast%3DRoymans%26aufirst%3DD.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DRouan%26aufirst%3DM.-C.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26aulast%3DBonfanti%26aufirst%3DJ.-F.%26aulast%3DVanstockem%26aufirst%3DM.%26aulast%3DSimmen%26aufirst%3DK.%26aulast%3DVerloes%26aufirst%3DR.%26atitle%3DAntiviral%2520activity%2520of%2520TMC353121%252C%2520a%2520respiratory%2520syncytial%2520virus%2520%2528rsv%2529%2520fusion%2520inhibitor%252C%2520in%2520a%2520non-human%2520primate%2520model%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26issue%3D5%26doi%3D10.1371%2Fjournal.pone.0126959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civiello, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combrink, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulgeze, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venables, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J. J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalterio, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadjura, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dando, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianci, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovesi, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">901</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.11.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1016%2Fj.bmcl.2006.11.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=17169560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht12rtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=895-901&author=K.-L.+Yuauthor=N.+Sinauthor=R.+L.+Civielloauthor=X.+A.+Wangauthor=K.+D.+Combrinkauthor=H.+B.+Gulgezeauthor=B.+L.+Venablesauthor=J.+J.+K.+Wrightauthor=R.+A.+Dalterioauthor=L.+Zadjuraauthor=A.+Marinoauthor=S.+Dandoauthor=C.+D%E2%80%99Arienzoauthor=K.+F.+Kadowauthor=C.+W.+Cianciauthor=Z.+Liauthor=J.+Clarkeauthor=E.+V.+Genovesiauthor=I.+Medinaauthor=L.+Lambauthor=R.+J.+Colonnoauthor=Z.+Yangauthor=M.+Krystalauthor=N.+A.+Meanwell&title=Respiratory+syncytial+virus+fusion+inhibitors.+Part+4%3A+optimization+for+oral+bioavailability&doi=10.1016%2Fj.bmcl.2006.11.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability</span></div><div class="casAuthors">Yu, Kuo-Long; Sin, Ny; Civiello, Rita L.; Wang, X. Alan; Combrink, Keith D.; Gulgeze, H. Belgin; Venables, Brian L.; Wright, J. J. Kim; Dalterio, Richard A.; Zadjura, Lisa; Marino, Anthony; Dando, Sandra; D'Arienzo, Celia; Kadow, Kathleen F.; Cianci, Christopher W.; Li, Zhufang; Clarke, Junius; Genovesi, Eugene V.; Medina, Ivette; Lamb, Lucinda; Colonno, Richard J.; Yang, Zheng; Krystal, Mark; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">895-901</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A series of benzimidazole-based inhibitors of respiratory syncytial virus (RSV) fusion were optimized for antiviral potency, membrane permeability and metabolic stability in human liver microsomes.  1-Cyclopropyl-1,3-dihydro-3-[[1-(4-hydroxybutyl)-1H-benzimidazol-2-yl]methyl]-2H-imidazo[4,5-c]pyridin-2-one (I, BMS-433771) was identified as a potent RSV inhibitor demonstrating good bioavailability in the mouse, rat, dog and cynomolgus monkey that demonstrated antiviral activity in the BALB/c and cotton rat models of infection following oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwTTCqYL_6iLVg90H21EOLACvtfcHk0lgB01kW2kJOSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht12rtLc%253D&md5=1df6d784bda1cabee0b57b799f1f165e</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.11.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.11.063%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DK.-L.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DCiviello%26aufirst%3DR.%2BL.%26aulast%3DWang%26aufirst%3DX.%2BA.%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DGulgeze%26aufirst%3DH.%2BB.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%2BK.%26aulast%3DDalterio%26aufirst%3DR.%2BA.%26aulast%3DZadjura%26aufirst%3DL.%26aulast%3DMarino%26aufirst%3DA.%26aulast%3DDando%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DKadow%26aufirst%3DK.%2BF.%26aulast%3DCianci%26aufirst%3DC.%2BW.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DClarke%26aufirst%3DJ.%26aulast%3DGenovesi%26aufirst%3DE.%2BV.%26aulast%3DMedina%26aufirst%3DI.%26aulast%3DLamb%26aufirst%3DL.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DRespiratory%2520syncytial%2520virus%2520fusion%2520inhibitors.%2520Part%25204%253A%2520optimization%2520for%2520oral%2520bioavailability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D895%26epage%3D901%26doi%3D10.1016%2Fj.bmcl.2006.11.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cianci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovesi, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadjura, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combrink, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span> <span> </span><span class="NLM_article-title">Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2448</span>– <span class="NLM_lpage">2454</span>, <span class="refDoi"> DOI: 10.1128/AAC.48.7.2448-2454.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1128%2FAAC.48.7.2448-2454.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=15215093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsFWmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2004&pages=2448-2454&issue=7&author=C.+Cianciauthor=E.+V.+Genovesiauthor=L.+Lambauthor=I.+Medinaauthor=Z.+Yangauthor=L.+Zadjuraauthor=H.+Yangauthor=C.+D%E2%80%99Arienzoauthor=N.+Sinauthor=K.-L.+Yuauthor=K.+Combrinkauthor=Z.+Liauthor=R.+Colonnoauthor=N.+Meanwellauthor=J.+Clarkauthor=M.+Krystal&title=Oral+efficacy+of+a+respiratory+syncytial+virus+inhibitor+in+rodent+models+of+infection&doi=10.1128%2FAAC.48.7.2448-2454.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection</span></div><div class="casAuthors">Cianci, Christopher; Genovesi, Eugene V.; Lamb, Lucinda; Medina, Ivette; Yang, Zheng; Zadjura, Lisa; Yang, Hyekyung; D'Arienzo, Celia; Sin, Ny; Yu, Kuo-Long; Combrink, Keith; Li, Zhufang; Colonno, Richard; Meanwell, Nicholas; Clark, Junius; Krystal, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2448-2454</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">BMS-433771 is a potent inhibitor of respiratory syncytial virus (RSV) replication in vitro.  Mechanism of action studies have demonstrated that BMS-433771 halts virus entry through inhibition of F protein-mediated membrane fusion.  BMS-433771 also exhibited in vivo efficacy following oral administration in a mouse model of RSV infection.  In this report, the in vivo efficacy of BMS-433771 against RSV was further examd. in the BALB/c mouse and cotton rat host models of infection.  By using the Long strain of RSV, prophylactic efficacy via oral dosing was obsd. in both animal models.  A single oral dose, administered 1 h prior to intranasal RSV inoculation, was as effective against infection as a 4-day b.i.d. dosing regimen in which the first oral dose was given 1 h prior to virus inoculation.  Results of dose titrn. expts. suggested that RSV infection was more sensitive to inhibition by BMS-433771 treatment in the BALB/c mouse host than in the cotton rat.  This was reflected by the pharmacokinetic and pharmacodynamic anal. of the efficacy data, where the area under the concn.-time curve required to achieve 50% of the max. response was ∼7.5-fold less for mice than for cotton rats.  Inhibition of RSV by BMS-433771 in the mouse is the result of F1-mediated inhibition, as shown by the fact that a virus selected for resistance to BMS-433771 in vitro and contg. a single amino acid change in the F1 region was also refractory to treatment in the mouse host.  BMS-433771 efficacy against RSV infection was also demonstrated for mice that were chem. immunosuppressed by cyclophosphamide treatment, indicating that compd. inhibition of the virus did not require an active host immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBKvJm5WDYz7Vg90H21EOLACvtfcHk0lheE06bGyEHPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsFWmtrY%253D&md5=c57e810ebd46f01c6dd2da43c45f9248</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1128%2FAAC.48.7.2448-2454.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.48.7.2448-2454.2004%26sid%3Dliteratum%253Aachs%26aulast%3DCianci%26aufirst%3DC.%26aulast%3DGenovesi%26aufirst%3DE.%2BV.%26aulast%3DLamb%26aufirst%3DL.%26aulast%3DMedina%26aufirst%3DI.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZadjura%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DK.-L.%26aulast%3DCombrink%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DMeanwell%26aufirst%3DN.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DOral%2520efficacy%2520of%2520a%2520respiratory%2520syncytial%2520virus%2520inhibitor%2520in%2520rodent%2520models%2520of%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2004%26volume%3D48%26issue%3D7%26spage%3D2448%26epage%3D2454%26doi%3D10.1128%2FAAC.48.7.2448-2454.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="note"><p class="first last">Internal assessment of PK parameters of BMS-433331 (<b>4</b>) in fed male SD rats after iv and oral administration at 2 and 10 mg/kg, respectively, using HP-β-CD 20% as vehicle: plasma Cl = 5.4 L h<sup>–1</sup> kg<sup>–1</sup>, Vd<sub>ss</sub> = 1.0 L/kg, <i>t</i><sub>1/2</sub> = 0.16 h, <i>C</i><sub>max</sub> = 53 ng/mL, AUC<sub>0–inf</sub> = 224 ng·h/mL, <i>F</i> = 8.4%, <i>L</i>/<i>P</i> = 0.22.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanzlik, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishore, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tullman, R.</span></span> <span> </span><span class="NLM_article-title">Cyclopropylamines as suicide substrates for cytochromes P-450</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">759</span>– <span class="NLM_lpage">761</span>, <span class="refDoi"> DOI: 10.1021/jm00193a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00193a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADyaE1MXksV2gsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1979&pages=759-761&issue=7&author=R.+P.+Hanzlikauthor=V.+Kishoreauthor=R.+Tullman&title=Cyclopropylamines+as+suicide+substrates+for+cytochromes+P-450&doi=10.1021%2Fjm00193a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclopropylamines as suicide substrates for cytochromes P-450</span></div><div class="casAuthors">Hanzlik, Robert P.; Kishore, Vimal; Tullman, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">759-61</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Evaluation of I (R = CHMe2 or cyclopropyl; X = H, Br, Cl, Me, or MeO) as suicide substrates for cytochrome P 450  [9035-51-2] showed that I with the cyclopropyl substituent were better inhibitors of rat liver microsomal aminopyrine demethylase  [9037-69-8] than those with CHMe2 .  The kinetics of the inhibition by N-cyclopropylbenzylamine  [13324-66-8] was a 1st order reaction with a 1/2 life of 6 min.  The reaction required NADPH and was inhibited by CO but not by glutathione or semicarbazide.  Apparently, I (R = cyclopropyl) are true suicide substrates for cytochrome P 450.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdVsppD1S9JLVg90H21EOLACvtfcHk0lheE06bGyEHPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXksV2gsbs%253D&md5=6d5dd3b1c9dae9d0ab8858babb1770dc</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm00193a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00193a002%26sid%3Dliteratum%253Aachs%26aulast%3DHanzlik%26aufirst%3DR.%2BP.%26aulast%3DKishore%26aufirst%3DV.%26aulast%3DTullman%26aufirst%3DR.%26atitle%3DCyclopropylamines%2520as%2520suicide%2520substrates%2520for%2520cytochromes%2520P-450%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1979%26volume%3D22%26issue%3D7%26spage%3D759%26epage%3D761%26doi%3D10.1021%2Fjm00193a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meals, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fok-Seang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntjens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariën, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remmerie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verloes, R.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of oral JNJ-53718678 in healthy adult volunteers challenged with respiratory syncytial virus: a placebo-controlled study</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>218</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">748</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1093/infdis/jiy227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1093%2Finfdis%2Fjiy227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=29684148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlCnt77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=218&publication_year=2018&pages=748-756&issue=5&author=M.+Stevensauthor=S.+Ruschauthor=J.+DeVincenzoauthor=Y.+I.+Kimauthor=L.+Harrisonauthor=E.+A.+Mealsauthor=A.+Boyersauthor=J.+Fok-Seangauthor=D.+Huntjensauthor=N.+Lounisauthor=K.+Mari%C3%ABnauthor=B.+Remmerieauthor=D.+Roymansauthor=A.+Koulauthor=R.+Verloes&title=Antiviral+activity+of+oral+JNJ-53718678+in+healthy+adult+volunteers+challenged+with+respiratory+syncytial+virus%3A+a+placebo-controlled+study&doi=10.1093%2Finfdis%2Fjiy227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of oral JNJ-53718678 in healthy adult volunteers challenged with respiratory syncytial virus: a placebo-controlled study</span></div><div class="casAuthors">Stevens, Marita; Rusch, Sarah; DeVincenzo, John; Kim, Young-In; Harrison, Lisa; Meals, Elizabeth A.; Boyers, Alison; Fok-Seang, Juin; Huntjens, Dymphy; Lounis, Nacer; Marien, Kris; Remmerie, Bart; Roymans, Dirk; Koul, Anil; Verloes, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">218</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">748-756</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">1537-6613</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background.  Respiratory syncytial virus (RSV) disease has no effective treatment.  JNJ-53718678 is a fusion inhibitor with selective activity against RSV.  After confirmation of RSV infection or 5 days after inoculation with RSV, participants (n = 69) were randomized to JNJ-53718678 75 mg (n = 15), 200 mg (n = 17), 500 mg (n = 18), or placebo (n = 17) orally once daily for 7 days.  Antiviral effects were evaluated by assessing RSV RNA viral load (VL) area under the curve (AUC) from baseline (before the first dose) until discharge, time-to-peak VL, duration of viral shedding, clin. symptoms, and quantity of nasal secretions.  Mean VL AUC was lower for individuals treated with different doses of JNJ-53718678 vs. placebo (203.8-253.8 vs 432.8 log10 PFUe.hour/mL).  Also, mean peak VL, time to peak VL, duration of viral shedding, mean overall symptom score, and nasal secretion wt. were lower in each JNJ-53718678-treated group vs. placebo.  No clear exposure-response relationship was obsd.  Three participants discontinued due to treatment-emergent adverse events of grade 2 and 1 ECG change (JNJ-53718678 75 mg and 200 mg, resp.) and grade 2 urticaria (placebo).  Conclusions.  JNJ-53718678 at all 3 doses substantially reduced VL and clin. disease severity, thus establishing clin. proof of concept and the compd.'s potential as a novel RSV treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9lct-FnOIM7Vg90H21EOLACvtfcHk0lheE06bGyEHPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlCnt77J&md5=a7da58b73e29e9c06537292a14dc3408</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjiy227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjiy227%26sid%3Dliteratum%253Aachs%26aulast%3DStevens%26aufirst%3DM.%26aulast%3DRusch%26aufirst%3DS.%26aulast%3DDeVincenzo%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DY.%2BI.%26aulast%3DHarrison%26aufirst%3DL.%26aulast%3DMeals%26aufirst%3DE.%2BA.%26aulast%3DBoyers%26aufirst%3DA.%26aulast%3DFok-Seang%26aufirst%3DJ.%26aulast%3DHuntjens%26aufirst%3DD.%26aulast%3DLounis%26aufirst%3DN.%26aulast%3DMari%25C3%25ABn%26aufirst%3DK.%26aulast%3DRemmerie%26aufirst%3DB.%26aulast%3DRoymans%26aufirst%3DD.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DVerloes%26aufirst%3DR.%26atitle%3DAntiviral%2520activity%2520of%2520oral%2520JNJ-53718678%2520in%2520healthy%2520adult%2520volunteers%2520challenged%2520with%2520respiratory%2520syncytial%2520virus%253A%2520a%2520placebo-controlled%2520study%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2018%26volume%3D218%26issue%3D5%26spage%3D748%26epage%3D756%26doi%3D10.1093%2Finfdis%2Fjiy227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit32b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Israel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fok-Seang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntjens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariën, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verloes, R.</span></span> <span> </span><span class="NLM_article-title">Effect of oral JNJ-53718678 (JNJ-678) on disease severity in healthy adult volunteers experimentally inoculated with live respiratory syncytial virus (rsv): a placebo-controlled challenge study</span>. <i>Open Forum Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">Issue suppl_1</span>),  <span class="NLM_fpage">650</span>, <span class="refDoi"> DOI: 10.1093/ofid/ofw172.513</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1093%2Fofid%2Fofw172.513" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=650&issue=Issue+suppl_1&author=S.+Israelauthor=S.+Ruschauthor=J.+DeVincenzoauthor=A.+Boyersauthor=J.+Fok-Seangauthor=D.+Huntjensauthor=N.+Lounisauthor=K.+Mari%C3%ABnauthor=M.+Stevensauthor=R.+Verloes&title=Effect+of+oral+JNJ-53718678+%28JNJ-678%29+on+disease+severity+in+healthy+adult+volunteers+experimentally+inoculated+with+live+respiratory+syncytial+virus+%28rsv%29%3A+a+placebo-controlled+challenge+study&doi=10.1093%2Fofid%2Fofw172.513"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1093%2Fofid%2Fofw172.513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fofid%252Fofw172.513%26sid%3Dliteratum%253Aachs%26aulast%3DIsrael%26aufirst%3DS.%26aulast%3DRusch%26aufirst%3DS.%26aulast%3DDeVincenzo%26aufirst%3DJ.%26aulast%3DBoyers%26aufirst%3DA.%26aulast%3DFok-Seang%26aufirst%3DJ.%26aulast%3DHuntjens%26aufirst%3DD.%26aulast%3DLounis%26aufirst%3DN.%26aulast%3DMari%25C3%25ABn%26aufirst%3DK.%26aulast%3DStevens%26aufirst%3DM.%26aulast%3DVerloes%26aufirst%3DR.%26atitle%3DEffect%2520of%2520oral%2520JNJ-53718678%2520%2528JNJ-678%2529%2520on%2520disease%2520severity%2520in%2520healthy%2520adult%2520volunteers%2520experimentally%2520inoculated%2520with%2520live%2520respiratory%2520syncytial%2520virus%2520%2528rsv%2529%253A%2520a%2520placebo-controlled%2520challenge%2520study%26jtitle%3DOpen%2520Forum%2520Infect.%2520Dis.%26date%3D2016%26volume%3D3%26issue%3DIssue%2520suppl_1%26spage%3D650%26doi%3D10.1093%2Fofid%2Fofw172.513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwanten, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clerck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span></span> <span> </span><span class="NLM_article-title">A fluorescence-based high-throughput antiviral compound screening assay against respiratory syncytial virus</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1030</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">344</span>, <span class="refDoi"> DOI: 10.1007/978-1-62703-484-5_26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1007%2F978-1-62703-484-5_26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=23821280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVSnu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1030&publication_year=2013&pages=337-344&author=L.+Kwantenauthor=B.+De+Clerckauthor=D.+Roymans&title=A+fluorescence-based+high-throughput+antiviral+compound+screening+assay+against+respiratory+syncytial+virus&doi=10.1007%2F978-1-62703-484-5_26"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A fluorescence-based high-throughput antiviral compound screening assay against respiratory syncytial virus</span></div><div class="casAuthors">Kwanten, Leen; De Clerck, Ben; Roymans, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1030</span>
        (<span class="NLM_cas:issue">Antiviral Methods and Protocols</span>),
    <span class="NLM_cas:pages">337-344</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) is a common virus that infects people of all ages and causes cold-like symptoms in most cases.  However, more serious infections occur in the younger and older extremities of the population causing severe lung infections such as bronchiolitis and pneumonia.  The current std. of care is mostly limited to supportive treatment, although prophylaxis by passive immunization with the humanized monoclonal antibody palivizumab and therapeutic intervention with aerosolized ribavirin are available.  Unfortunately, administration of palivizumab is restricted to at-risk infants up to the age of two and is assocd. with high cost, while ribavirin treatment is hindered by questionable efficacy and safety reasons.  Consequently, the development of novel specific RSV antiviral drugs is needed to help decrease RSV-related morbidity and mortality.  We describe here a fluorescence-based high-throughput screening assay to discover RSV inhibitors which is based on the infection of HeLa cells with a recombinant RSV strain that contains an enhanced green fluorescent protein coding sequence in its viral genome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFiCkq9AUY2LVg90H21EOLACvtfcHk0lgRaLg_PX_GHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVSnu7%252FM&md5=22eed7774eca0e9c93bdcf14c660d560</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2F978-1-62703-484-5_26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-62703-484-5_26%26sid%3Dliteratum%253Aachs%26aulast%3DKwanten%26aufirst%3DL.%26aulast%3DDe%2BClerck%26aufirst%3DB.%26aulast%3DRoymans%26aufirst%3DD.%26atitle%3DA%2520fluorescence-based%2520high-throughput%2520antiviral%2520compound%2520screening%2520assay%2520against%2520respiratory%2520syncytial%2520virus%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2013%26volume%3D1030%26spage%3D337%26epage%3D344%26doi%3D10.1007%2F978-1-62703-484-5_26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooymans, L. P.</span>; <span class="NLM_string-name">Hu, L.</span>; <span class="NLM_string-name">Jonckers, T. H. M.</span>; <span class="NLM_string-name">Raboisson, P. J.-M. B.</span>; <span class="NLM_string-name">Tahri, A.</span>; <span class="NLM_string-name">Van Hoof, S. M. P.</span>; <span class="NLM_string-name">Vendeville, S. M. H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Imidazopyridine Derivatives for Use as Respiratory Syncytial Virus Antiviral Agents</span>. PCT Int. Appl. <span class="NLM_patent">WO-2012/080451 A1</span>, <span class="NLM_year">2012</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=L.+P.+Cooymans&author=L.+Hu&author=T.+H.+M.+Jonckers&author=P.+J.-M.+B.+Raboisson&author=A.+Tahri&author=S.+M.+P.+Van+Hoof&author=S.+M.+H.+Vendeville&title=Preparation+of+Imidazopyridine+Derivatives+for+Use+as+Respiratory+Syncytial+Virus+Antiviral+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCooymans%26aufirst%3DL.%2BP.%26atitle%3DPreparation%2520of%2520Imidazopyridine%2520Derivatives%2520for%2520Use%2520as%2520Respiratory%2520Syncytial%2520Virus%2520Antiviral%2520Agents%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alnajjar, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battles, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitthicharoenchai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furmanova-Hollenstein, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigaux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, J. V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwanten, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginderen, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheyen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vranckx, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaensch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnoult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorzaat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallup, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larios-Mora, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crabbe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntjens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raboisson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langedijk, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackermann, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vendeville, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span> <span> </span><span class="NLM_article-title">Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-00170-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1038%2Fs41467-017-00170-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=28232747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC1cXos1Sls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1-15&issue=1&author=D.+Roymansauthor=S.+S.+Alnajjarauthor=M.+B.+Battlesauthor=P.+Sitthicharoenchaiauthor=P.+Furmanova-Hollensteinauthor=P.+Rigauxauthor=J.+V.+D.+Bergauthor=L.+Kwantenauthor=M.+V.+Ginderenauthor=N.+Verheyenauthor=L.+Vranckxauthor=S.+Jaenschauthor=E.+Arnoultauthor=R.+Voorzaatauthor=J.+M.+Gallupauthor=A.+Larios-Moraauthor=M.+Crabbeauthor=D.+Huntjensauthor=P.+Raboissonauthor=J.+P.+Langedijkauthor=M.+R.+Ackermannauthor=J.+S.+McLellanauthor=S.+Vendevilleauthor=A.+Koul&title=Therapeutic+efficacy+of+a+respiratory+syncytial+virus+fusion+inhibitor&doi=10.1038%2Fs41467-017-00170-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor</span></div><div class="casAuthors">Roymans, Dirk; Alnajjar, Sarhad S.; Battles, Michael B.; Sitthicharoenchai, Panchan; Furmanova-Hollenstein, Polina; Rigaux, Peter; Van den Berg, Joke; Kwanten, Leen; Van Ginderen, Marcia; Verheyen, Nick; Vranckx, Luc; Jaensch, Steffen; Arnoult, Eric; Voorzaat, Richard; Gallup, Jack M.; Larios-Mora, Alejandro; Crabbe, Marjolein; Huntjens, Dymphy; Raboisson, Pierre; Langedijk, Johannes P.; Ackermann, Mark R.; McLellan, Jason S.; Vendeville, Sandrine; Koul, Anil</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-15</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Respiratory syncytial virus is a major cause of acute lower respiratory tract infection in young children, immunocompromised adults, and the elderly.  Intervention with small-mol. antivirals specific for respiratory syncytial virus presents an important therapeutic opportunity, but no such compds. are approved today.  Here we report the structure of JNJ-53718678 bound to respiratory syncytial virus fusion (F) protein in its prefusion conformation, and we show that the potent nanomolar activity of JNJ-53718678, as well as the preliminary structure-activity relationship and the pharmaceutical optimization strategy of the series, are consistent with the binding mode of JNJ-53718678 and other respiratory syncytial virus fusion inhibitors.  Oral treatment of neonatal lambs with JNJ-53718678, or with an equally active close analog, efficiently inhibits established acute lower respiratory tract infection in the animals, even when treatment is delayed until external signs of respiratory syncytial virus illness have become visible.  Together, these data suggest that JNJ-53718678 is a promising candidate for further development as a potential therapeutic in patients at risk to develop respiratory syncytial virus acute lower respiratory tract infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTzBk8medi0rVg90H21EOLACvtfcHk0lgRaLg_PX_GHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXos1Sls7g%253D&md5=29cde932b5cb9139d6f5aeb57bb6db72</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-00170-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-00170-x%26sid%3Dliteratum%253Aachs%26aulast%3DRoymans%26aufirst%3DD.%26aulast%3DAlnajjar%26aufirst%3DS.%2BS.%26aulast%3DBattles%26aufirst%3DM.%2BB.%26aulast%3DSitthicharoenchai%26aufirst%3DP.%26aulast%3DFurmanova-Hollenstein%26aufirst%3DP.%26aulast%3DRigaux%26aufirst%3DP.%26aulast%3DBerg%26aufirst%3DJ.%2BV.%2BD.%26aulast%3DKwanten%26aufirst%3DL.%26aulast%3DGinderen%26aufirst%3DM.%2BV.%26aulast%3DVerheyen%26aufirst%3DN.%26aulast%3DVranckx%26aufirst%3DL.%26aulast%3DJaensch%26aufirst%3DS.%26aulast%3DArnoult%26aufirst%3DE.%26aulast%3DVoorzaat%26aufirst%3DR.%26aulast%3DGallup%26aufirst%3DJ.%2BM.%26aulast%3DLarios-Mora%26aufirst%3DA.%26aulast%3DCrabbe%26aufirst%3DM.%26aulast%3DHuntjens%26aufirst%3DD.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DLangedijk%26aufirst%3DJ.%2BP.%26aulast%3DAckermann%26aufirst%3DM.%2BR.%26aulast%3DMcLellan%26aufirst%3DJ.%2BS.%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DKoul%26aufirst%3DA.%26atitle%3DTherapeutic%2520efficacy%2520of%2520a%2520respiratory%2520syncytial%2520virus%2520fusion%2520inhibitor%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26issue%3D1%26spage%3D1%26epage%3D15%26doi%3D10.1038%2Fs41467-017-00170-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobunai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyagi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utsigi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierzba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, Y.</span></span> <span> </span><span class="NLM_article-title">Specific distribution of TOP-53 to the lung and lung localized tumor is determined by its interaction with phospholipids</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">4396</span>– <span class="NLM_lpage">4401</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=11106259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovVSgu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=4396-4401&author=M.+Yoshidaauthor=T.+Kobunaiauthor=K.+Aoyagiauthor=H.+Saitoauthor=T.+Utsigiauthor=K.+Wierzbaauthor=Y.+Yamada&title=Specific+distribution+of+TOP-53+to+the+lung+and+lung+localized+tumor+is+determined+by+its+interaction+with+phospholipids"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Specific distribution of TOP-53 to the lung and lung-localized tumor is determined by its interaction with phospholipids</span></div><div class="casAuthors">Yoshida, Masahiko; Kobunai, Takashi; Aoyagi, Kumio; Saito, Hitoshi; Utsugi, Teruhiro; Wierzba, Konstanty; Yamada, Yuji</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4396-4401</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The authors have investigated the mechanism of TOP-53 distribution to the lung and lung-localized tumor.  In contrast to etoposide (VP-16), TOP-53 contains a basic aminoalkyl group that may predispose it to interact specifically with phospholipids, consequently leading to an increase of drug accumulation in the tissues.  Therefore, the authors have studied its interaction with phospholipids in vitro using an org. solvent-water partition system.  TOP-53 appeared to have the most potent binding affinity (Ka = 563 × 10-2 μM) to phosphatidylserine (PhS), whereas VP-16 showed no interaction with any phospholipid tested.  PhS content detd. after HPLC sepn. varied among tested tissues; however, large quantities were found in normal lung and lung cancer tissues far exceeding those present in the liver and kidney.  The predicted tissue-to-plasma partition coeff. values, estd. based on PhS content and its binding affinity, resembled those exptl. detd.  The authors concluded that tissue distribution of TOP-53 is detd. by PhS content in the tissues and by binding affinity.  As a result of specific accumulation in the lung, TOP-53 appeared to show a strong antitumor activity (increase of life span = 171%) against cancer metastasizing to the lung, whereas VP-16 was less effective (increase of life span = 78%).  These results suggest that TOP-53 may have an advantage over VP-16 in the treatment of lung cancers in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6PO9ZSt9VwrVg90H21EOLACvtfcHk0lgLPpbFYKtFQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovVSgu7s%253D&md5=387a94d4ce880032107b3fa391617fb5</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DKobunai%26aufirst%3DT.%26aulast%3DAoyagi%26aufirst%3DK.%26aulast%3DSaito%26aufirst%3DH.%26aulast%3DUtsigi%26aufirst%3DT.%26aulast%3DWierzba%26aufirst%3DK.%26aulast%3DYamada%26aufirst%3DY.%26atitle%3DSpecific%2520distribution%2520of%2520TOP-53%2520to%2520the%2520lung%2520and%2520lung%2520localized%2520tumor%2520is%2520determined%2520by%2520its%2520interaction%2520with%2520phospholipids%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2000%26volume%3D6%26spage%3D4396%26epage%3D4401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zane, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindle, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gause, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Buck, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripp, S. L.</span></span> <span> </span><span class="NLM_article-title">Physicochemical factors associated with binding and retention of compounds in ocular melanin of rats: Correlations using data from whole-body autoradiography and molecular modeling for multiple linear regression analyses</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">935</span>– <span class="NLM_lpage">941</span>, <span class="refDoi"> DOI: 10.1023/A:1015997823755</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1023%2FA%3A1015997823755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=2235893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADyaK3cXmtVCnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1990&pages=935-941&author=P.+A.+Zaneauthor=S.+D.+Brindleauthor=D.+O.+Gauseauthor=A.+J.+O%E2%80%99Buckauthor=P.+R.+Raghavanauthor=S.+L.+Tripp&title=Physicochemical+factors+associated+with+binding+and+retention+of+compounds+in+ocular+melanin+of+rats%3A+Correlations+using+data+from+whole-body+autoradiography+and+molecular+modeling+for+multiple+linear+regression+analyses&doi=10.1023%2FA%3A1015997823755"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical factors associated with binding and retention of compounds in ocular melanin of rats:  correlations using data from whole-body autoradiography and molecular modeling for multiple linear regression analyses</span></div><div class="casAuthors">Zane, Patricia A.; Brindle, Shirley D.; Gause, Douglas O.; O'Buck, Arlene J.; Raghavan, Palayakotai R.; Tripp, Spencer L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">935-41</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    </div><div class="casAbstract">The relationship between the physicochem. characteristics of 27 new drug candidates and their distribution into the melanin-contg. structure of the rat eye, the uveal tract, was examd.  Tissue distribution data were obtained from whole-body autoradiograms of pigmented Long-Evans rats sacrificed at 5 min and 96 h after dosing.  The physicochem. parameters considered include mol. wt., pKa, degree of ionization, octanol/water partition coeff. (log Po/w), drug-melanin binding energy, and acid/base status of the functional groups within the mol.  Multiple linear regression anal. was used to describe the best model correlating physicochem. and/or biol. characteristics of these compds. to their initial distribution at 5 min and to the retention of residual radioactivity in ocular melanin at 96 h post-injection.  The early distribution was a function primarily of acid/base status, pKa, binding energy, and log P(o/w), whereas uveal tract retention in rats was a function of vol. of distribution (V1), log P(o/w), pKa, and binding energy.  Further, there was a relationship between the initial distribution of a compd. into the uveal tract and its retention 96 h later.  More specifically, the structures most likely to be distributed and ultimately retained at high concns. were those contg. strongly basic functionalities, such as piperidine or piperazine moieties and other amines.  Further, the more lipophilic and, hence, widely distributed the basic compd., the greater the likelihood that it interacts with ocular melanin.  In summary, the use of multiple linear regression anal. was useful in distinguishing which physicochem. characteristics of a compd. or group of compds. contributed to melanin binding in pigmented rats in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_eS88Ro4YLVg90H21EOLACvtfcHk0lgLPpbFYKtFQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXmtVCnsbk%253D&md5=2572c995dfd848505134d9bd3eaae30f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1023%2FA%3A1015997823755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1015997823755%26sid%3Dliteratum%253Aachs%26aulast%3DZane%26aufirst%3DP.%2BA.%26aulast%3DBrindle%26aufirst%3DS.%2BD.%26aulast%3DGause%26aufirst%3DD.%2BO.%26aulast%3DO%25E2%2580%2599Buck%26aufirst%3DA.%2BJ.%26aulast%3DRaghavan%26aufirst%3DP.%2BR.%26aulast%3DTripp%26aufirst%3DS.%2BL.%26atitle%3DPhysicochemical%2520factors%2520associated%2520with%2520binding%2520and%2520retention%2520of%2520compounds%2520in%2520ocular%2520melanin%2520of%2520rats%253A%2520Correlations%2520using%2520data%2520from%2520whole-body%2520autoradiography%2520and%2520molecular%2520modeling%2520for%2520multiple%2520linear%2520regression%2520analyses%26jtitle%3DPharm.%2520Res.%26date%3D1990%26volume%3D7%26spage%3D935%26epage%3D941%26doi%3D10.1023%2FA%3A1015997823755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Duve, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Barsy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poole, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trouet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulkens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Hoof, F.</span></span> <span> </span><span class="NLM_article-title">Lysosomotropic agents</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">2495</span>– <span class="NLM_lpage">2531</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(74)90174-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1016%2F0006-2952%2874%2990174-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=4606365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADyaE2MXotVajsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1974&pages=2495-2531&issue=18&author=C.+De%0ADuveauthor=T.+de+Barsyauthor=B.+Pooleauthor=A.+Trouetauthor=P.+Tulkensauthor=F.+Van+Hoof&title=Lysosomotropic+agents&doi=10.1016%2F0006-2952%2874%2990174-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosomotropic agents</span></div><div class="casAuthors">De Duve, Christian; De Barsy, Thierry; Poole, Brian; Trouet, Andre; Tulkens, Paul; Van Hoof, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2495-531</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">A review of the nature, mechanisms of entry, and therapeutic possibilities of lysosomotropic agents, i.e., substances that are taken up selectively into lysosomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg5ghnaqeC-7Vg90H21EOLACvtfcHk0lgLPpbFYKtFQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXotVajsg%253D%253D&md5=030336e8550d5fc2988796dac6772170</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2874%2990174-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252874%252990174-9%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BDuve%26aufirst%3DC.%26aulast%3Dde%2BBarsy%26aufirst%3DT.%26aulast%3DPoole%26aufirst%3DB.%26aulast%3DTrouet%26aufirst%3DA.%26aulast%3DTulkens%26aufirst%3DP.%26aulast%3DVan%2BHoof%26aufirst%3DF.%26atitle%3DLysosomotropic%2520agents%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1974%26volume%3D23%26issue%3D18%26spage%3D2495%26epage%3D2531%26doi%3D10.1016%2F0006-2952%2874%2990174-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chatman, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anway, S. D.</span></span> <span> </span><span class="NLM_article-title">A strategy for risk management of drug-induced phospholipidosis</span>. <i>Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1005</span>, <span class="refDoi"> DOI: 10.1177/0192623309352496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1177%2F0192623309352496" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=20008549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmvVKrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=997-1005&issue=7&author=L.+A.+Chatmanauthor=D.+Mortonauthor=T.+O.+Johnsonauthor=S.+D.+Anway&title=A+strategy+for+risk+management+of+drug-induced+phospholipidosis&doi=10.1177%2F0192623309352496"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">A strategy for risk management of drug-induced phospholipidosis</span></div><div class="casAuthors">Chatman, Linda A.; Morton, Daniel; Johnson, Theodore O.; Anway, Susan D.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">997-1005</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Drug-induced phospholipidosis (PL) is an excessive accumulation of phospholipids and drug in lysosomes.  Phospholipidosis signals a change in cell membrane integrity and accumulation of intracellular drug or metabolite in tissues.  The sensitivity and susceptibility of preclin. models to detect PL vary with therapeutic agents, and PL is expected to be reversible after discontinuation of drug treatment.  The prevailing scientific opinion is that PL by itself is not adverse; however, some regulatory authorities consider PL to be adverse because a small no. of chems. are able to cause PL and concurrent organ toxicity.  Until a greater understanding of PL emerges, a well-thought-out risk management strategy for PL will increase confidence in safety and improve selection and development of new drugs.  This paper provides a tiered approach to risk management of drug-induced PL.  It begins with use of in silico and in vitro tools to design and select compds. with reduced potential to produce PL.  Early in vivo studies in two species are used to better characterize potential for toxicity and PL.  Finally, routine risk management tools (i.e., translational biomarkers, assessment of reversibility) are used to support confidence in safety of compds. that induce PL in animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAM7cftU9FOLVg90H21EOLACvtfcHk0lgCKH_eJb9mbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmvVKrug%253D%253D&md5=9ce40ff60732ea1d6cfe718ed173d84e</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1177%2F0192623309352496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623309352496%26sid%3Dliteratum%253Aachs%26aulast%3DChatman%26aufirst%3DL.%2BA.%26aulast%3DMorton%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DAnway%26aufirst%3DS.%2BD.%26atitle%3DA%2520strategy%2520for%2520risk%2520management%2520of%2520drug-induced%2520phospholipidosis%26jtitle%3DToxicol.%2520Pathol.%26date%3D2009%26volume%3D37%26issue%3D7%26spage%3D997%26epage%3D1005%26doi%3D10.1177%2F0192623309352496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foss, F. W.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, T. L.</span></span> <span> </span><span class="NLM_article-title">In vitro metabolism of a model cyclopropylamine to reactive intermediate: insights into trovafloxacin-induced hepatotoxicity</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">719</span>, <span class="refDoi"> DOI: 10.1021/tx7003085</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx7003085" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisVWksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=711-719&author=Q.+Sunauthor=R.+Zhuauthor=F.+W.+Fossauthor=T.+L.+Macdonald&title=In+vitro+metabolism+of+a+model+cyclopropylamine+to+reactive+intermediate%3A+insights+into+trovafloxacin-induced+hepatotoxicity&doi=10.1021%2Ftx7003085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Metabolism of a Model Cyclopropylamine to Reactive Intermediate: Insights into Trovafloxacin-Induced Hepatotoxicity</span></div><div class="casAuthors">Sun, Qin; Zhu, Ran; Foss, Frank W.; Macdonald, Timothy L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">711-719</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trovafloxacin (Trovan) is a fluoroquinolone antibiotic drug with a long half-life and broad-spectrum activity.  Since its entry into the market in 1998, trovafloxacin has been assocd. with numerous cases of hepatotoxicity, which has limited its clin. usefulness.  Trovafloxacin possesses two substructural elements that have the potential to generate reactive intermediates: a cyclopropylamine moiety and a difluoroanilino system.  The results presented here describe the in vitro metabolic activation of a synthetic drug model (DM) of trovafloxacin that contains the cyclopropylamine moiety.  Cyclopropylamine can be oxidized to reactive ring-opened products-a carbon-centered radical and a subsequently oxidized α,β-unsatd. aldehyde.  Expts. with monoamine oxygenases, horseradish peroxidase, flavin monooxygenase 3, and cDNA-expressed P 450 isoenzymes revealed that P 450 1A2 oxidizes DM to a reactive α,β-unsatd. aldehyde, M1.  Furthermore, myeloperoxidase (MPO) was also demonstrated to oxidize DM in the presence of chloride ion to produce M1.  DM proved to be a suicide inhibitor of MPO while showing no inhibition of P 450 1A2.  The structure of the reactive metabolite was confirmed by LC-MS/MS anal. by comparison with a synthetic std. M1 was further shown to react with glutathione and the related thiol nucleophile, 4-bromobenzyl mercaptan, suggesting the potential of this intermediate to react with protein nucleophiles.  In summary, these data provide evidence that trovafloxacin-induced hepatotoxicity may be mediated through the oxidn. of the cyclopropylamine substructure to reactive intermediates that may form covalent adducts to hepatic proteins, resulting in damage to liver tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr211JADO6oxbVg90H21EOLACvtfcHk0lgCKH_eJb9mbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisVWksLY%253D&md5=cb587b2776c7af787f6527a01765ebdb</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Ftx7003085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx7003085%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DZhu%26aufirst%3DR.%26aulast%3DFoss%26aufirst%3DF.%2BW.%26aulast%3DMacdonald%26aufirst%3DT.%2BL.%26atitle%3DIn%2520vitro%2520metabolism%2520of%2520a%2520model%2520cyclopropylamine%2520to%2520reactive%2520intermediate%253A%2520insights%2520into%2520trovafloxacin-induced%2520hepatotoxicity%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26spage%3D711%26epage%3D719%26doi%3D10.1021%2Ftx7003085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsky, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatakrishnan, K.</span></span> <span> </span><span class="NLM_article-title">Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1124/dmd.106.012633</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1124%2Fdmd.106.012633" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=17093004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVKrs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=246-255&issue=2&author=R.+S.+Obachauthor=R.+L.+Walskyauthor=K.+Venkatakrishnan&title=Mechanism-based+inactivation+of+human+cytochrome+P450+enzymes+and+the+prediction+of+drug-drug+interactions&doi=10.1124%2Fdmd.106.012633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions</span></div><div class="casAuthors">Obach, R. Scott; Walsky, Robert L.; Venkatakrishnan, Karthik</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">246-255</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The ability to use vitro inactivation kinetic parameters in scaling to in vivo drug-drug interactions (DDIs) for mechanism-based inactivators of human cytochrome P 450 (P 450) enzymes was examd. using eight human P 450-selective marker activities in pooled human liver microsomes.  These data were combined with other parameters (systemic Cmax, estd. hepatic inlet Cmax, fraction unbound, in vivo P 450 enzyme degrdn. rate consts. estd. from clin. pharmacokinetic data, and fraction of the affected drug cleared by the inhibited enzyme) to predict increases in exposure to drugs, and the predictions were compared with in vivo DDIs gathered from clin. studies reported in the scientific literature.  In general, the use of unbound systemic Cmax as the inactivator concn. in vivo yielded the most accurate predictions of DDI with a mean -fold error of 1.64.  Abbreviated in vitro approaches to identifying mechanism-based inactivators were developed.  Testing potential inactivators at a single concn. (IC25) in a 30-min preincubation with human liver microsomes in the absence and presence of NADPH followed by assessment of P 450 marker activities readily identified those compds. known to be mechanism-based inactivators and represents an approach that can be used with greater throughput.  Measurement of decreases in IC50 occurring with a 30-min preincubation with liver microsomes and NADPH was also useful in identifying mechanism-based inactivators, and the IC50 measured after such a preincubation was highly correlated with the kinact/K1 ratio measured after a full characterization of inactivation.  Overall, these findings support the conclusion that P 450 in vitro inactivation data are valuable in predicting clin. DDIs that can occur via this mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpPRf5ZGrW6LVg90H21EOLACvtfcHk0lgCKH_eJb9mbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVKrs7k%253D&md5=71733cfafba3b2c9cc6b47a46e7b3f40</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1124%2Fdmd.106.012633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.106.012633%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DWalsky%26aufirst%3DR.%2BL.%26aulast%3DVenkatakrishnan%26aufirst%3DK.%26atitle%3DMechanism-based%2520inactivation%2520of%2520human%2520cytochrome%2520P450%2520enzymes%2520and%2520the%2520prediction%2520of%2520drug-drug%2520interactions%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2007%26volume%3D35%26issue%3D2%26spage%3D246%26epage%3D255%26doi%3D10.1124%2Fdmd.106.012633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardegger, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinnler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anselm, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ecabert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stihle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gsell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plancher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banner, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haap, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, F.</span></span> <span> </span><span class="NLM_article-title">Systematic investigation of halogen bonding in protein-ligand interactions</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">314</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1002/anie.201006781</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1002%2Fanie.201006781" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1alu73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=314-318&author=L.+A.+Hardeggerauthor=B.+Kuhnauthor=B.+Spinnlerauthor=L.+Anselmauthor=R.+Ecabertauthor=M.+Stihleauthor=B.+Gsellauthor=R.+Thomaauthor=J.+Diezauthor=J.+Benzauthor=J.+Plancherauthor=G.+Hartmannauthor=D.+W.+Bannerauthor=W.+Haapauthor=F.+Diederich&title=Systematic+investigation+of+halogen+bonding+in+protein-ligand+interactions&doi=10.1002%2Fanie.201006781"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic Investigation of Halogen Bonding in Protein-Ligand Interactions</span></div><div class="casAuthors">Hardegger, Leo A.; Kuhn, Bernd; Spinnler, Beat; Anselm, Lilli; Ecabert, Robert; Stihle, Martine; Gsell, Bernard; Thoma, Ralf; Diez, Joachim; Benz, Joerg; Plancher, Jean-Marc; Hartmann, Guido; Banner, David W.; Haap, Wolfgang; Diederich, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">314-318, S314/1-S314/145</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Halogen bonding triggers activity.  Increasing binding affinity was obsd. for a series of covalent human Cathepsin L inhibitors by exchanging an aryl ring H atom with Cl, Br, and I, which undergo halogen bonding with the C=O group of Gly61 in the S3 pocket of the enzyme.  Fluorine, in contrast, strongly avoids halogen bonding.  The strong distance and angle dependence of halogen bonding was confirmed for biol. systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbsbCNMQhVu7Vg90H21EOLACvtfcHk0lgCKH_eJb9mbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1alu73N&md5=1a7f2983a386fd133be0663657fc486b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fanie.201006781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201006781%26sid%3Dliteratum%253Aachs%26aulast%3DHardegger%26aufirst%3DL.%2BA.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DSpinnler%26aufirst%3DB.%26aulast%3DAnselm%26aufirst%3DL.%26aulast%3DEcabert%26aufirst%3DR.%26aulast%3DStihle%26aufirst%3DM.%26aulast%3DGsell%26aufirst%3DB.%26aulast%3DThoma%26aufirst%3DR.%26aulast%3DDiez%26aufirst%3DJ.%26aulast%3DBenz%26aufirst%3DJ.%26aulast%3DPlancher%26aufirst%3DJ.%26aulast%3DHartmann%26aufirst%3DG.%26aulast%3DBanner%26aufirst%3DD.%2BW.%26aulast%3DHaap%26aufirst%3DW.%26aulast%3DDiederich%26aufirst%3DF.%26atitle%3DSystematic%2520investigation%2520of%2520halogen%2520bonding%2520in%2520protein-ligand%2520interactions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2011%26volume%3D50%26spage%3D314%26epage%3D318%26doi%3D10.1002%2Fanie.201006781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
den Berg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwanten, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span></span> <span> </span><span class="NLM_article-title">Evaluation of antiviral efficacy against human respiratory syncytial virus using cotton rat and mouse models</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1030</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1007/978-1-62703-484-5_28</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1007%2F978-1-62703-484-5_28" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=23821282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVSnu7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1030&publication_year=2013&pages=365-372&author=J.+Van%0Aden+Bergauthor=L.+Kwantenauthor=D.+Roymans&title=Evaluation+of+antiviral+efficacy+against+human+respiratory+syncytial+virus+using+cotton+rat+and+mouse+models&doi=10.1007%2F978-1-62703-484-5_28"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of antiviral efficacy against human respiratory syncytial virus using cotton rat and mouse models</span></div><div class="casAuthors">Van den Berg, Joke; Kwanten, Leen; Roymans, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1030</span>
        (<span class="NLM_cas:issue">Antiviral Methods and Protocols</span>),
    <span class="NLM_cas:pages">365-372</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Infection with human respiratory syncytial virus (hRSV) causes a wide spectrum of respiratory disease in infants, young children, and elderly persons.  No vaccine is available today and hRSV treatment options are limited.  As a consequence, the treatment of hRSV infection remains largely supportive and new therapeutic options are needed to treat severe lower respiratory tract hRSV disease.  Several animal models have been developed to study hRSV disease and evaluate novel therapies or preventive measures such as vaccines.  However, each of these models reproduces different aspects of hRSV disease, and therefore, an appropriate model should be selected on the basis of the scientific question under investigation.  In this chapter, we describe how cotton rats and Balb/c mice are used in our lab. to test the in vivo efficacy of small-mol. inhibitors against hRSV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWs2PSt-lynbVg90H21EOLACvtfcHk0lhxCldgEuV59A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVSnu7%252FP&md5=368ffaca8850e3c74e19ed935e141015</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1007%2F978-1-62703-484-5_28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-62703-484-5_28%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bden%2BBerg%26aufirst%3DJ.%26aulast%3DKwanten%26aufirst%3DL.%26aulast%3DRoymans%26aufirst%3DD.%26atitle%3DEvaluation%2520of%2520antiviral%2520efficacy%2520against%2520human%2520respiratory%2520syncytial%2520virus%2520using%2520cotton%2520rat%2520and%2520mouse%2520models%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2013%26volume%3D1030%26spage%3D365%26epage%3D372%26doi%3D10.1007%2F978-1-62703-484-5_28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ackermann, M. R.</span></span> <span> </span><span class="NLM_article-title">Lamb model of respiratory syncytial virus-associated lung disease: insights to pathogenesis and novel treatments</span>. <i>ILAR J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1093/ilar/ilu003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1093%2Filar%2Filu003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=24936027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpvFCqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=4-15&author=M.+R.+Ackermann&title=Lamb+model+of+respiratory+syncytial+virus-associated+lung+disease%3A+insights+to+pathogenesis+and+novel+treatments&doi=10.1093%2Filar%2Filu003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Lamb Model of Respiratory Syncytial Virus-Associated Lung Disease: Insights to Pathogenesis and Novel Treatments</span></div><div class="casAuthors">Ackermann, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">ILAR Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-15</span>CODEN:
                <span class="NLM_cas:coden">IJLOAC</span>;
        ISSN:<span class="NLM_cas:issn">1084-2020</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Preterm birth is a risk factor for respiratory syncytial virus (RSV) bronchiolitis and hospitalization.  The pathogenesis underlying this is not fully understood, and in vivo studies are needed to better clarify essential cellular features and mol. mechanisms.  Such studies include anal. of lung tissue from affected human infants and various animal models.  The preterm and newborn lamb lung has developmental, structural, cellular, physiol., and immunol. features similar to that of human infants.  Also, the lamb lung is susceptible to various strains of RSV that infect infants and cause similar bronchiolar lesions.  Studies in lambs suggest that viral replication in airways (esp. bronchioles) is extensive by 4 days after infection, along with bronchiolitis characterized by degeneration and necrosis of epithelial cells, syncytial cell formation, neutrophil infiltration, epithelial cell hypertrophy and hyperplasia, and innate and adaptive immune responses.  RSV bronchiolitis greatly affects airflow and gaseous exchange.  RSV disease severity is increased in preterm lambs compared with full-term lambs; similar to human infants.  The lamb is conducive to exptl. assessment of novel, mechanistic therapeutic interventions such as delivery of vascular endothelial growth factor and enhancement of airway epithelial oxidative responses, Club (Clara) cell protein 10, and synthesized compds. such as nanobodies.  In contrast, exposure of the fetal ovine lung in vivo to ethanol, a risk factor for preterm birth, reduces pulmonary alveolar development and surfactant protein A expression.  Because the formalin-inactivated RSV vaccination enhances some inflammatory responses to RSV infection in lambs, this model has the potential to assess mechanisms of formalin-inactivated RSV enhanced disease as well as newly developed vaccines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk3_OBeuTEM7Vg90H21EOLACvtfcHk0lhxCldgEuV59A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpvFCqurg%253D&md5=923b6391e1374bb791cecc3ddb65baf1</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1093%2Filar%2Filu003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Filar%252Filu003%26sid%3Dliteratum%253Aachs%26aulast%3DAckermann%26aufirst%3DM.%2BR.%26atitle%3DLamb%2520model%2520of%2520respiratory%2520syncytial%2520virus-associated%2520lung%2520disease%253A%2520insights%2520to%2520pathogenesis%2520and%2520novel%2520treatments%26jtitle%3DILAR%2520J.%26date%3D2014%26volume%3D55%26spage%3D4%26epage%3D15%26doi%3D10.1093%2Filar%2Filu003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Derscheid, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackermann, M. R.</span></span> <span> </span><span class="NLM_article-title">Perinatal lamb model of respiratory syncytial virus (RSV) infection</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2359</span>– <span class="NLM_lpage">2378</span>, <span class="refDoi"> DOI: 10.3390/v4102359</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.3390%2Fv4102359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=23202468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVSrtrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=2359-2378&author=R.+J.+Derscheidauthor=M.+R.+Ackermann&title=Perinatal+lamb+model+of+respiratory+syncytial+virus+%28RSV%29+infection&doi=10.3390%2Fv4102359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Perinatal lamb model of respiratory syncytial virus (RSV) infection</span></div><div class="casAuthors">Derscheid, Rachel J.; Ackermann, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2359-2378</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Respiratory syncytial virus (RSV) is the most frequent cause of bronchiolitis in infants and children worldwide.  Many animal models are used to study RSV, but most studies investigate disease in adult animals which does not address the unique physiol. and immunol. that makes infants more susceptible.  The perinatal (preterm and term) lamb is a useful model of infant RSV disease as lambs have similar pulmonary structure including airway branching, Clara and type II cells, submucosal glands and Duox/lactoperoxidase (LPO) oxidative system and prenatal alveologenesis.  Lambs can be born preterm (90% gestation) and survive for experimentation although both preterm and term lambs are susceptible to ovine, bovine and human strains of RSV and develop clin. symptoms including fever, tachypnea and malaise as well as mild to moderate gross and histol. lesions including bronchiolitis with epithelial injury, neutrophil infiltration and syncytial cell formation.  RSV disease in preterm lambs is more severe than in term lambs; disease is progressively less in adults and age-dependent susceptibility is a feature similar to humans.  Innate and adaptive immune responses by perinatal lambs closely parallel those of infants.  The model is used to test therapeutic regimens, risk factors such as maternal ethanol consumption and formalin inactivated RSV vaccines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE9T5kS4AUfrVg90H21EOLACvtfcHk0lhxCldgEuV59A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVSrtrrO&md5=a9ee493b6cd26a77171d371be4293bea</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.3390%2Fv4102359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv4102359%26sid%3Dliteratum%253Aachs%26aulast%3DDerscheid%26aufirst%3DR.%2BJ.%26aulast%3DAckermann%26aufirst%3DM.%2BR.%26atitle%3DPerinatal%2520lamb%2520model%2520of%2520respiratory%2520syncytial%2520virus%2520%2528RSV%2529%2520infection%26jtitle%3DViruses%26date%3D2012%26volume%3D4%26spage%3D2359%26epage%3D2378%26doi%3D10.3390%2Fv4102359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinon-Torres, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntjens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remmerie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vingerhoets, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFadyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrero, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epalza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics, safety and antiviral effects of multiple doses of the respiratory syncytial virus fusion protein inhibitor, JNJ-53718678, in infants hospitalized with rsv infection: a randomized phase 1b study</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="NLM_elocation-id">ciaa283</span> <span class="refDoi"> DOI: 10.1093/cid/ciaa283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1093%2Fcid%2Fciaa283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=32201897" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=F.+Martinon-Torresauthor=S.+Ruschauthor=D.+Huntjensauthor=B.+Remmerieauthor=J.+Vingerhoetsauthor=K.+McFadyenauthor=F.+Ferreroauthor=E.+Baraldiauthor=P.+Rojoauthor=C.+Epalzaauthor=M.+Stevens&title=Pharmacokinetics%2C+safety+and+antiviral+effects+of+multiple+doses+of+the+respiratory+syncytial+virus+fusion+protein+inhibitor%2C+JNJ-53718678%2C+in+infants+hospitalized+with+rsv+infection%3A+a+randomized+phase+1b+study&doi=10.1093%2Fcid%2Fciaa283"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciaa283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciaa283%26sid%3Dliteratum%253Aachs%26aulast%3DMartinon-Torres%26aufirst%3DF.%26aulast%3DRusch%26aufirst%3DS.%26aulast%3DHuntjens%26aufirst%3DD.%26aulast%3DRemmerie%26aufirst%3DB.%26aulast%3DVingerhoets%26aufirst%3DJ.%26aulast%3DMcFadyen%26aufirst%3DK.%26aulast%3DFerrero%26aufirst%3DF.%26aulast%3DBaraldi%26aufirst%3DE.%26aulast%3DRojo%26aufirst%3DP.%26aulast%3DEpalza%26aufirst%3DC.%26aulast%3DStevens%26aufirst%3DM.%26atitle%3DPharmacokinetics%252C%2520safety%2520and%2520antiviral%2520effects%2520of%2520multiple%2520doses%2520of%2520the%2520respiratory%2520syncytial%2520virus%2520fusion%2520protein%2520inhibitor%252C%2520JNJ-53718678%252C%2520in%2520infants%2520hospitalized%2520with%2520rsv%2520infection%253A%2520a%2520randomized%2520phase%25201b%2520study%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2020%26doi%3D10.1093%2Fcid%2Fciaa283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swamy, K. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N. N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaraman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K. V. P. P.</span></span> <span> </span><span class="NLM_article-title">Mitsunobu and related reactions: advances and applications</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2551</span>– <span class="NLM_lpage">2651</span>, <span class="refDoi"> DOI: 10.1021/cr800278z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr800278z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVagt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=2551-2651&issue=6&author=K.+C.+K.+Swamyauthor=N.+N.+B.+Kumarauthor=E.+Balaramanauthor=K.+V.+P.+P.+Kumar&title=Mitsunobu+and+related+reactions%3A+advances+and+applications&doi=10.1021%2Fcr800278z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Mitsunobu and Related Reactions: Advances and Applications</span></div><div class="casAuthors">Swamy, K. C. Kumara; Kumar, N. N. Bhuvan; Balaraman, E.; Kumar, K. V. P. Pavan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2551-2651</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this review is an attempt to detail the Mitsunobu reaction, along with its modifications, which has been versatile and applicable for a variety of org. transformations.  The ease with which stereochem. at the chiral secondary alc. can be reversed is a valuable asset.  The large no. of publications, particularly in the area of nucleobase alkylation, reflects its popularity, mainly as a result of the mild conditions employed during the reaction.  It is expected that this aspect is going to be much sought after, particularly by the pharmaceutical industry.  Synthetic chemists tend to rely on its various facets, be it natural product synthesis or nucleobase alkylation or etherification.  As far as the future of this reaction is concerned, an efficient and inexpensive way to recycle the reagents or to make the reaction fully catalytic is desirable.  Another aspect worth looking into would be to synthesize a water sol. but degradable phosphine/phosphite of low toxicity, to simplify the purifn. process.  The aforesaid points become important if we desire to employ the Mitsunobu route for large scale synthesis.  Recoverable polymer bound phosphonium salts of type 565 that avoid the wastage of phosphine as well as azodicarboxylate, and hence make the system more atom economical and greener, also need to be considered in the future.  Finally, although a major part of the mechanistic pathways is fairly well understood, the complexity of the initial steps when different P precursors are used is intriguing.  This could also be a fruitful area for a phys. org. chemist to probe in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmJ2PTO4x-17Vg90H21EOLACvtfcHk0ljEpMWveHRlsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVagt78%253D&md5=f7da5265d707fafe71cb40dea76dc1e9</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fcr800278z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr800278z%26sid%3Dliteratum%253Aachs%26aulast%3DSwamy%26aufirst%3DK.%2BC.%2BK.%26aulast%3DKumar%26aufirst%3DN.%2BN.%2BB.%26aulast%3DBalaraman%26aufirst%3DE.%26aulast%3DKumar%26aufirst%3DK.%2BV.%2BP.%2BP.%26atitle%3DMitsunobu%2520and%2520related%2520reactions%253A%2520advances%2520and%2520applications%26jtitle%3DChem.%2520Rev.%26date%3D2009%26volume%3D109%26issue%3D6%26spage%3D2551%26epage%3D2651%26doi%3D10.1021%2Fcr800278z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="note"><p class="first last">NMR HSQC experiments were performed on all final compounds to confirm their structure as the N-alkylated product and not O-alkylated side-product <b>75x</b>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':[],'ref31':['cit31'],'ref32':['cit32a','cit32b'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref43':['cit43'],'ref42':['cit42'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':[]}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 2 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">G. Stuart Cockerill, Richard M. Angell, Alexandre Bedernjak, Irina Chuckowree, Ian Fraser, Jose Gascon-Simorte, Morgan S. A. Gilman, James A. D. Good, Rachel Harland, Sara M. Johnson, John H Ludes-Meyers, Edward Littler, James Lumley, Graham Lunn, Neil Mathews, Jason S. McLellan, Michael Paradowski, Mark E. Peeples, Claire Scott, Dereck Tait, Geraldine Taylor, Michelle Thom, Elaine Thomas, Carol Villalonga Barber, Simon E. Ward, Daniel Watterson, Gareth Williams, Paul Young, <span class="NLM_string-name hlFld-ContribAuthor">Kenneth Powell</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 3658-3676. <a href="https://doi.org/10.1021/acs.jmedchem.0c01882" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01882</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01882%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BSisunatovir%252B%252528RV521%252529%25252C%252Ban%252BInhibitor%252Bof%252BRespiratory%252BSyncytial%252BVirus%252BFusion%26aulast%3DCockerill%26aufirst%3DG.%2BStuart%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D30102020%26date%3D17032021%26volume%3D64%26issue%3D7%26spage%3D3658%26epage%3D3676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">G. Stuart Cockerill</span>. </span><span class="cited-content_cbyCitation_article-title">JNJ-5371678, Defining a Role for Fusion Inhibitors in the Treatment of Respiratory Syncytial Virus. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (15)
                                     , 8043-8045. <a href="https://doi.org/10.1021/acs.jmedchem.0c01184" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01184</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01184%26sid%3Dliteratum%253Aachs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26doi%3D10.1021%2Facs.jmedchem.0c00226%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DJNJ-5371678%25252C%252BDefining%252Ba%252BRole%252Bfor%252BFusion%252BInhibitors%252Bin%252Bthe%252BTreatment%252Bof%252BRespiratory%252BSyncytial%252BVirus%26aulast%3DCockerill%26aufirst%3DG.%2BStuart%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D08072020%26date%3D03082020%26volume%3D63%26issue%3D15%26spage%3D8043%26epage%3D8045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/medium/jm0c00226_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00226&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/medium/jm0c00226_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of compounds <b>1</b>–<b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00226&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/medium/jm0c00226_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. SAR Summary Leading to JNJ-53718678</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00226&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/medium/jm0c00226_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cocrystal structure of JNJ-53718678 bound to prefusion RSV F (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KWW">5KWW</a>): (a) view of the central cavity looking down toward the viral membrane; (b) side view of the central cavity view parallel to the viral membrane. The three RSV F protomers are colored green, pink, and tan. Water molecules are represented as red spheres. JNJ-53718678 (compound <b>53</b>) is shown in ball-and-stick representation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00226&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/medium/jm0c00226_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cocrystal structure of compounds <b>39</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VKC">6VKC</a>), <b>41</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VKD">6VKD</a>), and <b>64</b> (code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VKE">6VKE</a>) bound to prefusion RSV F, showing side view of the central cavity, view parallel to the viral membrane. The three RSV F protomers are colored green, pink, and tan. Compounds are shown in ball-and-stick representation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00226&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/medium/jm0c00226_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Pathway for the Synthesis of Final Compounds <b>5</b>–<b>71</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00226/20200806/images/large/jm0c00226_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00226&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (i) <b>I</b>, <b>II</b>, DIAD, Ph<sub>3</sub>P, DMF, or THF, 12–97% yield. (ii) (a) For <b>30</b>: <b>27</b>, KOH, <sup><i>i</i></sup>PrOH, H<sub>2</sub>O, 120 °C, 1 h, 96% yield. (b) For <b>31</b>: <b>27</b>, NH<sub>2</sub>OH, Et<sub>3</sub>N, EtOH, 80 °C, 16 h, 15% yield. (c) For <b>32</b>: <b>27</b>, NH<sub>2</sub>OH, K<sub>2</sub>CO<sub>3</sub>, EtOH, H<sub>2</sub>O, 80 °C. (iii) <b>IIIa</b>, H<sub>2</sub>, Pd/C, CH<sub>3</sub>COOK, MeOH, 50 °C, 32–36% yield. (iv) <b>IIIb</b>, ammonium fluoride, MeOH, 60 °C, 32–95% yield. (v) <b>IIIc</b>, HCl 6 M in <sup><i>i</i></sup>PrOH, H<sub>2</sub>0, 70% yield. (vi) <b>45</b>, ClCH<sub>2</sub>CN, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 62% yield. (vii) <b>IIId</b>, TFA, DCM, 77% yield. (viii) <b>51</b>, ClSO<sub>2</sub>Me, Et<sub>3</sub>N, DCM, 32% yield. (ix) <b>IIIe</b>, LiOH, H<sub>2</sub>O/THF 1/3, 48% yield. (x) <b>57</b>, cyclopropylamine, Et<sub>2</sub>CNPO<sub>3</sub>, Et<sub>3</sub>N, DMF, 68% yield.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i34">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54251" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54251" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 48 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nair, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nokes, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessner, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dherani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhi, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theodoratou, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutanto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedyaningsih, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munywoki, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kartasasmita, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simões, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, H.</span></span> <span> </span><span class="NLM_article-title">Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>375</i></span> (<span class="NLM_issue">9725</span>),  <span class="NLM_fpage">1545</span>– <span class="NLM_lpage">1555</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(10)60206-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1016%2FS0140-6736%2810%2960206-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=20399493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A280%3ADC%252BC3czgtlaqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2010&pages=1545-1555&issue=9725&author=H.+Nairauthor=J.+D.+Nokesauthor=B.+D.+Gessnerauthor=M.+Dheraniauthor=S.+A.+Madhiauthor=R.+J.+Singletonauthor=K.+L.+O%E2%80%99Brienauthor=A.+Rocaauthor=P.+F.+Wrightauthor=N.+Bruceauthor=A.+Chandranauthor=E.+Theodoratouauthor=A.+Sutantoauthor=E.+R.+Sedyaningsihauthor=M.+Ngamaauthor=P.+K.+Munywokiauthor=C.+Kartasasmitaauthor=E.+A.+Sim%C3%B5esauthor=I.+Rudanauthor=M.+W.+Weberauthor=H.+Campbell&title=Global+burden+of+acute+lower+respiratory+infections+due+to+respiratory+syncytial+virus+in+young+children%3A+a+systematic+review+and+meta-analysis&doi=10.1016%2FS0140-6736%2810%2960206-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis</span></div><div class="casAuthors">Nair Harish; Nokes D James; Gessner Bradford D; Dherani Mukesh; Madhi Shabir A; Singleton Rosalyn J; O'Brien Katherine L; Roca Anna; Wright Peter F; Bruce Nigel; Chandran Aruna; Theodoratou Evropi; Sutanto Agustinus; Sedyaningsih Endang R; Ngama Mwanajuma; Munywoki Patrick K; Kartasasmita Cissy; Simoes Eric A F; Rudan Igor; Weber Martin W; Campbell Harry</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">9725</span>),
    <span class="NLM_cas:pages">1545-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The global burden of disease attributable to respiratory syncytial virus (RSV) remains unknown.  We aimed to estimate the global incidence of and mortality from episodes of acute lower respiratory infection (ALRI) due to RSV in children younger than 5 years in 2005.  METHODS:  We estimated the incidence of RSV-associated ALRI in children younger than 5 years, stratified by age, using data from a systematic review of studies published between January, 1995, and June, 2009, and ten unpublished population-based studies.  We estimated possible boundaries for RSV-associated ALRI mortality by combining case fatality ratios with incidence estimates from hospital-based reports from published and unpublished studies and identifying studies with population-based data for RSV seasonality and monthly ALRI mortality.  FINDINGS:  In 2005, an estimated 33.8 (95% CI 19.3-46.2) million new episodes of RSV-associated ALRI occurred worldwide in children younger than 5 years (22% of ALRI episodes), with at least 3.4 (2.8-4.3) million episodes representing severe RSV-associated ALRI necessitating hospital admission.  We estimated that 66 000-199 000 children younger than 5 years died from RSV-associated ALRI in 2005, with 99% of these deaths occurring in developing countries.  Incidence and mortality can vary substantially from year to year in any one setting.  INTERPRETATION:  Globally, RSV is the most common cause of childhood ALRI and a major cause of admission to hospital as a result of severe ALRI.  Mortality data suggest that RSV is an important cause of death in childhood from ALRI, after pneumococcal pneumonia and Haemophilus influenzae type b.  The development of novel prevention and treatment strategies should be accelerated as a priority.  FUNDING:  WHO; Bill & Melinda Gates Foundation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSnFoanGZgE-0EksK8CslK8fW6udTcc2eame1_rmrDmfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czgtlaqug%253D%253D&md5=6f2c5f53dae65be05c020454d010f32c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2810%2960206-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252810%252960206-1%26sid%3Dliteratum%253Aachs%26aulast%3DNair%26aufirst%3DH.%26aulast%3DNokes%26aufirst%3DJ.%2BD.%26aulast%3DGessner%26aufirst%3DB.%2BD.%26aulast%3DDherani%26aufirst%3DM.%26aulast%3DMadhi%26aufirst%3DS.%2BA.%26aulast%3DSingleton%26aufirst%3DR.%2BJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DK.%2BL.%26aulast%3DRoca%26aufirst%3DA.%26aulast%3DWright%26aufirst%3DP.%2BF.%26aulast%3DBruce%26aufirst%3DN.%26aulast%3DChandran%26aufirst%3DA.%26aulast%3DTheodoratou%26aufirst%3DE.%26aulast%3DSutanto%26aufirst%3DA.%26aulast%3DSedyaningsih%26aufirst%3DE.%2BR.%26aulast%3DNgama%26aufirst%3DM.%26aulast%3DMunywoki%26aufirst%3DP.%2BK.%26aulast%3DKartasasmita%26aufirst%3DC.%26aulast%3DSim%25C3%25B5es%26aufirst%3DE.%2BA.%26aulast%3DRudan%26aufirst%3DI.%26aulast%3DWeber%26aufirst%3DM.%2BW.%26aulast%3DCampbell%26aufirst%3DH.%26atitle%3DGlobal%2520burden%2520of%2520acute%2520lower%2520respiratory%2520infections%2520due%2520to%2520respiratory%2520syncytial%2520virus%2520in%2520young%2520children%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DLancet%26date%3D2010%26volume%3D375%26issue%3D9725%26spage%3D1545%26epage%3D1555%26doi%3D10.1016%2FS0140-6736%2810%2960206-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boschi-Pinto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biloglav, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulholland, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, H.</span></span> <span> </span><span class="NLM_article-title">Epidemiology and etiology of childhood pneumonia</span>. <i>Bull. World Health Organ.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>86</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">408</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.2471/BLT.07.048769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.2471%2FBLT.07.048769" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=18545744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A280%3ADC%252BD1cznsleqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2008&pages=408-416&issue=5&author=I.+Rudanauthor=C.+Boschi-Pintoauthor=Z.+Biloglavauthor=K.+Mulhollandauthor=H.+Campbell&title=Epidemiology+and+etiology+of+childhood+pneumonia&doi=10.2471%2FBLT.07.048769"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology and etiology of childhood pneumonia</span></div><div class="casAuthors">Rudan Igor; Boschi-Pinto Cynthia; Biloglav Zrinka; Mulholland Kim; Campbell Harry</div><div class="citationInfo"><span class="NLM_cas:title">Bulletin of the World Health Organization</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">408-16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Childhood pneumonia is the leading single cause of mortality in children aged less than 5 years.  The incidence in this age group is estimated to be 0.29 episodes per child-year in developing and 0.05 episodes per child-year in developed countries.  This translates into about 156 million new episodes each year worldwide, of which 151 million episodes are in the developing world.  Most cases occur in India (43 million), China (21 million) and Pakistan (10 million), with additional high numbers in Bangladesh, Indonesia and Nigeria (6 million each).  Of all community cases, 7-13% are severe enough to be life-threatening and require hospitalization.  Substantial evidence revealed that the leading risk factors contributing to pneumonia incidence are lack of exclusive breastfeeding, undernutrition, indoor air pollution, low birth weight, crowding and lack of measles immunization.  Pneumonia is responsible for about 19% of all deaths in children aged less than 5 years, of which more than 70% take place in sub-Saharan Africa and south-east Asia.  Although based on limited available evidence, recent studies have identified Streptococcus pneumoniae, Haemophilus influenzae and respiratory syncytial virus as the main pathogens associated with childhood pneumonia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjSg8oBVMgIcuCWE5mhx1RfW6udTcc2eZhnTfl4mNKpLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cznsleqsw%253D%253D&md5=98002bcca488350c6a878fd496bfe4cf</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2471%2FBLT.07.048769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2471%252FBLT.07.048769%26sid%3Dliteratum%253Aachs%26aulast%3DRudan%26aufirst%3DI.%26aulast%3DBoschi-Pinto%26aufirst%3DC.%26aulast%3DBiloglav%26aufirst%3DZ.%26aulast%3DMulholland%26aufirst%3DK.%26aulast%3DCampbell%26aufirst%3DH.%26atitle%3DEpidemiology%2520and%2520etiology%2520of%2520childhood%2520pneumonia%26jtitle%3DBull.%2520World%2520Health%2520Organ.%26date%3D2008%26volume%3D86%26issue%3D5%26spage%3D408%26epage%3D416%26doi%3D10.2471%2FBLT.07.048769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feltes, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondheimer, H. M.</span></span> <span> </span><span class="NLM_article-title">Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease</span>. <i>Expert Opin. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1471</span>– <span class="NLM_lpage">1480</span>, <span class="refDoi"> DOI: 10.1517/14712598.7.9.1471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1517%2F14712598.7.9.1471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=17727335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BD2sXps1Wnsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1471-1480&issue=9&author=T.+F.+Feltesauthor=H.+M.+Sondheimer&title=Palivizumab+and+the+prevention+of+respiratory+syncytial+virus+illness+in+pediatric+patients+with+congenital+heart+disease&doi=10.1517%2F14712598.7.9.1471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease</span></div><div class="casAuthors">Feltes, Timothy F.; Sondheimer, Henry M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1471-1480</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Respiratory syncytial virus (RSV) is a significant pathogen for infants and children with congenital heart disease.  Non-sustained immunity and failure to develop an effective vaccine has steered RSV management toward a passive immunotherapy strategy in at-risk children.  Palivizumab is a humanized murine monoclonal antibody targeting the RSV envelope F glycoprotein.  In a Phase III clin. trial palivizumab significantly reduced RSV hospitalization in children with significant congenital heart disease and was proven to be safe.  Palivizumab is one of the first monoclonal antibodies to significantly impact a pediatric disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYl03zv6kWuLVg90H21EOLACvtfcHk0liP9tIrSjq8iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXps1Wnsb8%253D&md5=48c600df4bf1fbd64e784d794e1af2a3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1517%2F14712598.7.9.1471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.7.9.1471%26sid%3Dliteratum%253Aachs%26aulast%3DFeltes%26aufirst%3DT.%2BF.%26aulast%3DSondheimer%26aufirst%3DH.%2BM.%26atitle%3DPalivizumab%2520and%2520the%2520prevention%2520of%2520respiratory%2520syncytial%2520virus%2520illness%2520in%2520pediatric%2520patients%2520with%2520congenital%2520heart%2520disease%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2007%26volume%3D7%26issue%3D9%26spage%3D1471%26epage%3D1480%26doi%3D10.1517%2F14712598.7.9.1471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falsey, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennessey, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Formica, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, E. E.</span></span> <span> </span><span class="NLM_article-title">Respiratory syncytial virus infection in the elderly and high-risk adults</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">1749</span>– <span class="NLM_lpage">1759</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa043951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1056%2FNEJMoa043951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=15858184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsFyhsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=1749-1759&issue=17&author=A.+R.+Falseyauthor=P.+A.+Hennesseyauthor=M.+A.+Formicaauthor=C.+Coxauthor=E.+E.+Walsh&title=Respiratory+syncytial+virus+infection+in+the+elderly+and+high-risk+adults&doi=10.1056%2FNEJMoa043951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus infection in elderly and high-risk adults</span></div><div class="casAuthors">Falsey, Ann R.; Hennessey, Patricia A.; Formica, Maria A.; Cox, Christopher; Walsh, Edward E.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1749-1759</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Respiratory syncytial virus (RSV) is an increasingly recognized cause of illness in adults.  Data on the epidemiol. and clin. effects in community-dwelling elderly persons and high-risk adults can help in assessing the need for vaccine development.  METHODS During four consecutive winters, we evaluated all respiratory illnesses in prospective cohorts of healthy elderly patients (≥65 years of age) and high-risk adults (those with chronic heart or lung disease) and in patients hospitalized with acute cardiopulmonary conditions.  RSV infection and influenza A were diagnosed on the basis of culture, reverse-transcriptase polymerase chain reaction, and serol. studies.  RESULTS A total of 608 healthy elderly patients and 540 high-risk adults were enrolled in prospective surveillance, and 1388 hospitalized patients were enrolled.  A total of 2514 illnesses were evaluated.  RSV infection was identified in 102 patients in the prospective cohorts and 142 hospitalized patients, and influenza A was diagnosed in 44 patients in the prospective cohorts and 154 hospitalized patients.  RSV infection developed annually in 3 to 7 percent of healthy elderly patients and in 4 to 10 percent of high-risk adults.  Among healthy elderly patients, RSV infection generated fewer office visits than influenza; however, the use of health care services by high-risk adults was similar in the two groups.  In the hospitalized cohort, RSV infection and influenza A resulted in similar lengths of stay, rates of use of intensive care (15 percent and 12 percent, resp.), and mortality (8 percent and 7 percent, resp.).  On the basis of the diagnostic codes of the International Classification of Diseases, 9th Revision, Clin. Modification at discharge, RSV infection accounted for 10.6 percent of hospitalizations for pneumonia, 11.4 percent for chronic obstructive pulmonary disease, 5.4 percent for congestive heart failure, and 7.2 percent for asthma.  CONCLUSIONS RSV infection is an important illness in elderly and high-risk adults, with a disease burden similar to that of nonpandemic influenza A in a population in which the prevalence of vaccination for influenza is high.  An effective RSV vaccine may offer benefits for these adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC4DLnaPCjP7Vg90H21EOLACvtfcHk0ljudYBqEl1LNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsFyhsr8%253D&md5=84051565564c0794974fde0b28a0e887</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa043951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa043951%26sid%3Dliteratum%253Aachs%26aulast%3DFalsey%26aufirst%3DA.%2BR.%26aulast%3DHennessey%26aufirst%3DP.%2BA.%26aulast%3DFormica%26aufirst%3DM.%2BA.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DWalsh%26aufirst%3DE.%2BE.%26atitle%3DRespiratory%2520syncytial%2520virus%2520infection%2520in%2520the%2520elderly%2520and%2520high-risk%2520adults%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26issue%3D17%26spage%3D1749%26epage%3D1759%26doi%3D10.1056%2FNEJMoa043951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wainwright, C.</span></span> <span> </span><span class="NLM_article-title">Acute viral bronchiolitis in children - a very common condition with few therapeutic options</span>. <i>Paediatr. Respir. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/j.prrv.2009.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1016%2Fj.prrv.2009.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=20113991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252Fotlyhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=39-45&issue=1&author=C.+Wainwright&title=Acute+viral+bronchiolitis+in+children+-+a+very+common+condition+with+few+therapeutic+options&doi=10.1016%2Fj.prrv.2009.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Acute viral bronchiolitis in children- a very common condition with few therapeutic options</span></div><div class="casAuthors">Wainwright Claire</div><div class="citationInfo"><span class="NLM_cas:title">Paediatric respiratory reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-45; quiz 45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acute viral bronchiolitis remains a cause of substantial morbidity and health care costs in young infants.  It is the most common lower respiratory tract condition and most common reason for admission to hospital in infants.  Many respiratory viruses have been associated with acute viral bronchiolitis although respiratory syncytial virus (RSV) remains the most frequently identified virus.  Most infants have a mild self limiting illness while others have more severe illness and require hospital admission and some will need ventilatory support.  Differences in innate immune function in response to the respiratory viral insult as well as differences in the geometry of the airways may explain some of the variability in clinical pattern.  Young age and history of prematurity remain the most important risk factors although male gender, indigenous status, exposure to tobacco smoke, poor socioeconomic factors and associated co-morbidities such as chronic lung disease and congenital heart disease increase the risks of more severe illness.  Supportive therapy remains the major treatment option as no specific treatments to date have been shown to provide clinically important benefits except for inhaled hypertonic saline.  Prophylaxis of high risk infants with palivizumab should be considered although the cost effectiveness is still unclear.  Many questions remain regarding optimal management approaches for infants requiring hospitalisation with bronchiolitis including use of nasogastric feeding, the optimal role of supplemental oxygen, optimal use of hypertonic saline and the role of combinations of therapies, the use of heliox or modern physiotherapy approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQjYoMkmkNtP-Lt9HypzAgQfW6udTcc2eYKwvh3jljOzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252Fotlyhsw%253D%253D&md5=ef94d9327375911261d3d3cf730c66bd</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.prrv.2009.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.prrv.2009.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DWainwright%26aufirst%3DC.%26atitle%3DAcute%2520viral%2520bronchiolitis%2520in%2520children%2520-%2520a%2520very%2520common%2520condition%2520with%2520few%2520therapeutic%2520options%26jtitle%3DPaediatr.%2520Respir.%2520Rev.%26date%3D2010%26volume%3D11%26issue%3D1%26spage%3D39%26epage%3D45%26doi%3D10.1016%2Fj.prrv.2009.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Empey, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peebles, R. S.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolls, J. K.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic advances in the treatment and prevention of respiratory syncytial virus</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1258</span>– <span class="NLM_lpage">1267</span>, <span class="refDoi"> DOI: 10.1086/651603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1086%2F651603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=20235830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVehtL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=1258-1267&issue=9&author=K.+M.+Empeyauthor=R.+S.+Peeblesauthor=J.+K.+Kolls&title=Pharmacologic+advances+in+the+treatment+and+prevention+of+respiratory+syncytial+virus&doi=10.1086%2F651603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic advances in the treatment and prevention of respiratory syncytial virus</span></div><div class="casAuthors">Empey, Kerry M.; Peebles, R. Stokes, Jr.; Kolls, Jay K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1258-1267</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">A review.  Currently, only 2 drugs have been approved for the treatment of respiratory syncytial virus (RSV).  Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children.  Ribavirin is approved for treatment of severe RSV disease; however, its effectiveness in improving outcomes is questionable.  During the past 40 years, many obstacles have delayed the development of safe and effective vaccines and treatment regimens.  This article reviews these obstacles and presents the novel development strategies used to overcome many of them.  Also discussed are promising new antiviral treatment candidates and their assocd. mechanism of action, the significant advances made in vaccine development, and exciting, new studies directed at improving outcomes through pharmacol. manipulation of the host response to RSV disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowVNHvx4G3Z7Vg90H21EOLACvtfcHk0lgfLbt-nydbEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVehtL3N&md5=f5b23cc6db487b8e50ceb7379cdd107f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1086%2F651603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F651603%26sid%3Dliteratum%253Aachs%26aulast%3DEmpey%26aufirst%3DK.%2BM.%26aulast%3DPeebles%26aufirst%3DR.%2BS.%26aulast%3DKolls%26aufirst%3DJ.%2BK.%26atitle%3DPharmacologic%2520advances%2520in%2520the%2520treatment%2520and%2520prevention%2520of%2520respiratory%2520syncytial%2520virus%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2010%26volume%3D50%26issue%3D9%26spage%3D1258%26epage%3D1267%26doi%3D10.1086%2F651603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span> <span> </span><span class="NLM_article-title">Respiratory syncytial virus: a prioritized or neglected target?</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1523</span>– <span class="NLM_lpage">1527</span>, <span class="refDoi"> DOI: 10.4155/fmc.10.235</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.4155%2Ffmc.10.235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=21426146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1yqsbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=1523-1527&issue=10&author=D.+Roymansauthor=A.+Koul&title=Respiratory+syncytial+virus%3A+a+prioritized+or+neglected+target%3F&doi=10.4155%2Ffmc.10.235"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus: a prioritized or neglected target?</span></div><div class="casAuthors">Roymans, Dirk; Koul, Anil</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1523-1527</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5WHK0tco01LVg90H21EOLACvtfcHk0lgfLbt-nydbEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1yqsbjO&md5=78297af20cb3e9afb2878c2eb70f2be4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.4155%2Ffmc.10.235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.10.235%26sid%3Dliteratum%253Aachs%26aulast%3DRoymans%26aufirst%3DD.%26aulast%3DKoul%26aufirst%3DA.%26atitle%3DRespiratory%2520syncytial%2520virus%253A%2520a%2520prioritized%2520or%2520neglected%2520target%253F%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2010%26volume%3D2%26issue%3D10%26spage%3D1523%26epage%3D1527%26doi%3D10.4155%2Ffmc.10.235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span>; <span class="NLM_string-name">Koul, A.</span></span> <span> </span><span class="NLM_article-title">Treatment of respiratory syncytial virus infection: Past, present and future</span>. In  <i>Human Respiratory Syncytial Virus Infection</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resch, B</span></span>, Ed.; <span class="NLM_publisher-name">InTech</span>: <span class="NLM_publisher-loc">Rijeka, Croatia</span>, <span class="NLM_year">2011</span>; pp  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">215</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.5772%2F26528" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=197-215&author=D.+Roymans&author=A.+Koulauthor=B+Resch&title=Human+Respiratory+Syncytial+Virus+Infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.5772%2F26528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.5772%252F26528%26sid%3Dliteratum%253Aachs%26aulast%3DRoymans%26aufirst%3DD.%26atitle%3DTreatment%2520of%2520respiratory%2520syncytial%2520virus%2520infection%253A%2520Past%252C%2520present%2520and%2520future%26btitle%3DHuman%2520Respiratory%2520Syncytial%2520Virus%2520Infection%26aulast%3DResch%26aufirst%3DB%26pub%3DInTech%26date%3D2011%26spage%3D197%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Saleeby, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, A. J.</span></span> <span> </span><span class="NLM_article-title">Respiratory syncytial virus load predicts disease severity in previously healthy infants</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>191</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1861</span>– <span class="NLM_lpage">1868</span>, <span class="refDoi"> DOI: 10.1086/430008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1086%2F430008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=15871119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A280%3ADC%252BD2Mzitl2ktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2005&pages=1861-1868&issue=11&author=J.+P.+DeVincenzoauthor=C.+M.+El+Saleebyauthor=A.+J.+Bush&title=Respiratory+syncytial+virus+load+predicts+disease+severity+in+previously+healthy+infants&doi=10.1086%2F430008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus load predicts disease severity in previously healthy infants</span></div><div class="casAuthors">DeVincenzo John P; El Saleeby Chadi M; Bush Andrew J</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of infectious diseases</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1861-8</span>
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    </div><div class="casAbstract">BACKGROUND:  Elucidating the relationship between viral load and respiratory syncytial virus (RSV) disease severity is critical to understanding pathogenesis and predicting the utility of antivirals.  METHODS:  Previously healthy, naturally RSV-infected infants <24 months old not treated with ribavirin, passive antibody, or corticosteroids were prospectively studied (n=141).  Viral loads were measured by fresh quantitative culture from nasal washes collected at a single time point shortly after hospitalization.  RESULTS:  The subjects' mean age was 112.1 days, and the mean estimated gestational age at birth was 38.38 weeks.  RSV load decreased with longer durations of symptoms before specimen collection (P=.01).  Male subjects had higher RSV loads than female subjects (P=.036).  Significant independent predictors of longer hospitalization were congenital anomaly (P<.0001), lower weight on admission (P=.028), and higher nasal RSV load (P=.008).  A 1-log higher RSV load predicted a 0.8-day longer hospitalization.  Lower weight and higher RSV load were also independently associated with respiratory failure (P<.0005 and P=.0049, respectively) and requirement for intensive care (P=.0007 and P=.0048, respectively).  CONCLUSIONS:  In previously healthy infants, higher RSV loads measured at capturable time points after symptom onset predict clinically relevant measures of increased disease severity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT2TotJolUTY6Nc3HjJRoFAfW6udTcc2ebQNgQvtoVwRLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mzitl2ktA%253D%253D&md5=bbc73709fc42da99a8a9d950120972a3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1086%2F430008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F430008%26sid%3Dliteratum%253Aachs%26aulast%3DDeVincenzo%26aufirst%3DJ.%2BP.%26aulast%3DEl%2BSaleeby%26aufirst%3DC.%2BM.%26aulast%3DBush%26aufirst%3DA.%2BJ.%26atitle%3DRespiratory%2520syncytial%2520virus%2520load%2520predicts%2520disease%2520severity%2520in%2520previously%2520healthy%2520infants%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2005%26volume%3D191%26issue%3D11%26spage%3D1861%26epage%3D1868%26doi%3D10.1086%2F430008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cehelsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nochur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeking, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pareek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studholme, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsett, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambkin-Williams, R.</span></span> <span> </span><span class="NLM_article-title">Viral load drives disease in humans experimentally infected with respiratory syncytial virus</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>182</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">1314</span>, <span class="refDoi"> DOI: 10.1164/rccm.201002-0221OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1164%2Frccm.201002-0221OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=20622030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1equg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2010&pages=1305-1314&issue=10&author=J.+P.+DeVincenzoauthor=T.+Wilkinsonauthor=A.+Vaishnawauthor=J.+Cehelskyauthor=R.+Meyersauthor=S.+Nochurauthor=L.+Harrisonauthor=P.+Meekingauthor=A.+Mannauthor=E.+Moaneauthor=J.+Oxfordauthor=R.+Pareekauthor=R.+Mooreauthor=E.+Walshauthor=R.+Studholmeauthor=P.+Dorsettauthor=R.+Alvarezauthor=R.+Lambkin-Williams&title=Viral+load+drives+disease+in+humans+experimentally+infected+with+respiratory+syncytial+virus&doi=10.1164%2Frccm.201002-0221OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Viral load drives disease in humans experimentally infected with respiratory syncytial virus</span></div><div class="casAuthors">DeVincenzo, John P.; Wilkinson, Tom; Vaishnaw, Akshay; Cehelsky, Jeff; Meyers, Rachel; Nochur, Saraswathy; Harrison, Lisa; Meeking, Patricia; Mann, Alex; Moane, Elizabeth; Oxford, John; Pareek, Rajat; Moore, Ryves; Walsh, Ed; Studholme, Robert; Dorsett, Preston; Alvarez, Rene; Lambkin-Williams, Robert</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1305-1314</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) is the leading cause of childhood lower respiratory infection, yet viable therapies are lacking.  Two major challenges have stalled antiviral development: ethical difficulties in performing pediatric proof-of-concept studies and the prevailing concept that the disease is immune-mediated rather than being driven by viral load.  The development of a human exptl. wild-type RSV infection model to address these challenges.  Healthy volunteers (n = 35), in five cohorts, received increasing quantities (3.0-5.4 log plaque-forming units/person) of wild-type RSV-A intranasally.  Overall, 77% of volunteers consistently shed virus.  Infection rate, viral loads, disease severity, and safety were similar between cohorts and were unrelated to quantity of RSV received.  Symptoms began near the time of initial viral detection, peaked in severity near when viral load peaked, and subsided as viral loads (measured by real-time polymerase chain reaction) slowly declined.  Viral loads correlated significantly with intranasal proinflammatory cytokine concns. (IL-6 and IL-8).  Increased viral load correlated consistently with increases in multiple different disease measurements (symptoms, phys. examn., and amt. of nasal mucus).  Viral load appears to drive disease manifestations in humans with RSV infection.  The obsd. parallel viral and disease kinetics support a potential clin. benefit of RSV antivirals.  This reproducible model facilitates the development of future RSV therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-DVpVkrytZ7Vg90H21EOLACvtfcHk0ljg4-E9WdvLsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1equg%253D%253D&md5=baadbf1735812bf00a63b9499a2fe3bd</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1164%2Frccm.201002-0221OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201002-0221OC%26sid%3Dliteratum%253Aachs%26aulast%3DDeVincenzo%26aufirst%3DJ.%2BP.%26aulast%3DWilkinson%26aufirst%3DT.%26aulast%3DVaishnaw%26aufirst%3DA.%26aulast%3DCehelsky%26aufirst%3DJ.%26aulast%3DMeyers%26aufirst%3DR.%26aulast%3DNochur%26aufirst%3DS.%26aulast%3DHarrison%26aufirst%3DL.%26aulast%3DMeeking%26aufirst%3DP.%26aulast%3DMann%26aufirst%3DA.%26aulast%3DMoane%26aufirst%3DE.%26aulast%3DOxford%26aufirst%3DJ.%26aulast%3DPareek%26aufirst%3DR.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DWalsh%26aufirst%3DE.%26aulast%3DStudholme%26aufirst%3DR.%26aulast%3DDorsett%26aufirst%3DP.%26aulast%3DAlvarez%26aufirst%3DR.%26aulast%3DLambkin-Williams%26aufirst%3DR.%26atitle%3DViral%2520load%2520drives%2520disease%2520in%2520humans%2520experimentally%2520infected%2520with%2520respiratory%2520syncytial%2520virus%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2010%26volume%3D182%26issue%3D10%26spage%3D1305%26epage%3D1314%26doi%3D10.1164%2Frccm.201002-0221OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El Saleeby, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aitken, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J. P.</span></span> <span> </span><span class="NLM_article-title">Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>204</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">996</span>– <span class="NLM_lpage">1002</span>, <span class="refDoi"> DOI: 10.1093/infdis/jir494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1093%2Finfdis%2Fjir494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=21881113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A280%3ADC%252BC3Mfgt1GnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2011&pages=996-1002&issue=7&author=C.+M.+El+Saleebyauthor=A.+J.+Bushauthor=L.+M.+Harrisonauthor=J.+A.+Aitkenauthor=J.+P.+DeVincenzo&title=Respiratory+syncytial+virus+load%2C+viral+dynamics%2C+and+disease+severity+in+previously+healthy+naturally+infected+children&doi=10.1093%2Finfdis%2Fjir494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children</span></div><div class="casAuthors">El Saleeby Chadi M; Bush Andy J; Harrison Lisa M; Aitken Jody A; Devincenzo John P</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of infectious diseases</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">996-1002</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Respiratory syncytial virus (RSV) disease severity was thought to be a result of host immunopathology but alternatively may be driven by high-level viral replication.  The relationships between RSV load, viral clearance dynamics, and disease severity have not been carefully evaluated.  METHODS:  Previously healthy RSV-infected children <2 years old were recruited.  RSV load was measured in respiratory secretions by fresh quantitative culture over 3 hospital days.  Measures of disease severity were hospital admission, duration of hospitalization, requirement for intensive care, and respiratory failure.  RESULTS:  Multivariate logistic regression models revealed independent predictors of increased duration of hospitalization: male sex, lower weight, and higher viral load on any day.  Viral loads at day 3 were more significantly associated with requirement for intensive care and respiratory failure than were viral loads at earlier time points.  Faster RSV clearance was independently associated with shorter hospitalization.  DISCUSSION:  These observations challenge the immunopathology-based pathogenesis paradigm.  They also have major therapeutic implications, suggesting that application of antiviral agents early in the disease course, even at a time when viral replication is at its highest, might improve subsequent morbidity by significantly lowering viral load and direct viral cytopathic effects, and aborting the potential downstream immunopathology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmIt942YeXHUPI-fCgwosgfW6udTcc2eZBnM9EAzbFObntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mfgt1GnsQ%253D%253D&md5=df2aee4217ba4325199646ac70599049</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjir494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjir494%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BSaleeby%26aufirst%3DC.%2BM.%26aulast%3DBush%26aufirst%3DA.%2BJ.%26aulast%3DHarrison%26aufirst%3DL.%2BM.%26aulast%3DAitken%26aufirst%3DJ.%2BA.%26aulast%3DDeVincenzo%26aufirst%3DJ.%2BP.%26atitle%3DRespiratory%2520syncytial%2520virus%2520load%252C%2520viral%2520dynamics%252C%2520and%2520disease%2520severity%2520in%2520previously%2520healthy%2520naturally%2520infected%2520children%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2011%26volume%3D204%26issue%3D7%26spage%3D996%26epage%3D1002%26doi%3D10.1093%2Finfdis%2Fjir494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperandio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrish, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boojamra, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babaoglu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piedra, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stray, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinkade, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theodore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human rsv challenge Study</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1630</span>– <span class="NLM_lpage">1643</span>, <span class="refDoi"> DOI: 10.1021/jm5017768</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5017768" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1yltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1630-1643&issue=4&author=R.+L.+Mackmanauthor=M.+Sangiauthor=D.+Sperandioauthor=J.+P.+Parrishauthor=E.+Eisenbergauthor=M.+Perronauthor=H.+Huiauthor=L.+Zhangauthor=D.+Siegelauthor=H.+Yangauthor=O.+Saundersauthor=O.+Boojamraauthor=G.+Leeauthor=D.+Samuelauthor=K.+Babaogluauthor=A.+Careyauthor=B.+E.+Gilbertauthor=P.+A.+Piedraauthor=R.+Strickleyauthor=Q.+Iwataauthor=J.+Hayesauthor=K.+Strayauthor=A.+Kinkadeauthor=D.+Theodoreauthor=R.+Jordanauthor=M.+Desaiauthor=T.+Cihlar&title=Discovery+of+an+oral+respiratory+syncytial+virus+%28RSV%29+fusion+inhibitor+%28GS-5806%29+and+clinical+proof+of+concept+in+a+human+rsv+challenge+Study&doi=10.1021%2Fjm5017768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Oral Respiratory Syncytial Virus (RSV) Fusion Inhibitor (GS-5806) and Clinical Proof of Concept in a Human RSV Challenge Study</span></div><div class="casAuthors">Mackman, Richard L.; Sangi, Michael; Sperandio, David; Parrish, Jay P.; Eisenberg, Eugene; Perron, Michel; Hui, Hon; Zhang, Lijun; Siegel, Dustin; Yang, Hai; Saunders, Oliver; Boojamra, Constantine; Lee, Gary; Samuel, Dharmaraj; Babaoglu, Kerim; Carey, Anne; Gilbert, Brian E.; Piedra, Pedro A.; Strickley, Robert; Iwata, Quynh; Hayes, Jaclyn; Stray, Kirsten; Kinkade, April; Theodore, Dorothy; Jordan, Robert; Desai, Manoj; Cihlar, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1630-1643</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">GS-5806 I is a novel, orally bioavailable RSV fusion inhibitor discovered following a lead optimization campaign on a screening hit.  The oral absorption properties were optimized by converting to the pyrazolo[1,5-a]-pyrimidine heterocycle, while potency, metabolic, and physicochem. properties were optimized by introducing the para-chloro and aminopyrrolidine groups.  A mean EC50 = 0.43 nM was found toward a panel of 75 RSV A and B clin. isolates and dose-dependent antiviral efficacy in the cotton rat model of RSV infection.  Oral bioavailability in preclin. species ranged from 46 to 100%, with evidence of efficient penetration into lung tissue.  In healthy human volunteers exptl. infected with RSV, a potent antiviral effect was obsd. with a mean 4.2 log10 redn. in peak viral load and a significant redn. in disease severity compared to placebo.  In conclusion, a potent, once daily, oral RSV fusion inhibitor with the potential to treat RSV infection in infants and adults is reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL4lY74Xv7GbVg90H21EOLACvtfcHk0lh8LXUl78xTrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1yltw%253D%253D&md5=5a723ce1defe717da8cb7985ee297811</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm5017768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5017768%26sid%3Dliteratum%253Aachs%26aulast%3DMackman%26aufirst%3DR.%2BL.%26aulast%3DSangi%26aufirst%3DM.%26aulast%3DSperandio%26aufirst%3DD.%26aulast%3DParrish%26aufirst%3DJ.%2BP.%26aulast%3DEisenberg%26aufirst%3DE.%26aulast%3DPerron%26aufirst%3DM.%26aulast%3DHui%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DSaunders%26aufirst%3DO.%26aulast%3DBoojamra%26aufirst%3DO.%26aulast%3DLee%26aufirst%3DG.%26aulast%3DSamuel%26aufirst%3DD.%26aulast%3DBabaoglu%26aufirst%3DK.%26aulast%3DCarey%26aufirst%3DA.%26aulast%3DGilbert%26aufirst%3DB.%2BE.%26aulast%3DPiedra%26aufirst%3DP.%2BA.%26aulast%3DStrickley%26aufirst%3DR.%26aulast%3DIwata%26aufirst%3DQ.%26aulast%3DHayes%26aufirst%3DJ.%26aulast%3DStray%26aufirst%3DK.%26aulast%3DKinkade%26aufirst%3DA.%26aulast%3DTheodore%26aufirst%3DD.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DDesai%26aufirst%3DM.%26aulast%3DCihlar%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520an%2520oral%2520respiratory%2520syncytial%2520virus%2520%2528RSV%2529%2520fusion%2520inhibitor%2520%2528GS-5806%2529%2520and%2520clinical%2520proof%2520of%2520concept%2520in%2520a%2520human%2520rsv%2520challenge%2520Study%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D4%26spage%3D1630%26epage%3D1643%26doi%3D10.1021%2Fjm5017768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deval, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyatkina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prhavc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serebryany, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symons, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4′-Chloromethyl-2′-deoxy-3′,5′-di-O-isobutyryl-2′-fluorocytidine (ALS-8176), A first-in-class rsv polymerase inhibitor for treatment of human respiratory syncytial virus infection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1862</span>– <span class="NLM_lpage">1878</span>, <span class="refDoi"> DOI: 10.1021/jm5017279</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5017279" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisF2jsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1862-1878&issue=4&author=G.+Wangauthor=J.+Devalauthor=J.+Hongauthor=N.+Dyatkinaauthor=M.+Prhavcauthor=J.+Taylorauthor=A.+Fungauthor=Z.+Jinauthor=S.+K.+Stevensauthor=V.+Serebryanyauthor=J.+Liuauthor=Q.+Zhangauthor=Y.+Tamauthor=S.+M.+Chandaauthor=D.+B.+Smithauthor=J.+A.+Symonsauthor=L.+M.+Blattauthor=L.+Beigelman&title=Discovery+of+4%E2%80%B2-Chloromethyl-2%E2%80%B2-deoxy-3%E2%80%B2%2C5%E2%80%B2-di-O-isobutyryl-2%E2%80%B2-fluorocytidine+%28ALS-8176%29%2C+A+first-in-class+rsv+polymerase+inhibitor+for+treatment+of+human+respiratory+syncytial+virus+infection&doi=10.1021%2Fjm5017279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4'-Chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), A First-in-Class RSV Polymerase Inhibitor for Treatment of Human Respiratory Syncytial Virus Infection</span></div><div class="casAuthors">Wang, Guangyi; Deval, Jerome; Hong, Jin; Dyatkina, Natalia; Prhavc, Marija; Taylor, Joshua; Fung, Amy; Jin, Zhinan; Stevens, Sarah K.; Serebryany, Vladimir; Liu, Jyanwei; Zhang, Qingling; Tam, Yuen; Chanda, Sushmita M.; Smith, David B.; Symons, Julian A.; Blatt, Lawrence M.; Beigelman, Leo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1862-1878</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) is a leading pathogen of childhood and is assocd. with significant morbidity and mortality.  To date, ribavirin is the only approved small mol. drug, which has limited use.  The only other RSV drug is palivizumab, a monoclonal antibody, which is used for RSV prophylaxis.  Clearly, there is an urgent need for small mol. RSV drugs.  This article reports the design, synthesis, anti-RSV activity, metab., and pharmacokinetics of a series of 4'-substituted cytidine nucleosides.  Among tested compds. 4'-chloromethyl-2'-deoxy-2'-fluorocytidine I exhibited the most promising activity in the RSV replicon assay with an EC50 of 0.15 μM.  The 5'-triphosphate of I (I-TP)inhibited RSV polymerase with an IC50 of 0.02 μM without appreciable inhibition of human DNA and RNA polymerases at 100 μM.  ALS-8176 II, the 3',5'-di-O-isobutyryl prodrug of I, demonstrated good oral bioavailability and a high level of I-TP in vivo.  Compd. II is a first-in-class nucleoside RSV polymerase inhibitor that demonstrated excellent anti-RSV efficacy and safety in a phase 2 clin. RSV challenge study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaKHh4AhV9drVg90H21EOLACvtfcHk0lh8LXUl78xTrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisF2jsL4%253D&md5=da9e883eb67f20ca259dec06a6a05367</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm5017279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5017279%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DG.%26aulast%3DDeval%26aufirst%3DJ.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DDyatkina%26aufirst%3DN.%26aulast%3DPrhavc%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DJ.%26aulast%3DFung%26aufirst%3DA.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DStevens%26aufirst%3DS.%2BK.%26aulast%3DSerebryany%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DTam%26aufirst%3DY.%26aulast%3DChanda%26aufirst%3DS.%2BM.%26aulast%3DSmith%26aufirst%3DD.%2BB.%26aulast%3DSymons%26aufirst%3DJ.%2BA.%26aulast%3DBlatt%26aufirst%3DL.%2BM.%26aulast%3DBeigelman%26aufirst%3DL.%26atitle%3DDiscovery%2520of%25204%25E2%2580%25B2-Chloromethyl-2%25E2%2580%25B2-deoxy-3%25E2%2580%25B2%252C5%25E2%2580%25B2-di-O-isobutyryl-2%25E2%2580%25B2-fluorocytidine%2520%2528ALS-8176%2529%252C%2520A%2520first-in-class%2520rsv%2520polymerase%2520inhibitor%2520for%2520treatment%2520of%2520human%2520respiratory%2520syncytial%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D4%26spage%3D1862%26epage%3D1878%26doi%3D10.1021%2Fjm5017279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaglioni-Weinlich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambkin-Williams, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Riordan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toback, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, J. W.</span></span> <span> </span><span class="NLM_article-title">Oral GS-5806 activity in a respiratory syncytial virus challenge study</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">722</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1401184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1056%2FNEJMoa1401184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=25140957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Cjsb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=711-722&author=J.+P.+DeVincenzoauthor=R.+J.+Whitleyauthor=R.+L.+Mackmanauthor=C.+Scaglioni-Weinlichauthor=L.+Harrisonauthor=E.+Farrellauthor=S.+McBrideauthor=R.+Lambkin-Williamsauthor=R.+Jordanauthor=Y.+Xinauthor=S.+Ramanathanauthor=T.+O%E2%80%99Riordanauthor=S.+A.+Lewisauthor=X.+Liauthor=S.+L.+Tobackauthor=S.+Linauthor=J.+W.+Chien&title=Oral+GS-5806+activity+in+a+respiratory+syncytial+virus+challenge+study&doi=10.1056%2FNEJMoa1401184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Oral GS-5806 activity in a respiratory syncytial virus challenge study</span></div><div class="casAuthors">DeVincenzo, John P.; Whitley, Richard J.; Mackman, Richard L.; Scaglioni-Weinlich, Cecilia; Harrison, Lisa; Farrell, Eric; McBride, Stephen; Lambkin-Williams, Robert; Jordan, Robert; Xin, Yan; Ramanathan, Srini; O'Riordan, Thomas; Lewis, Sandra A.; Li, Xiaoming; Toback, Seth L.; Lin, Shao-Lee; Chien, Jason W.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">711-722, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Respiratory syncytial virus (RSV) is a common cause of infant hospitalizations and is increasingly recognized as a cause of considerable morbidity and mortality.  No accepted antiviral treatment exists.  Methods: We conducted a double-blind, placebo-controlled study of GS-5806, an oral RSV-entry inhibitor, in healthy adults who received a clin. challenge strain of RSV intranasally.  Participants were monitored for 12 days.  At the time of a pos. test for RSV infection or 5 days after inoculation, whichever occurred first, participants were randomly assigned to receive GS-5806 or placebo in one of seven sequential cohorts.  Cohorts 1 to 4 received a first dose of 50 mg of GS-5806 and then 25 mg daily for the next 4 days, cohort 5 received a first dose of 50 mg and then 25 mg daily for the next 2 days, cohort 6 received one 100-mg dose, and cohort 7 received a first dose of 10 mg and then 5 mg daily for the next 4 days.  Dose selection for cohorts 5, 6, and 7 occurred after an interim anal. of data for cohorts 1 to 4.  The primary end point was the area under the curve (AUC) for the viral load, which was assessed after administration of the first dose through the 12th day after inoculation.  Secondary end points were mucus wt. and symptom scores.  Results: Among the 54 participants in cohorts 1 to 4 who were infected with RSV, active treatment was assocd. with a lower viral load (adjusted mean, 250.7 vs. 757.7 log10 plaque-forming-unit equiv. [PFUe] × hours per mL; P<0.001), lower total mucus wt. (mean, 6.9 g vs. 15.1 g; P = 0.03), and a lower AUC for the change from baseline in symptom scores (adjusted mean, -20.2 vs. 204.9 × hours; P = 0.005).  The results were similar in cohorts 5, 6, and 7.  Adverse events, including low neutrophil counts and increased levels of alanine aminotransferase, were more common among participants receiving GS-5806.  Conclusions: Treatment with GS-5806 reduced the viral load and the severity of clin. disease in a challenge study of healthy adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqxDrIVO5aQLVg90H21EOLACvtfcHk0lhUkZK0L1B7tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Cjsb7O&md5=72276739a80d55a732269359e338fb95</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1401184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1401184%26sid%3Dliteratum%253Aachs%26aulast%3DDeVincenzo%26aufirst%3DJ.%2BP.%26aulast%3DWhitley%26aufirst%3DR.%2BJ.%26aulast%3DMackman%26aufirst%3DR.%2BL.%26aulast%3DScaglioni-Weinlich%26aufirst%3DC.%26aulast%3DHarrison%26aufirst%3DL.%26aulast%3DFarrell%26aufirst%3DE.%26aulast%3DMcBride%26aufirst%3DS.%26aulast%3DLambkin-Williams%26aufirst%3DR.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DXin%26aufirst%3DY.%26aulast%3DRamanathan%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Riordan%26aufirst%3DT.%26aulast%3DLewis%26aufirst%3DS.%2BA.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DToback%26aufirst%3DS.%2BL.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DChien%26aufirst%3DJ.%2BW.%26atitle%3DOral%2520GS-5806%2520activity%2520in%2520a%2520respiratory%2520syncytial%2520virus%2520challenge%2520study%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D711%26epage%3D722%26doi%3D10.1056%2FNEJMoa1401184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClure, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symons, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fathi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westland, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambkin-Williams, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, J.</span></span> <span> </span><span class="NLM_article-title">Activity of oral ALS-008176 in a respiratory syncytial virus challenge study</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">2048</span>– <span class="NLM_lpage">2058</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1413275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1056%2FNEJMoa1413275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=26580997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC28XntVSrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=2048-2058&author=J.+P.+DeVincenzoauthor=M.+W.+McClureauthor=J.+A.+Symonsauthor=H.+Fathiauthor=C.+Westlandauthor=S.+Chandaauthor=R.+Lambkin-Williamsauthor=P.+Smithauthor=Q.+Zhangauthor=L.+Beigelmanauthor=L.+M.+Blattauthor=J.+Fry&title=Activity+of+oral+ALS-008176+in+a+respiratory+syncytial+virus+challenge+study&doi=10.1056%2FNEJMoa1413275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of oral ALS-008176 in a respiratory syncytial virus challenge study</span></div><div class="casAuthors">DeVincenzo, John P.; McClure, Matthew W.; Symons, Julian A.; Fathi, Hosnieh; Westland, Christopher; Chanda, Sushmita; Lambkin-Williams, Rob; Smith, Patrick; Zhang, Qingling; Beigelman, Leo; Blatt, Lawrence M.; Fry, John</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2048-2058</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) infection is a cause of substantial morbidity and mortality.  There is no known effective therapy.  We conducted a randomized, double-blind, clin. trial in healthy adults inoculated with RSV.  Participants received the oral nucleoside analog ALS-008176 or placebo 12 h after confirmation of RSV infection or 6 days after inoculation.  Treatment was administered every 12 h for 5 days.  Viral load, disease severity, resistance, and safety were measured throughout the 28-day study period, with measurement beginning before inoculation.  The primary end point was the area under the curve (AUC) for viral load, which was assessed immediately before administration of the first dose through the 12th day after inoculation in participants infected with RSV.  A total of 62 participants received placebo or one of three ALS-008176 dosing regimens: 1 loading dose of 750 mg followed by 9 maintenance doses of 500 mg (group 1), 1 loading dose of 750 mg followed by 9 maintenance doses of 150 mg (group 2), or 10 doses of 375 mg (group 3).  In the 35 infected participants (23 of whom were treated with ALS-008176), the AUCs for viral load for groups 1, 2, and 3 and the placebo group were 59.9, 73.7, 133.4, and 500.9 log10 plaque-forming-unit equiv. × hours per mL, resp. (P≤0.001).  The time to nondetectability on polymerase-chain-reaction assay (P<0.001), the peak viral load (P≤0.001), the AUC for symptom score (P<0.05), and the AUC for mucus wt. were lower in all groups receiving ALS-008176 than in the placebo group.  Antiviral activity was greatest in the two groups that received a loading dose - viral clearance was accelerated (P≤0.05), and the AUC for viral load decreased by 85 to 88% as compared with the placebo group.  Within this small trial, no viral rebound or resistance was identified.  There were no serious adverse events, and there was no need for premature discontinuation of the study drug.  In this RSV challenge study, more rapid RSV clearance and a greater redn. of viral load, with accompanying improvements in the severity of clin. disease, were obsd. in the groups treated with ALS-008176 than in the placebo group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVhsAaDKW-4bVg90H21EOLACvtfcHk0lhUkZK0L1B7tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntVSrsro%253D&md5=e1cac2ef1b91f47abf768403cb072ec0</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1413275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1413275%26sid%3Dliteratum%253Aachs%26aulast%3DDeVincenzo%26aufirst%3DJ.%2BP.%26aulast%3DMcClure%26aufirst%3DM.%2BW.%26aulast%3DSymons%26aufirst%3DJ.%2BA.%26aulast%3DFathi%26aufirst%3DH.%26aulast%3DWestland%26aufirst%3DC.%26aulast%3DChanda%26aufirst%3DS.%26aulast%3DLambkin-Williams%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DBeigelman%26aufirst%3DL.%26aulast%3DBlatt%26aufirst%3DL.%2BM.%26aulast%3DFry%26aufirst%3DJ.%26atitle%3DActivity%2520of%2520oral%2520ALS-008176%2520in%2520a%2520respiratory%2520syncytial%2520virus%2520challenge%2520study%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D2048%26epage%3D2058%26doi%3D10.1056%2FNEJMoa1413275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagga, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veldman, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaratnam, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambkin-Williams, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxford, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClain, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsburg, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devincenzo, J. P.</span></span> <span> </span><span class="NLM_article-title">Comparing influenza and rsvviral and disease dynamics in experimentally infected adults predicts clinical effectiveness of rsv antivirals</span>. <i>Antiviral Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">785</span>– <span class="NLM_lpage">791</span>, <span class="refDoi"> DOI: 10.3851/IMP2629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.3851%2FIMP2629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=23714753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjsVentbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=785-791&author=B.+Baggaauthor=C.+W.+Woodsauthor=T.+H.+Veldmanauthor=A.+Gilbertauthor=A.+Mannauthor=G.+Balaratnamauthor=R.+Lambkin-Williamsauthor=J.+S.+Oxfordauthor=M.+T.+McClainauthor=T.+Wilkinsonauthor=B.+P.+Nicholsonauthor=G.+S.+Ginsburgauthor=J.+P.+Devincenzo&title=Comparing+influenza+and+rsvviral+and+disease+dynamics+in+experimentally+infected+adults+predicts+clinical+effectiveness+of+rsv+antivirals&doi=10.3851%2FIMP2629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals</span></div><div class="casAuthors">Bagga, Bindiya; Woods, Christopher W.; Veldman, Timothy H.; Gilbert, Anthony; Mann, Alex; Balaratnam, Ganesh; Lambkin-Williams, Robert; Oxford, John S.; McClain, Micah T.; Wilkinson, Tom; Nicholson, Brad P.; Ginsburg, Geoffrey S.; DeVincenzo, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">785-791</span>CODEN:
                <span class="NLM_cas:coden">ANTHFA</span>;
        ISSN:<span class="NLM_cas:issn">1359-6535</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press</span>)
        </div><div class="casAbstract">Background: Antivirals reduce influenza viral replication and illness measures, particularly if initiated early, within 48 h of symptom onset.  Whether exptl. antivirals that reduce respiratory syncytial virus (RSV) load would also reduce disease is unknown.  This study compares viral and disease dynamics in humans exptl. infected with influenza or RSV.  Methods: Clin. strains of RSV-A and influenza A were inoculated intranasally into 20 and 17 healthy volunteers, resp., on day 0.  Symptom scores and nasal washes were performed twice daily, and daily mucus wts. were collected.  Viral loads in nasal washes were quantified by culture (plaque assay in HEp-2 cells for RSV and by end point diln. in Madin-Darby canine kidney cells for influenza).  Results: After influenza inoculation, influenza viral load and illness markers increased simultaneously until day 2.  Within individual subjects, peak influenza load occurred 0.4 days (95% CI -0.4, 1.3) before peak symptoms.  Influenza viral load and disease declined thereafter.  After RSV inoculation, a longer incubation period occurred prior to viral detection and symptom onset.  RSV load and disease increased together until day 5.  Within individual subjects, peak RSV loads occurred 0.2 days (95% CI -0.7, 1.05) before peak symptoms, after which both illness measures and viral load declined together.  Conclusions: Viral and disease dynamics in exptl. human infections suggest that reducing RSV load, if timed similarly to clin.-effective influenza antivirals, might be expected to have a similar or greater window of opportunity for reducing clin. RSV disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIQJMu3gqtHLVg90H21EOLACvtfcHk0lj0SZx9l1kb5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjsVentbY%253D&md5=4c7a76da9b4a9c760292886ae3326b84</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.3851%2FIMP2629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3851%252FIMP2629%26sid%3Dliteratum%253Aachs%26aulast%3DBagga%26aufirst%3DB.%26aulast%3DWoods%26aufirst%3DC.%2BW.%26aulast%3DVeldman%26aufirst%3DT.%2BH.%26aulast%3DGilbert%26aufirst%3DA.%26aulast%3DMann%26aufirst%3DA.%26aulast%3DBalaratnam%26aufirst%3DG.%26aulast%3DLambkin-Williams%26aufirst%3DR.%26aulast%3DOxford%26aufirst%3DJ.%2BS.%26aulast%3DMcClain%26aufirst%3DM.%2BT.%26aulast%3DWilkinson%26aufirst%3DT.%26aulast%3DNicholson%26aufirst%3DB.%2BP.%26aulast%3DGinsburg%26aufirst%3DG.%2BS.%26aulast%3DDevincenzo%26aufirst%3DJ.%2BP.%26atitle%3DComparing%2520influenza%2520and%2520rsvviral%2520and%2520disease%2520dynamics%2520in%2520experimentally%2520infected%2520adults%2520predicts%2520clinical%2520effectiveness%2520of%2520rsv%2520antivirals%26jtitle%3DAntiviral%2520Ther.%26date%3D2013%26volume%3D18%26spage%3D785%26epage%3D791%26doi%3D10.3851%2FIMP2629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beigel, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krafft, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ince, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kamary, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, A. C.</span></span> <span> </span><span class="NLM_article-title">Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2019.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1016%2Fj.antiviral.2019.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=30974127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsVCjsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2019&pages=45-67&author=J.+H.+Beigelauthor=H.+H.+Namauthor=P.+L.+Adamsauthor=A.+Krafftauthor=W.+L.+Inceauthor=S.+S.+El-Kamaryauthor=A.+C.+Sims&title=Advances+in+respiratory+virus+therapeutics+-+A+meeting+report+from+the+6th+isirv+Antiviral+Group+conference&doi=10.1016%2Fj.antiviral.2019.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference</span></div><div class="casAuthors">Beigel, John H.; Nam, Hannah H.; Adams, Peter L.; Krafft, Amy; Ince, William L.; El-Kamary, Samer S.; Sims, Amy C.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">45-67</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The International Society for Influenza and other Respiratory Virus Diseases held its 6th Antiviral Group (isirv-AVG) conference in Rockville, Maryland, Nov. 13-15, 2018.  The three-day program was focused on therapeutics towards seasonal and pandemic influenza, respiratory syncytial virus, coronaviruses including MERS-CoV and SARS-CoV, human rhinovirus, and other respiratory viruses.  Updates were presented on several influenza antivirals including baloxavir, CC-42344, VIS410, Ig, immune plasma, MHAA4549A, pimodivir (JNJ-63623872), umifenovir, and HA minibinders; RSV antivirals including presatovir (GS-5806), ziresovir (AK0529), lumicitabine (ALS-008176), JNJ-53718678, JNJ-64417184, and EDP-938; broad spectrum antivirals such as favipiravir, VH244, remdesivir, and EIDD-1931/EIDD-2801; and host directed strategies including nitazoxanide, eritoran, and diltiazem.  Other topics included considerations of novel endpoints such as ordinal scales and patient reported outcomes (PRO), and study design issues, and other regulatory considerations for antiviral drug development.  The aim of this report is to provide a summary of the presentations given at this meeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1dbwsivcYWLVg90H21EOLACvtfcHk0lj0SZx9l1kb5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsVCjsLw%253D&md5=2c6ccc83bc1a3677ca70191a3bbc4e06</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2019.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2019.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DBeigel%26aufirst%3DJ.%2BH.%26aulast%3DNam%26aufirst%3DH.%2BH.%26aulast%3DAdams%26aufirst%3DP.%2BL.%26aulast%3DKrafft%26aufirst%3DA.%26aulast%3DInce%26aufirst%3DW.%2BL.%26aulast%3DEl-Kamary%26aufirst%3DS.%2BS.%26aulast%3DSims%26aufirst%3DA.%2BC.%26atitle%3DAdvances%2520in%2520respiratory%2520virus%2520therapeutics%2520-%2520A%2520meeting%2520report%2520from%2520the%25206th%2520isirv%2520Antiviral%2520Group%2520conference%26jtitle%3DAntiviral%2520Res.%26date%3D2019%26volume%3D167%26spage%3D45%26epage%3D67%26doi%3D10.1016%2Fj.antiviral.2019.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jardetzky, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, R. A.</span></span> <span> </span><span class="NLM_article-title">Activation of paramyxovirus membrane fusion and virus entry</span>. <i>Curr. Opin. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1016/j.coviro.2014.01.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1016%2Fj.coviro.2014.01.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=24530984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVWhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=24-33&author=T.+S.+Jardetzkyauthor=R.+A.+Lamb&title=Activation+of+paramyxovirus+membrane+fusion+and+virus+entry&doi=10.1016%2Fj.coviro.2014.01.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of paramyxovirus membrane fusion and virus entry</span></div><div class="casAuthors">Jardetzky, Theodore S.; Lamb, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Virology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">24-33</span>CODEN:
                <span class="NLM_cas:coden">COVUAF</span>;
        ISSN:<span class="NLM_cas:issn">1879-6257</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  The paramyxoviruses represent a diverse virus family responsible for a wide range of human and animal diseases.  In contrast to other viruses, such as HIV and influenza virus, which use a single glycoprotein to mediate host receptor binding and virus entry, the paramyxoviruses require two distinct proteins.  One of these is an attachment glycoprotein that binds receptor, while the second is a fusion glycoprotein, which undergoes conformational changes that drive virus-cell membrane fusion and virus entry.  The details of how receptor binding by one protein activates the second to undergo conformational changes have been poorly understood until recently.  Over the past couple of years, structural and functional data have accumulated on representative members of this family, including parainfluenza virus 5, Newcastle disease virus, measles virus, Nipah virus and others, which suggest a mechanistic convergence of activation models.  Here we review the data indicating that paramyxovirus attachment glycoproteins shield activating residues within their N-terminal stalk domains, which are then exposed upon receptor binding, leading to the activation of the fusion protein by a 'provocateur' mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6zT4qEZFqp7Vg90H21EOLACvtfcHk0lj0SZx9l1kb5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVWhtrY%253D&md5=1b7c091182b48ab98d452c6edcaaabef</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.coviro.2014.01.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coviro.2014.01.005%26sid%3Dliteratum%253Aachs%26aulast%3DJardetzky%26aufirst%3DT.%2BS.%26aulast%3DLamb%26aufirst%3DR.%2BA.%26atitle%3DActivation%2520of%2520paramyxovirus%2520membrane%2520fusion%2520and%2520virus%2520entry%26jtitle%3DCurr.%2520Opin.%2520Virol.%26date%3D2014%26volume%3D5%26spage%3D24%26epage%3D33%26doi%3D10.1016%2Fj.coviro.2014.01.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeples, M. E.</span></span> <span> </span><span class="NLM_article-title">Structure and function of rsv surface glycoproteins</span>. <i>Curr. Top. Microbiol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1007/978-3-642-38919-1_4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1007%2F978-3-642-38919-1_4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=24362685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsl2qtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2013&pages=83-104&author=J.+S.+McLellanauthor=W.+C.+Rayauthor=M.+E.+Peeples&title=Structure+and+function+of+rsv+surface+glycoproteins&doi=10.1007%2F978-3-642-38919-1_4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Function of Respiratory Syncytial Virus Surface Glycoproteins</span></div><div class="casAuthors">McLellan, Jason S.; Ray, William C.; Peeples, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Microbiology and Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">Challenges and Opportunities for Respiratory Syncytial Virus Vaccines</span>),
    <span class="NLM_cas:pages">83-104</span>CODEN:
                <span class="NLM_cas:coden">CTMIA3</span>;
        ISSN:<span class="NLM_cas:issn">2196-9965</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">The two major glycoproteins on the surface of the respiratory syncytial virus (RSV) virion, the attachment glycoprotein (G) and the fusion glycoprotein (F), control the initial phases of infection.  G targets the ciliated cells of the airways, and F causes the virion membrane to fuse with the target cell membrane.  The F protein is the major target for antiviral drug development, and both G and F glycoproteins are the antigens targeted by neutralizing antibodies induced by infection.  In this chapter, we review the structure and function of the RSV surface glycoproteins, including recent X-ray crystallog. data of the F glycoprotein in its pre- and postfusion conformations, and discuss how this information informs antigen selection and vaccine development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLjhvYg5ZfUrVg90H21EOLACvtfcHk0lhAJW5Sdx2dAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsl2qtrk%253D&md5=4b6fe29a55e09542541be00f7f30ab67</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-38919-1_4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-38919-1_4%26sid%3Dliteratum%253Aachs%26aulast%3DMcLellan%26aufirst%3DJ.%2BS.%26aulast%3DRay%26aufirst%3DW.%2BC.%26aulast%3DPeeples%26aufirst%3DM.%2BE.%26atitle%3DStructure%2520and%2520function%2520of%2520rsv%2520surface%2520glycoproteins%26jtitle%3DCurr.%2520Top.%2520Microbiol.%2520Immunol.%26date%3D2013%26volume%3D372%26spage%3D83%26epage%3D104%26doi%3D10.1007%2F978-3-642-38919-1_4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Battles, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langedijk, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furmanova-Hollenstein, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaiwatpongsakorn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costello, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwanten, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vranckx, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vink, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaensch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonckers, T. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnoult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeples, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, J. S.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of respiratory syncytial virus fusion inhibitors</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1038%2Fnchembio.1982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=26641933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFemsbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=87-93&author=M.+B.+Battlesauthor=J.+P.+Langedijkauthor=P.+Furmanova-Hollensteinauthor=S.+Chaiwatpongsakornauthor=H.+M.+Costelloauthor=L.+Kwantenauthor=L.+Vranckxauthor=P.+Vinkauthor=S.+Jaenschauthor=T.+H.+M.+Jonckersauthor=A.+Koulauthor=E.+Arnoultauthor=M.+E.+Peeplesauthor=D.+Roymansauthor=J.+S.+McLellan&title=Molecular+mechanism+of+respiratory+syncytial+virus+fusion+inhibitors&doi=10.1038%2Fnchembio.1982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of respiratory syncytial virus fusion inhibitors</span></div><div class="casAuthors">Battles, Michael B.; Langedijk, Johannes P.; Furmanova-Hollenstein, Polina; Chaiwatpongsakorn, Supranee; Costello, Heather M.; Kwanten, Leen; Vranckx, Luc; Vink, Paul; Jaensch, Steffen; Jonckers, Tim H. M.; Koul, Anil; Arnoult, Eric; Peeples, Mark E.; Roymans, Dirk; McLellan, Jason S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-93</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) is a leading cause of pneumonia and bronchiolitis in young children and the elderly.  Therapeutic small mols. have been developed that bind the RSV F glycoprotein and inhibit membrane fusion, yet their binding sites and mol. mechanisms of action remain largely unknown.  Here we show that these inhibitors bind to a three-fold-sym. pocket within the central cavity of the metastable prefusion conformation of RSV F.  Inhibitor binding stabilizes this conformation by tethering two regions that must undergo a structural rearrangement to facilitate membrane fusion.  Inhibitor-escape mutations occur in residues that directly contact the inhibitors or are involved in the conformational rearrangements required to accommodate inhibitor binding.  Resistant viruses do not propagate as well as wild-type RSV in vitro, indicating a fitness cost for inhibitor escape.  Collectively, these findings provide new insight into class I viral fusion proteins and should facilitate development of optimal RSV fusion inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowEnQ0xJnoFLVg90H21EOLACvtfcHk0lhDE6ZL-WFDeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFemsbrK&md5=c126990069d3f23d95d06693fe90a061</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1982%26sid%3Dliteratum%253Aachs%26aulast%3DBattles%26aufirst%3DM.%2BB.%26aulast%3DLangedijk%26aufirst%3DJ.%2BP.%26aulast%3DFurmanova-Hollenstein%26aufirst%3DP.%26aulast%3DChaiwatpongsakorn%26aufirst%3DS.%26aulast%3DCostello%26aufirst%3DH.%2BM.%26aulast%3DKwanten%26aufirst%3DL.%26aulast%3DVranckx%26aufirst%3DL.%26aulast%3DVink%26aufirst%3DP.%26aulast%3DJaensch%26aufirst%3DS.%26aulast%3DJonckers%26aufirst%3DT.%2BH.%2BM.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DArnoult%26aufirst%3DE.%26aulast%3DPeeples%26aufirst%3DM.%2BE.%26aulast%3DRoymans%26aufirst%3DD.%26aulast%3DMcLellan%26aufirst%3DJ.%2BS.%26atitle%3DMolecular%2520mechanism%2520of%2520respiratory%2520syncytial%2520virus%2520fusion%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26spage%3D87%26epage%3D93%26doi%3D10.1038%2Fnchembio.1982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span> <span> </span><span class="NLM_article-title">Respiratory syncytial virus entry inhibitors targeting the F protein</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.3390/v5010211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.3390%2Fv5010211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=23325327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1yqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=211-225&author=Z.+Sunauthor=Y.+Panauthor=S.+Jiangauthor=L.+Lu&title=Respiratory+syncytial+virus+entry+inhibitors+targeting+the+F+protein&doi=10.3390%2Fv5010211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus entry inhibitors targeting the F protein</span></div><div class="casAuthors">Sun, Zhiwu; Pan, Yanbin; Jiang, Shibo; Lu, Lu</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">211-225</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Human respiratory syncytial virus (RSV) is the main viral cause of respiratory tract infection in infants as well as some elderly and high-risk adults with chronic pulmonary disease and the severely immunocompromised.  So far, no specific anti-R SV therapeutics or effective anti-RSV vaccines have been reported.  Only one humanized monoclonal antibody, Palivizumab, has been approved for use in high-risk infants to prevent RSV infection.  Ribavirin is the only drug licensed for therapy of RSV infection, but its clin. use is limited by its nonspecific anti-RSV activity, toxic effect, and relatively high cost.  Therefore, development of novel effective anti-RSV therapeutics is urgently needed.  The RSV envelope glycoprotein F plays an important role in RSV fusion with, and entry into, the host cell and, consequently, serves as an attractive target for developing RSV entry inhibitors.  This article reviews advances made in studies of the structure and function of the F protein and the development of RSV entry inhibitors targeting it.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPOeEk3HJ9DbVg90H21EOLACvtfcHk0lhDE6ZL-WFDeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1yqtLY%253D&md5=845867182964c18a459de59ed022f6d1</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.3390%2Fv5010211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv5010211%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DZ.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DL.%26atitle%3DRespiratory%2520syncytial%2520virus%2520entry%2520inhibitors%2520targeting%2520the%2520F%2520protein%26jtitle%3DViruses%26date%3D2013%26volume%3D5%26spage%3D211%26epage%3D225%26doi%3D10.3390%2Fv5010211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of piperazinylquinoline derivatives as novel respiratory syncytial virus fusion inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00234</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00234" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsVamsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=558-562&author=X.+Zhengauthor=L.+Wangauthor=B.+Wangauthor=K.+Miaoauthor=K.+Xiangauthor=S.+Fengauthor=L.+Gaoauthor=H.+C.+Shenauthor=H.+Yun&title=Discovery+of+piperazinylquinoline+derivatives+as+novel+respiratory+syncytial+virus+fusion+inhibitors&doi=10.1021%2Facsmedchemlett.5b00234"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Piperazinylquinoline Derivatives as Novel Respiratory Syncytial Virus Fusion Inhibitors</span></div><div class="casAuthors">Zheng, Xiufang; Wang, Lisha; Wang, Baoxia; Miao, Kun; Xiang, Kunlun; Feng, Song; Gao, Lu; Shen, Hong C.; Yun, Hongying</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">558-562</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of piperazinylquinoline derivs. were discovered as respiratory syncytial virus (RSV) fusion inhibitors by the ligand-based screening approach.  Among 3000 hits, 1-amino-3-[[2-(4-phenyl-1-piperidyl)-4-quinolyl]amino]propan-2-ol was proven to be active against the RSV long (A) strain.  The anti-RSV activity was improved by converting piperidine to benzylcarbonyl substituted piperazine.  The basic side chain was also found to be crucial for anti-RSV activity.  The selected analogs, I and II, demonstrated anti-RSV activities up to EC50 = 0.028 μM and 0.033 μM, resp.  A direct anti-RSV effect was confirmed by a plaque redn. assay and a fusion inhibition assay.  Both I and II showed promising DMPK properties with good oral bioavailability, and could potentially lead to novel therapeutic agents targeting the RSV fusion process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr98VDNFO7a27Vg90H21EOLACvtfcHk0lhDE6ZL-WFDeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsVamsb8%253D&md5=086def8b4fdde5bad248aa1f65106c9e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00234%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DMiao%26aufirst%3DK.%26aulast%3DXiang%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DYun%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520piperazinylquinoline%2520derivatives%2520as%2520novel%2520respiratory%2520syncytial%2520virus%2520fusion%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D558%26epage%3D562%26doi%3D10.1021%2Facsmedchemlett.5b00234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bond, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Draffan, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luttick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nearn, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanford, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayes, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, S. P.</span></span> <span> </span><span class="NLM_article-title">1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (rsv) fusion inhibitors. part 2: identification of BTA9881 as a preclinical candidate</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">976</span>– <span class="NLM_lpage">981</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.11.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1016%2Fj.bmcl.2014.11.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=25595685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGis7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=976-981&author=S.+Bondauthor=A.+G.+Draffanauthor=J.+E.+Fennerauthor=J.+Lambertauthor=C.+Y.+Limauthor=B.+Linauthor=A.+Luttickauthor=J.+P.+Mitchellauthor=C.+J.+Mortonauthor=R.+H.+Nearnauthor=V.+Sanfordauthor=K.+H.+Andersonauthor=P.+A.+Mayesauthor=S.+P.+Tucker&title=1%2C2%2C3%2C9b-Tetrahydro-5H-imidazo%5B2%2C1-a%5Disoindol-5-ones+as+a+new+class+of+respiratory+syncytial+virus+%28rsv%29+fusion+inhibitors.+part+2%3A+identification+of+BTA9881+as+a+preclinical+candidate&doi=10.1016%2Fj.bmcl.2014.11.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: Identification of BTA9881 as a preclinical candidate</span></div><div class="casAuthors">Bond, Silas; Draffan, Alistair G.; Fenner, Jennifer E.; Lambert, John; Lim, Chin Yu; Lin, Bo; Luttick, Angela; Mitchell, Jeffrey P.; Morton, Craig J.; Nearn, Roland H.; Sanford, Vanessa; Anderson, Kelly H.; Mayes, Penelope A.; Tucker, Simon P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">976-981</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections in infants, young children and adults. 1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones with general structure 1 were previously identified as promising inhibitors of RSV targeting the fusion glycoprotein.  In particular, the introduction of a nitrogen at the 8-position of the tricyclic core yielded lead compds.  Extensive exploration of the R2 group established that certain heterocyclic amides conferred potent RSV A&B activity and a good balance of physicochem. and pharmacokinetic properties.  The antiviral activity was found to reside in a single enantiomer and BTA9881 (I) was identified as a candidate for preclin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozl2YGFANzObVg90H21EOLACvtfcHk0ljHnhWPoT314g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGis7rN&md5=6a0df66bad0f8c19627d2cf31bccca61</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.11.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.11.024%26sid%3Dliteratum%253Aachs%26aulast%3DBond%26aufirst%3DS.%26aulast%3DDraffan%26aufirst%3DA.%2BG.%26aulast%3DFenner%26aufirst%3DJ.%2BE.%26aulast%3DLambert%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DC.%2BY.%26aulast%3DLin%26aufirst%3DB.%26aulast%3DLuttick%26aufirst%3DA.%26aulast%3DMitchell%26aufirst%3DJ.%2BP.%26aulast%3DMorton%26aufirst%3DC.%2BJ.%26aulast%3DNearn%26aufirst%3DR.%2BH.%26aulast%3DSanford%26aufirst%3DV.%26aulast%3DAnderson%26aufirst%3DK.%2BH.%26aulast%3DMayes%26aufirst%3DP.%2BA.%26aulast%3DTucker%26aufirst%3DS.%2BP.%26atitle%3D1%252C2%252C3%252C9b-Tetrahydro-5H-imidazo%255B2%252C1-a%255Disoindol-5-ones%2520as%2520a%2520new%2520class%2520of%2520respiratory%2520syncytial%2520virus%2520%2528rsv%2529%2520fusion%2520inhibitors.%2520part%25202%253A%2520identification%2520of%2520BTA9881%2520as%2520a%2520preclinical%2520candidate%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D976%26epage%3D981%26doi%3D10.1016%2Fj.bmcl.2014.11.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">359</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00008</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVWgtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=359-362&author=S.+Fengauthor=D.+Hongauthor=B.+Wangauthor=X.+Zhengauthor=K.+Miaoauthor=L.+Wangauthor=H.+Yunauthor=L.+Gaoauthor=S.+Zhaoauthor=H.+C.+Shen&title=Discovery+of+imidazopyridine+derivatives+as+highly+potent+respiratory+syncytial+virus+fusion+inhibitors&doi=10.1021%2Facsmedchemlett.5b00008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Imidazopyridine Derivatives as Highly Potent Respiratory Syncytial Virus Fusion Inhibitors</span></div><div class="casAuthors">Feng, Song; Hong, Di; Wang, Baoxia; Zheng, Xiufang; Miao, Kun; Wang, Lisha; Yun, Hongying; Gao, Lu; Zhao, Shuhai; Shen, Hong C.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">359-362</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of imidazolepyridine derivs. were designed and synthesized according to the established docking studies.  The imidazopyridine derivs. were found to have good potency and phys.-chem. properties.  Several highly potent compds. such as I (R = CONH2, SO2Me, SO2Et) were identified with single nanomolar activities.  The most potent compd. I (R = SO2Et) showed an IC50 of 3 nM, lower microsome clearance and no CYP inhibition.  The profile of I (R = SO2Et) appeared to be superior to BMS433771, and supported further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI1B0vZ3s1JbVg90H21EOLACvtfcHk0ljHnhWPoT314g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVWgtL8%253D&md5=308e4626c4162c04d89ed4d9afc7e3b3</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00008%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DMiao%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DH.%2BC.%26atitle%3DDiscovery%2520of%2520imidazopyridine%2520derivatives%2520as%2520highly%2520potent%2520respiratory%2520syncytial%2520virus%2520fusion%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D359%26epage%3D362%26doi%3D10.1021%2Facsmedchemlett.5b00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonfanti, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doublet, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacrampe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queguiner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnoult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gevers, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willebrords, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmerman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuyts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigerinck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span> <span> </span><span class="NLM_article-title">Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">4572</span>– <span class="NLM_lpage">4584</span>, <span class="refDoi"> DOI: 10.1021/jm070143x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070143x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFCisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=4572-4584&author=J.-F.+Bonfantiauthor=F.+Doubletauthor=J.+Fortinauthor=J.+Lacrampeauthor=J.+Guillemontauthor=P.+Mullerauthor=L.+Queguinerauthor=E.+Arnoultauthor=T.+Geversauthor=P.+Janssensauthor=H.+Szelauthor=R.+Willebrordsauthor=P.+Timmermanauthor=K.+Wuytsauthor=F.+Janssensauthor=C.+Sommenauthor=P.+Wigerinckauthor=K.+Andries&title=Selection+of+a+respiratory+syncytial+virus+fusion+inhibitor+clinical+candidate%2C+part+1%3A+improving+the+pharmacokinetic+profile+using+the+structure-property+relationship&doi=10.1021%2Fjm070143x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate. Improving the Pharmacokinetic Profile Using the Structure-Property Relationship</span></div><div class="casAuthors">Bonfanti, Jean-Francois; Doublet, Frederic; Fortin, Jerome; Lacrampe, Jean; Guillemont, Jerome; Muller, Philippe; Queguiner, Laurence; Arnoult, Eric; Gevers, Tom; Janssens, Peggy; Szel, Heidi; Willebrords, Rudy; Timmerman, Philip; Wuyts, Koen; Janssens, Frans; Sommen, Cois; Wigerinck, Piet; Andries, Koen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4572-4584</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors previously reported the discovery of substituted benzimidazole fusion inhibitors with nanomolar activity against respiratory syncytial virus.  A lead compd. of the series was selected for preclin. evaluation.  This drug candidate, JNJ-2408068 (formerly R170591, 1), showed long tissue retention times in several species (rat, dog, and monkey), creating cause for concern.  The authors herein describe the optimization program to develop compds. with improved properties in terms of tissue retention.  The authors have identified the aminoethyl-piperidine moiety as being responsible for the long tissue retention time of 1.  The authors have investigated the replacement or the modification of this group, and suggest that the pKa of this part of the mols. influences both the antiviral activity and the pharmacokinetic profile.  The authors were able to identify new respiratory syncytial virus inhibitors with shorter half-lives in lung tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx3B5eDxxv-rVg90H21EOLACvtfcHk0ljHnhWPoT314g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFCisr8%253D&md5=9f1f68c5c62f0179098fdebe25612a1a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm070143x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070143x%26sid%3Dliteratum%253Aachs%26aulast%3DBonfanti%26aufirst%3DJ.-F.%26aulast%3DDoublet%26aufirst%3DF.%26aulast%3DFortin%26aufirst%3DJ.%26aulast%3DLacrampe%26aufirst%3DJ.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DMuller%26aufirst%3DP.%26aulast%3DQueguiner%26aufirst%3DL.%26aulast%3DArnoult%26aufirst%3DE.%26aulast%3DGevers%26aufirst%3DT.%26aulast%3DJanssens%26aufirst%3DP.%26aulast%3DSzel%26aufirst%3DH.%26aulast%3DWillebrords%26aufirst%3DR.%26aulast%3DTimmerman%26aufirst%3DP.%26aulast%3DWuyts%26aufirst%3DK.%26aulast%3DJanssens%26aufirst%3DF.%26aulast%3DSommen%26aufirst%3DC.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3DAndries%26aufirst%3DK.%26atitle%3DSelection%2520of%2520a%2520respiratory%2520syncytial%2520virus%2520fusion%2520inhibitor%2520clinical%2520candidate%252C%2520part%25201%253A%2520improving%2520the%2520pharmacokinetic%2520profile%2520using%2520the%2520structure-property%2520relationship%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D4572%26epage%3D4584%26doi%3D10.1021%2Fjm070143x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3,3′-spiro[azetidine]-2-oxo-indoline derivatives as fusion inhibitors for treatment of rsv infection</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00418</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00418" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVOrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=94-97&author=W.+Shiauthor=Z.+Jiangauthor=H.+Heauthor=F.+Xiaoauthor=F.+Linauthor=Y.+Sunauthor=L.+Houauthor=L.+Shenauthor=L.+Hanauthor=M.+Zengauthor=K.+Laiauthor=Z.+Guauthor=X.+Chenauthor=T.+Zhaoauthor=L.+Guoauthor=C.+Yangauthor=J.+Liauthor=S.+Chen&title=Discovery+of+3%2C3%E2%80%B2-spiro%5Bazetidine%5D-2-oxo-indoline+derivatives+as+fusion+inhibitors+for+treatment+of+rsv+infection&doi=10.1021%2Facsmedchemlett.7b00418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3,3'-Spiro[Azetidine]-2-oxo-indoline Derivatives as Fusion Inhibitors for Treatment of RSV Infection</span></div><div class="casAuthors">Shi, Weihua; Jiang, Zhigan; He, Haiying; Xiao, Fubiao; Lin, Fusen; Sun, Ya; Hou, Lijuan; Shen, Liang; Han, Lixia; Zeng, Minggao; Lai, Kunmin; Gu, Zhengxian; Chen, Xinsheng; Zhao, Tao; Guo, Li; Yang, Chun; Li, Jian; Chen, Shuhui</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">94-97</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new series of 3,3'-spirocyclic 2-oxo-indoline derivs. was synthesized and evaluated against respiratory syncytial virus (RSV) in a cell-based assay and animal model.  Extensive structure-activity relationship study led to a lead compd. 14h, which exhibited excellent in vitro potency with an EC50 value of 0.8 nM and demonstrated 71% oral bioavailability in mice.  In a mouse challenge model of RVS infection, 14h demonstrated superior efficacy with a 3.9log RSV virus load redn. in the lung following an oral dose of 50 mg/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruT_jDJyP0T7Vg90H21EOLACvtfcHk0liG7B8H-A5LSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVOrsw%253D%253D&md5=86701de4a59fb764fe1eea6a79d1cac4</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00418%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DW.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DLin%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DZeng%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DK.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26atitle%3DDiscovery%2520of%25203%252C3%25E2%2580%25B2-spiro%255Bazetidine%255D-2-oxo-indoline%2520derivatives%2520as%2520fusion%2520inhibitors%2520for%2520treatment%2520of%2520rsv%2520infection%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D94%26epage%3D97%26doi%3D10.1021%2Facsmedchemlett.7b00418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ispas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbeeck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders-Beer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouan, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonfanti, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanstockem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verloes, R.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of TMC353121, a respiratory syncytial virus (rsv) fusion inhibitor, in a non-human primate model</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">5</span>), <span class="NLM_elocation-id">e0126959</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0126959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1371%2Fjournal.pone.0126959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=26010881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOqurzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&issue=5&author=G.+Ispasauthor=A.+Koulauthor=J.+Verbeeckauthor=J.+Sheehanauthor=B.+Sanders-Beerauthor=D.+Roymansauthor=K.+Andriesauthor=M.-C.+Rouanauthor=S.+De+Jongheauthor=J.-F.+Bonfantiauthor=M.+Vanstockemauthor=K.+Simmenauthor=R.+Verloes&title=Antiviral+activity+of+TMC353121%2C+a+respiratory+syncytial+virus+%28rsv%29+fusion+inhibitor%2C+in+a+non-human+primate+model&doi=10.1371%2Fjournal.pone.0126959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of TMC353121, a respiratory syncytial virus (RSV) fusion inhibitor, in a non-human primate model</span></div><div class="casAuthors">Ispas, Gabriela; Koul, Anil; Verbeeck, Johan; Sheehan, Jennifer; Sanders-Beer, Brigitte; Roymans, Dirk; Andries, Koen; Rouan, Marie-Claude; De Jonghe, Sandra; Bonfanti, Jean-Francois; Vanstockem, Marc; Simmen, Kenneth; Verloes, Rene</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e0126959/1-e0126959/16</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background The study assessed the antiviral activity of TMC353121, a respiratory syncytial virus (RSV) fusion inhibitor, in a preclin. non-human primate challenge model with a viral shedding pattern similar to that seen in humans, following continuous infusion (CI).  Methods African green monkeys were administered TMC353121 through CI, in 2 studies.  Study 1 evaluated the prophylactic and therapeutic efficacy of TMC353121 at a target plasma level of 50 ng/mL (n =15; Group 1: prophylactic arm [P×50], 0.033 mg/mL TMC353121, flow rate 2.5 mL/kg/h from 24 h pre-infection to 10 days; Group 2: therapeutic arm [T×50], 0.033mg/mL TMC353121 from 24 h postinfection to 8 days; Group 3: control [Vh1] vehicle, 24 h post-infection to 8 days).  Study 2 evaluated the prophylactic efficacy of TMC353121 at target plasma levels of 5 and 500 ng/mL (n = 12; Group 1: prophylactic 5 arm [P×5], 0.0033 mg/mL TMC353121, flow rate 2.5 mL/kg/h from 72 h pre-infection to 14 days; Group 2: prophylactic 500 arm [P×500], 0.33 mg/mL TMC353121; Group 3:control [Vh2] vehicle, 14 days).  Bronchoalveolar lavage fluid and plasma were collected every 2 days from day 1 postinfection for pharmacokinetics and safety anal.  Findings TMC353121 showed a dose-dependent antiviral activity, varying from 1log10 redn. of peak viral load to complete inhibition of the RSV replication.  Complete inhibition of RSV shedding was obsd. for a relatively low plasma exposure (0.39 μg/mL) and was assocd. with a dose-dependent redn. in INFγ, IL6 and MIP1α.  TMC353121 administered as CI for 16 days was generally well-tolerated.  Conclusion TMC353121 exerted dose-dependent antiviral effect ranging from full inhibition to absence of antiviral activity, in a preclin. model highly permissive for RSV replication.  No new safety findings emerged from the study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_bXyz9PIFS7Vg90H21EOLACvtfcHk0liG7B8H-A5LSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOqurzP&md5=94a5819dad3fa1b836ad2c08f667345b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0126959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0126959%26sid%3Dliteratum%253Aachs%26aulast%3DIspas%26aufirst%3DG.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DVerbeeck%26aufirst%3DJ.%26aulast%3DSheehan%26aufirst%3DJ.%26aulast%3DSanders-Beer%26aufirst%3DB.%26aulast%3DRoymans%26aufirst%3DD.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DRouan%26aufirst%3DM.-C.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26aulast%3DBonfanti%26aufirst%3DJ.-F.%26aulast%3DVanstockem%26aufirst%3DM.%26aulast%3DSimmen%26aufirst%3DK.%26aulast%3DVerloes%26aufirst%3DR.%26atitle%3DAntiviral%2520activity%2520of%2520TMC353121%252C%2520a%2520respiratory%2520syncytial%2520virus%2520%2528rsv%2529%2520fusion%2520inhibitor%252C%2520in%2520a%2520non-human%2520primate%2520model%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26issue%3D5%26doi%3D10.1371%2Fjournal.pone.0126959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civiello, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combrink, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulgeze, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venables, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J. J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalterio, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadjura, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dando, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianci, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovesi, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">901</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.11.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1016%2Fj.bmcl.2006.11.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=17169560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht12rtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=895-901&author=K.-L.+Yuauthor=N.+Sinauthor=R.+L.+Civielloauthor=X.+A.+Wangauthor=K.+D.+Combrinkauthor=H.+B.+Gulgezeauthor=B.+L.+Venablesauthor=J.+J.+K.+Wrightauthor=R.+A.+Dalterioauthor=L.+Zadjuraauthor=A.+Marinoauthor=S.+Dandoauthor=C.+D%E2%80%99Arienzoauthor=K.+F.+Kadowauthor=C.+W.+Cianciauthor=Z.+Liauthor=J.+Clarkeauthor=E.+V.+Genovesiauthor=I.+Medinaauthor=L.+Lambauthor=R.+J.+Colonnoauthor=Z.+Yangauthor=M.+Krystalauthor=N.+A.+Meanwell&title=Respiratory+syncytial+virus+fusion+inhibitors.+Part+4%3A+optimization+for+oral+bioavailability&doi=10.1016%2Fj.bmcl.2006.11.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability</span></div><div class="casAuthors">Yu, Kuo-Long; Sin, Ny; Civiello, Rita L.; Wang, X. Alan; Combrink, Keith D.; Gulgeze, H. Belgin; Venables, Brian L.; Wright, J. J. Kim; Dalterio, Richard A.; Zadjura, Lisa; Marino, Anthony; Dando, Sandra; D'Arienzo, Celia; Kadow, Kathleen F.; Cianci, Christopher W.; Li, Zhufang; Clarke, Junius; Genovesi, Eugene V.; Medina, Ivette; Lamb, Lucinda; Colonno, Richard J.; Yang, Zheng; Krystal, Mark; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">895-901</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A series of benzimidazole-based inhibitors of respiratory syncytial virus (RSV) fusion were optimized for antiviral potency, membrane permeability and metabolic stability in human liver microsomes.  1-Cyclopropyl-1,3-dihydro-3-[[1-(4-hydroxybutyl)-1H-benzimidazol-2-yl]methyl]-2H-imidazo[4,5-c]pyridin-2-one (I, BMS-433771) was identified as a potent RSV inhibitor demonstrating good bioavailability in the mouse, rat, dog and cynomolgus monkey that demonstrated antiviral activity in the BALB/c and cotton rat models of infection following oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwTTCqYL_6iLVg90H21EOLACvtfcHk0li1dROwonMUgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht12rtLc%253D&md5=1df6d784bda1cabee0b57b799f1f165e</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.11.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.11.063%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DK.-L.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DCiviello%26aufirst%3DR.%2BL.%26aulast%3DWang%26aufirst%3DX.%2BA.%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DGulgeze%26aufirst%3DH.%2BB.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%2BK.%26aulast%3DDalterio%26aufirst%3DR.%2BA.%26aulast%3DZadjura%26aufirst%3DL.%26aulast%3DMarino%26aufirst%3DA.%26aulast%3DDando%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DKadow%26aufirst%3DK.%2BF.%26aulast%3DCianci%26aufirst%3DC.%2BW.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DClarke%26aufirst%3DJ.%26aulast%3DGenovesi%26aufirst%3DE.%2BV.%26aulast%3DMedina%26aufirst%3DI.%26aulast%3DLamb%26aufirst%3DL.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DRespiratory%2520syncytial%2520virus%2520fusion%2520inhibitors.%2520Part%25204%253A%2520optimization%2520for%2520oral%2520bioavailability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D895%26epage%3D901%26doi%3D10.1016%2Fj.bmcl.2006.11.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cianci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovesi, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadjura, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combrink, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span> <span> </span><span class="NLM_article-title">Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2448</span>– <span class="NLM_lpage">2454</span>, <span class="refDoi"> DOI: 10.1128/AAC.48.7.2448-2454.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1128%2FAAC.48.7.2448-2454.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=15215093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsFWmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2004&pages=2448-2454&issue=7&author=C.+Cianciauthor=E.+V.+Genovesiauthor=L.+Lambauthor=I.+Medinaauthor=Z.+Yangauthor=L.+Zadjuraauthor=H.+Yangauthor=C.+D%E2%80%99Arienzoauthor=N.+Sinauthor=K.-L.+Yuauthor=K.+Combrinkauthor=Z.+Liauthor=R.+Colonnoauthor=N.+Meanwellauthor=J.+Clarkauthor=M.+Krystal&title=Oral+efficacy+of+a+respiratory+syncytial+virus+inhibitor+in+rodent+models+of+infection&doi=10.1128%2FAAC.48.7.2448-2454.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection</span></div><div class="casAuthors">Cianci, Christopher; Genovesi, Eugene V.; Lamb, Lucinda; Medina, Ivette; Yang, Zheng; Zadjura, Lisa; Yang, Hyekyung; D'Arienzo, Celia; Sin, Ny; Yu, Kuo-Long; Combrink, Keith; Li, Zhufang; Colonno, Richard; Meanwell, Nicholas; Clark, Junius; Krystal, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2448-2454</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">BMS-433771 is a potent inhibitor of respiratory syncytial virus (RSV) replication in vitro.  Mechanism of action studies have demonstrated that BMS-433771 halts virus entry through inhibition of F protein-mediated membrane fusion.  BMS-433771 also exhibited in vivo efficacy following oral administration in a mouse model of RSV infection.  In this report, the in vivo efficacy of BMS-433771 against RSV was further examd. in the BALB/c mouse and cotton rat host models of infection.  By using the Long strain of RSV, prophylactic efficacy via oral dosing was obsd. in both animal models.  A single oral dose, administered 1 h prior to intranasal RSV inoculation, was as effective against infection as a 4-day b.i.d. dosing regimen in which the first oral dose was given 1 h prior to virus inoculation.  Results of dose titrn. expts. suggested that RSV infection was more sensitive to inhibition by BMS-433771 treatment in the BALB/c mouse host than in the cotton rat.  This was reflected by the pharmacokinetic and pharmacodynamic anal. of the efficacy data, where the area under the concn.-time curve required to achieve 50% of the max. response was ∼7.5-fold less for mice than for cotton rats.  Inhibition of RSV by BMS-433771 in the mouse is the result of F1-mediated inhibition, as shown by the fact that a virus selected for resistance to BMS-433771 in vitro and contg. a single amino acid change in the F1 region was also refractory to treatment in the mouse host.  BMS-433771 efficacy against RSV infection was also demonstrated for mice that were chem. immunosuppressed by cyclophosphamide treatment, indicating that compd. inhibition of the virus did not require an active host immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBKvJm5WDYz7Vg90H21EOLACvtfcHk0li1dROwonMUgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsFWmtrY%253D&md5=c57e810ebd46f01c6dd2da43c45f9248</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1128%2FAAC.48.7.2448-2454.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.48.7.2448-2454.2004%26sid%3Dliteratum%253Aachs%26aulast%3DCianci%26aufirst%3DC.%26aulast%3DGenovesi%26aufirst%3DE.%2BV.%26aulast%3DLamb%26aufirst%3DL.%26aulast%3DMedina%26aufirst%3DI.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZadjura%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DK.-L.%26aulast%3DCombrink%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DMeanwell%26aufirst%3DN.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DOral%2520efficacy%2520of%2520a%2520respiratory%2520syncytial%2520virus%2520inhibitor%2520in%2520rodent%2520models%2520of%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2004%26volume%3D48%26issue%3D7%26spage%3D2448%26epage%3D2454%26doi%3D10.1128%2FAAC.48.7.2448-2454.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="note"><p class="first last">Internal assessment of PK parameters of BMS-433331 (<b>4</b>) in fed male SD rats after iv and oral administration at 2 and 10 mg/kg, respectively, using HP-β-CD 20% as vehicle: plasma Cl = 5.4 L h<sup>–1</sup> kg<sup>–1</sup>, Vd<sub>ss</sub> = 1.0 L/kg, <i>t</i><sub>1/2</sub> = 0.16 h, <i>C</i><sub>max</sub> = 53 ng/mL, AUC<sub>0–inf</sub> = 224 ng·h/mL, <i>F</i> = 8.4%, <i>L</i>/<i>P</i> = 0.22.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanzlik, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishore, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tullman, R.</span></span> <span> </span><span class="NLM_article-title">Cyclopropylamines as suicide substrates for cytochromes P-450</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">759</span>– <span class="NLM_lpage">761</span>, <span class="refDoi"> DOI: 10.1021/jm00193a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00193a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADyaE1MXksV2gsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1979&pages=759-761&issue=7&author=R.+P.+Hanzlikauthor=V.+Kishoreauthor=R.+Tullman&title=Cyclopropylamines+as+suicide+substrates+for+cytochromes+P-450&doi=10.1021%2Fjm00193a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclopropylamines as suicide substrates for cytochromes P-450</span></div><div class="casAuthors">Hanzlik, Robert P.; Kishore, Vimal; Tullman, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">759-61</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Evaluation of I (R = CHMe2 or cyclopropyl; X = H, Br, Cl, Me, or MeO) as suicide substrates for cytochrome P 450  [9035-51-2] showed that I with the cyclopropyl substituent were better inhibitors of rat liver microsomal aminopyrine demethylase  [9037-69-8] than those with CHMe2 .  The kinetics of the inhibition by N-cyclopropylbenzylamine  [13324-66-8] was a 1st order reaction with a 1/2 life of 6 min.  The reaction required NADPH and was inhibited by CO but not by glutathione or semicarbazide.  Apparently, I (R = cyclopropyl) are true suicide substrates for cytochrome P 450.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdVsppD1S9JLVg90H21EOLACvtfcHk0li1dROwonMUgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXksV2gsbs%253D&md5=6d5dd3b1c9dae9d0ab8858babb1770dc</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm00193a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00193a002%26sid%3Dliteratum%253Aachs%26aulast%3DHanzlik%26aufirst%3DR.%2BP.%26aulast%3DKishore%26aufirst%3DV.%26aulast%3DTullman%26aufirst%3DR.%26atitle%3DCyclopropylamines%2520as%2520suicide%2520substrates%2520for%2520cytochromes%2520P-450%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1979%26volume%3D22%26issue%3D7%26spage%3D759%26epage%3D761%26doi%3D10.1021%2Fjm00193a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meals, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fok-Seang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntjens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariën, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remmerie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verloes, R.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of oral JNJ-53718678 in healthy adult volunteers challenged with respiratory syncytial virus: a placebo-controlled study</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>218</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">748</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1093/infdis/jiy227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1093%2Finfdis%2Fjiy227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=29684148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlCnt77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=218&publication_year=2018&pages=748-756&issue=5&author=M.+Stevensauthor=S.+Ruschauthor=J.+DeVincenzoauthor=Y.+I.+Kimauthor=L.+Harrisonauthor=E.+A.+Mealsauthor=A.+Boyersauthor=J.+Fok-Seangauthor=D.+Huntjensauthor=N.+Lounisauthor=K.+Mari%C3%ABnauthor=B.+Remmerieauthor=D.+Roymansauthor=A.+Koulauthor=R.+Verloes&title=Antiviral+activity+of+oral+JNJ-53718678+in+healthy+adult+volunteers+challenged+with+respiratory+syncytial+virus%3A+a+placebo-controlled+study&doi=10.1093%2Finfdis%2Fjiy227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of oral JNJ-53718678 in healthy adult volunteers challenged with respiratory syncytial virus: a placebo-controlled study</span></div><div class="casAuthors">Stevens, Marita; Rusch, Sarah; DeVincenzo, John; Kim, Young-In; Harrison, Lisa; Meals, Elizabeth A.; Boyers, Alison; Fok-Seang, Juin; Huntjens, Dymphy; Lounis, Nacer; Marien, Kris; Remmerie, Bart; Roymans, Dirk; Koul, Anil; Verloes, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">218</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">748-756</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">1537-6613</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background.  Respiratory syncytial virus (RSV) disease has no effective treatment.  JNJ-53718678 is a fusion inhibitor with selective activity against RSV.  After confirmation of RSV infection or 5 days after inoculation with RSV, participants (n = 69) were randomized to JNJ-53718678 75 mg (n = 15), 200 mg (n = 17), 500 mg (n = 18), or placebo (n = 17) orally once daily for 7 days.  Antiviral effects were evaluated by assessing RSV RNA viral load (VL) area under the curve (AUC) from baseline (before the first dose) until discharge, time-to-peak VL, duration of viral shedding, clin. symptoms, and quantity of nasal secretions.  Mean VL AUC was lower for individuals treated with different doses of JNJ-53718678 vs. placebo (203.8-253.8 vs 432.8 log10 PFUe.hour/mL).  Also, mean peak VL, time to peak VL, duration of viral shedding, mean overall symptom score, and nasal secretion wt. were lower in each JNJ-53718678-treated group vs. placebo.  No clear exposure-response relationship was obsd.  Three participants discontinued due to treatment-emergent adverse events of grade 2 and 1 ECG change (JNJ-53718678 75 mg and 200 mg, resp.) and grade 2 urticaria (placebo).  Conclusions.  JNJ-53718678 at all 3 doses substantially reduced VL and clin. disease severity, thus establishing clin. proof of concept and the compd.'s potential as a novel RSV treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9lct-FnOIM7Vg90H21EOLACvtfcHk0lisBYfse-mklg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlCnt77J&md5=a7da58b73e29e9c06537292a14dc3408</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjiy227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjiy227%26sid%3Dliteratum%253Aachs%26aulast%3DStevens%26aufirst%3DM.%26aulast%3DRusch%26aufirst%3DS.%26aulast%3DDeVincenzo%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DY.%2BI.%26aulast%3DHarrison%26aufirst%3DL.%26aulast%3DMeals%26aufirst%3DE.%2BA.%26aulast%3DBoyers%26aufirst%3DA.%26aulast%3DFok-Seang%26aufirst%3DJ.%26aulast%3DHuntjens%26aufirst%3DD.%26aulast%3DLounis%26aufirst%3DN.%26aulast%3DMari%25C3%25ABn%26aufirst%3DK.%26aulast%3DRemmerie%26aufirst%3DB.%26aulast%3DRoymans%26aufirst%3DD.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DVerloes%26aufirst%3DR.%26atitle%3DAntiviral%2520activity%2520of%2520oral%2520JNJ-53718678%2520in%2520healthy%2520adult%2520volunteers%2520challenged%2520with%2520respiratory%2520syncytial%2520virus%253A%2520a%2520placebo-controlled%2520study%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2018%26volume%3D218%26issue%3D5%26spage%3D748%26epage%3D756%26doi%3D10.1093%2Finfdis%2Fjiy227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Israel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fok-Seang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntjens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariën, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verloes, R.</span></span> <span> </span><span class="NLM_article-title">Effect of oral JNJ-53718678 (JNJ-678) on disease severity in healthy adult volunteers experimentally inoculated with live respiratory syncytial virus (rsv): a placebo-controlled challenge study</span>. <i>Open Forum Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">Issue suppl_1</span>),  <span class="NLM_fpage">650</span>, <span class="refDoi"> DOI: 10.1093/ofid/ofw172.513</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1093%2Fofid%2Fofw172.513" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=650&issue=Issue+suppl_1&author=S.+Israelauthor=S.+Ruschauthor=J.+DeVincenzoauthor=A.+Boyersauthor=J.+Fok-Seangauthor=D.+Huntjensauthor=N.+Lounisauthor=K.+Mari%C3%ABnauthor=M.+Stevensauthor=R.+Verloes&title=Effect+of+oral+JNJ-53718678+%28JNJ-678%29+on+disease+severity+in+healthy+adult+volunteers+experimentally+inoculated+with+live+respiratory+syncytial+virus+%28rsv%29%3A+a+placebo-controlled+challenge+study&doi=10.1093%2Fofid%2Fofw172.513"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1093%2Fofid%2Fofw172.513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fofid%252Fofw172.513%26sid%3Dliteratum%253Aachs%26aulast%3DIsrael%26aufirst%3DS.%26aulast%3DRusch%26aufirst%3DS.%26aulast%3DDeVincenzo%26aufirst%3DJ.%26aulast%3DBoyers%26aufirst%3DA.%26aulast%3DFok-Seang%26aufirst%3DJ.%26aulast%3DHuntjens%26aufirst%3DD.%26aulast%3DLounis%26aufirst%3DN.%26aulast%3DMari%25C3%25ABn%26aufirst%3DK.%26aulast%3DStevens%26aufirst%3DM.%26aulast%3DVerloes%26aufirst%3DR.%26atitle%3DEffect%2520of%2520oral%2520JNJ-53718678%2520%2528JNJ-678%2529%2520on%2520disease%2520severity%2520in%2520healthy%2520adult%2520volunteers%2520experimentally%2520inoculated%2520with%2520live%2520respiratory%2520syncytial%2520virus%2520%2528rsv%2529%253A%2520a%2520placebo-controlled%2520challenge%2520study%26jtitle%3DOpen%2520Forum%2520Infect.%2520Dis.%26date%3D2016%26volume%3D3%26issue%3DIssue%2520suppl_1%26spage%3D650%26doi%3D10.1093%2Fofid%2Fofw172.513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwanten, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clerck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span></span> <span> </span><span class="NLM_article-title">A fluorescence-based high-throughput antiviral compound screening assay against respiratory syncytial virus</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1030</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">344</span>, <span class="refDoi"> DOI: 10.1007/978-1-62703-484-5_26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1007%2F978-1-62703-484-5_26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=23821280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVSnu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1030&publication_year=2013&pages=337-344&author=L.+Kwantenauthor=B.+De+Clerckauthor=D.+Roymans&title=A+fluorescence-based+high-throughput+antiviral+compound+screening+assay+against+respiratory+syncytial+virus&doi=10.1007%2F978-1-62703-484-5_26"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A fluorescence-based high-throughput antiviral compound screening assay against respiratory syncytial virus</span></div><div class="casAuthors">Kwanten, Leen; De Clerck, Ben; Roymans, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1030</span>
        (<span class="NLM_cas:issue">Antiviral Methods and Protocols</span>),
    <span class="NLM_cas:pages">337-344</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) is a common virus that infects people of all ages and causes cold-like symptoms in most cases.  However, more serious infections occur in the younger and older extremities of the population causing severe lung infections such as bronchiolitis and pneumonia.  The current std. of care is mostly limited to supportive treatment, although prophylaxis by passive immunization with the humanized monoclonal antibody palivizumab and therapeutic intervention with aerosolized ribavirin are available.  Unfortunately, administration of palivizumab is restricted to at-risk infants up to the age of two and is assocd. with high cost, while ribavirin treatment is hindered by questionable efficacy and safety reasons.  Consequently, the development of novel specific RSV antiviral drugs is needed to help decrease RSV-related morbidity and mortality.  We describe here a fluorescence-based high-throughput screening assay to discover RSV inhibitors which is based on the infection of HeLa cells with a recombinant RSV strain that contains an enhanced green fluorescent protein coding sequence in its viral genome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFiCkq9AUY2LVg90H21EOLACvtfcHk0lisBYfse-mklg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVSnu7%252FM&md5=22eed7774eca0e9c93bdcf14c660d560</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2F978-1-62703-484-5_26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-62703-484-5_26%26sid%3Dliteratum%253Aachs%26aulast%3DKwanten%26aufirst%3DL.%26aulast%3DDe%2BClerck%26aufirst%3DB.%26aulast%3DRoymans%26aufirst%3DD.%26atitle%3DA%2520fluorescence-based%2520high-throughput%2520antiviral%2520compound%2520screening%2520assay%2520against%2520respiratory%2520syncytial%2520virus%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2013%26volume%3D1030%26spage%3D337%26epage%3D344%26doi%3D10.1007%2F978-1-62703-484-5_26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooymans, L. P.</span>; <span class="NLM_string-name">Hu, L.</span>; <span class="NLM_string-name">Jonckers, T. H. M.</span>; <span class="NLM_string-name">Raboisson, P. J.-M. B.</span>; <span class="NLM_string-name">Tahri, A.</span>; <span class="NLM_string-name">Van Hoof, S. M. P.</span>; <span class="NLM_string-name">Vendeville, S. M. H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Imidazopyridine Derivatives for Use as Respiratory Syncytial Virus Antiviral Agents</span>. PCT Int. Appl. <span class="NLM_patent">WO-2012/080451 A1</span>, <span class="NLM_year">2012</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=L.+P.+Cooymans&author=L.+Hu&author=T.+H.+M.+Jonckers&author=P.+J.-M.+B.+Raboisson&author=A.+Tahri&author=S.+M.+P.+Van+Hoof&author=S.+M.+H.+Vendeville&title=Preparation+of+Imidazopyridine+Derivatives+for+Use+as+Respiratory+Syncytial+Virus+Antiviral+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCooymans%26aufirst%3DL.%2BP.%26atitle%3DPreparation%2520of%2520Imidazopyridine%2520Derivatives%2520for%2520Use%2520as%2520Respiratory%2520Syncytial%2520Virus%2520Antiviral%2520Agents%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alnajjar, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battles, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitthicharoenchai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furmanova-Hollenstein, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigaux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, J. V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwanten, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginderen, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheyen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vranckx, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaensch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnoult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorzaat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallup, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larios-Mora, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crabbe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntjens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raboisson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langedijk, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackermann, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vendeville, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span> <span> </span><span class="NLM_article-title">Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-00170-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1038%2Fs41467-017-00170-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=28232747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC1cXos1Sls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1-15&issue=1&author=D.+Roymansauthor=S.+S.+Alnajjarauthor=M.+B.+Battlesauthor=P.+Sitthicharoenchaiauthor=P.+Furmanova-Hollensteinauthor=P.+Rigauxauthor=J.+V.+D.+Bergauthor=L.+Kwantenauthor=M.+V.+Ginderenauthor=N.+Verheyenauthor=L.+Vranckxauthor=S.+Jaenschauthor=E.+Arnoultauthor=R.+Voorzaatauthor=J.+M.+Gallupauthor=A.+Larios-Moraauthor=M.+Crabbeauthor=D.+Huntjensauthor=P.+Raboissonauthor=J.+P.+Langedijkauthor=M.+R.+Ackermannauthor=J.+S.+McLellanauthor=S.+Vendevilleauthor=A.+Koul&title=Therapeutic+efficacy+of+a+respiratory+syncytial+virus+fusion+inhibitor&doi=10.1038%2Fs41467-017-00170-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor</span></div><div class="casAuthors">Roymans, Dirk; Alnajjar, Sarhad S.; Battles, Michael B.; Sitthicharoenchai, Panchan; Furmanova-Hollenstein, Polina; Rigaux, Peter; Van den Berg, Joke; Kwanten, Leen; Van Ginderen, Marcia; Verheyen, Nick; Vranckx, Luc; Jaensch, Steffen; Arnoult, Eric; Voorzaat, Richard; Gallup, Jack M.; Larios-Mora, Alejandro; Crabbe, Marjolein; Huntjens, Dymphy; Raboisson, Pierre; Langedijk, Johannes P.; Ackermann, Mark R.; McLellan, Jason S.; Vendeville, Sandrine; Koul, Anil</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-15</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Respiratory syncytial virus is a major cause of acute lower respiratory tract infection in young children, immunocompromised adults, and the elderly.  Intervention with small-mol. antivirals specific for respiratory syncytial virus presents an important therapeutic opportunity, but no such compds. are approved today.  Here we report the structure of JNJ-53718678 bound to respiratory syncytial virus fusion (F) protein in its prefusion conformation, and we show that the potent nanomolar activity of JNJ-53718678, as well as the preliminary structure-activity relationship and the pharmaceutical optimization strategy of the series, are consistent with the binding mode of JNJ-53718678 and other respiratory syncytial virus fusion inhibitors.  Oral treatment of neonatal lambs with JNJ-53718678, or with an equally active close analog, efficiently inhibits established acute lower respiratory tract infection in the animals, even when treatment is delayed until external signs of respiratory syncytial virus illness have become visible.  Together, these data suggest that JNJ-53718678 is a promising candidate for further development as a potential therapeutic in patients at risk to develop respiratory syncytial virus acute lower respiratory tract infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTzBk8medi0rVg90H21EOLACvtfcHk0litu1b33Swkeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXos1Sls7g%253D&md5=29cde932b5cb9139d6f5aeb57bb6db72</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-00170-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-00170-x%26sid%3Dliteratum%253Aachs%26aulast%3DRoymans%26aufirst%3DD.%26aulast%3DAlnajjar%26aufirst%3DS.%2BS.%26aulast%3DBattles%26aufirst%3DM.%2BB.%26aulast%3DSitthicharoenchai%26aufirst%3DP.%26aulast%3DFurmanova-Hollenstein%26aufirst%3DP.%26aulast%3DRigaux%26aufirst%3DP.%26aulast%3DBerg%26aufirst%3DJ.%2BV.%2BD.%26aulast%3DKwanten%26aufirst%3DL.%26aulast%3DGinderen%26aufirst%3DM.%2BV.%26aulast%3DVerheyen%26aufirst%3DN.%26aulast%3DVranckx%26aufirst%3DL.%26aulast%3DJaensch%26aufirst%3DS.%26aulast%3DArnoult%26aufirst%3DE.%26aulast%3DVoorzaat%26aufirst%3DR.%26aulast%3DGallup%26aufirst%3DJ.%2BM.%26aulast%3DLarios-Mora%26aufirst%3DA.%26aulast%3DCrabbe%26aufirst%3DM.%26aulast%3DHuntjens%26aufirst%3DD.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DLangedijk%26aufirst%3DJ.%2BP.%26aulast%3DAckermann%26aufirst%3DM.%2BR.%26aulast%3DMcLellan%26aufirst%3DJ.%2BS.%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DKoul%26aufirst%3DA.%26atitle%3DTherapeutic%2520efficacy%2520of%2520a%2520respiratory%2520syncytial%2520virus%2520fusion%2520inhibitor%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26issue%3D1%26spage%3D1%26epage%3D15%26doi%3D10.1038%2Fs41467-017-00170-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobunai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyagi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utsigi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierzba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, Y.</span></span> <span> </span><span class="NLM_article-title">Specific distribution of TOP-53 to the lung and lung localized tumor is determined by its interaction with phospholipids</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">4396</span>– <span class="NLM_lpage">4401</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=11106259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovVSgu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=4396-4401&author=M.+Yoshidaauthor=T.+Kobunaiauthor=K.+Aoyagiauthor=H.+Saitoauthor=T.+Utsigiauthor=K.+Wierzbaauthor=Y.+Yamada&title=Specific+distribution+of+TOP-53+to+the+lung+and+lung+localized+tumor+is+determined+by+its+interaction+with+phospholipids"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Specific distribution of TOP-53 to the lung and lung-localized tumor is determined by its interaction with phospholipids</span></div><div class="casAuthors">Yoshida, Masahiko; Kobunai, Takashi; Aoyagi, Kumio; Saito, Hitoshi; Utsugi, Teruhiro; Wierzba, Konstanty; Yamada, Yuji</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4396-4401</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The authors have investigated the mechanism of TOP-53 distribution to the lung and lung-localized tumor.  In contrast to etoposide (VP-16), TOP-53 contains a basic aminoalkyl group that may predispose it to interact specifically with phospholipids, consequently leading to an increase of drug accumulation in the tissues.  Therefore, the authors have studied its interaction with phospholipids in vitro using an org. solvent-water partition system.  TOP-53 appeared to have the most potent binding affinity (Ka = 563 × 10-2 μM) to phosphatidylserine (PhS), whereas VP-16 showed no interaction with any phospholipid tested.  PhS content detd. after HPLC sepn. varied among tested tissues; however, large quantities were found in normal lung and lung cancer tissues far exceeding those present in the liver and kidney.  The predicted tissue-to-plasma partition coeff. values, estd. based on PhS content and its binding affinity, resembled those exptl. detd.  The authors concluded that tissue distribution of TOP-53 is detd. by PhS content in the tissues and by binding affinity.  As a result of specific accumulation in the lung, TOP-53 appeared to show a strong antitumor activity (increase of life span = 171%) against cancer metastasizing to the lung, whereas VP-16 was less effective (increase of life span = 78%).  These results suggest that TOP-53 may have an advantage over VP-16 in the treatment of lung cancers in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6PO9ZSt9VwrVg90H21EOLACvtfcHk0litu1b33Swkeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovVSgu7s%253D&md5=387a94d4ce880032107b3fa391617fb5</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DKobunai%26aufirst%3DT.%26aulast%3DAoyagi%26aufirst%3DK.%26aulast%3DSaito%26aufirst%3DH.%26aulast%3DUtsigi%26aufirst%3DT.%26aulast%3DWierzba%26aufirst%3DK.%26aulast%3DYamada%26aufirst%3DY.%26atitle%3DSpecific%2520distribution%2520of%2520TOP-53%2520to%2520the%2520lung%2520and%2520lung%2520localized%2520tumor%2520is%2520determined%2520by%2520its%2520interaction%2520with%2520phospholipids%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2000%26volume%3D6%26spage%3D4396%26epage%3D4401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zane, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindle, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gause, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Buck, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripp, S. L.</span></span> <span> </span><span class="NLM_article-title">Physicochemical factors associated with binding and retention of compounds in ocular melanin of rats: Correlations using data from whole-body autoradiography and molecular modeling for multiple linear regression analyses</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">935</span>– <span class="NLM_lpage">941</span>, <span class="refDoi"> DOI: 10.1023/A:1015997823755</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1023%2FA%3A1015997823755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=2235893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADyaK3cXmtVCnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1990&pages=935-941&author=P.+A.+Zaneauthor=S.+D.+Brindleauthor=D.+O.+Gauseauthor=A.+J.+O%E2%80%99Buckauthor=P.+R.+Raghavanauthor=S.+L.+Tripp&title=Physicochemical+factors+associated+with+binding+and+retention+of+compounds+in+ocular+melanin+of+rats%3A+Correlations+using+data+from+whole-body+autoradiography+and+molecular+modeling+for+multiple+linear+regression+analyses&doi=10.1023%2FA%3A1015997823755"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical factors associated with binding and retention of compounds in ocular melanin of rats:  correlations using data from whole-body autoradiography and molecular modeling for multiple linear regression analyses</span></div><div class="casAuthors">Zane, Patricia A.; Brindle, Shirley D.; Gause, Douglas O.; O'Buck, Arlene J.; Raghavan, Palayakotai R.; Tripp, Spencer L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">935-41</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    </div><div class="casAbstract">The relationship between the physicochem. characteristics of 27 new drug candidates and their distribution into the melanin-contg. structure of the rat eye, the uveal tract, was examd.  Tissue distribution data were obtained from whole-body autoradiograms of pigmented Long-Evans rats sacrificed at 5 min and 96 h after dosing.  The physicochem. parameters considered include mol. wt., pKa, degree of ionization, octanol/water partition coeff. (log Po/w), drug-melanin binding energy, and acid/base status of the functional groups within the mol.  Multiple linear regression anal. was used to describe the best model correlating physicochem. and/or biol. characteristics of these compds. to their initial distribution at 5 min and to the retention of residual radioactivity in ocular melanin at 96 h post-injection.  The early distribution was a function primarily of acid/base status, pKa, binding energy, and log P(o/w), whereas uveal tract retention in rats was a function of vol. of distribution (V1), log P(o/w), pKa, and binding energy.  Further, there was a relationship between the initial distribution of a compd. into the uveal tract and its retention 96 h later.  More specifically, the structures most likely to be distributed and ultimately retained at high concns. were those contg. strongly basic functionalities, such as piperidine or piperazine moieties and other amines.  Further, the more lipophilic and, hence, widely distributed the basic compd., the greater the likelihood that it interacts with ocular melanin.  In summary, the use of multiple linear regression anal. was useful in distinguishing which physicochem. characteristics of a compd. or group of compds. contributed to melanin binding in pigmented rats in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_eS88Ro4YLVg90H21EOLACvtfcHk0litu1b33Swkeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXmtVCnsbk%253D&md5=2572c995dfd848505134d9bd3eaae30f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1023%2FA%3A1015997823755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1015997823755%26sid%3Dliteratum%253Aachs%26aulast%3DZane%26aufirst%3DP.%2BA.%26aulast%3DBrindle%26aufirst%3DS.%2BD.%26aulast%3DGause%26aufirst%3DD.%2BO.%26aulast%3DO%25E2%2580%2599Buck%26aufirst%3DA.%2BJ.%26aulast%3DRaghavan%26aufirst%3DP.%2BR.%26aulast%3DTripp%26aufirst%3DS.%2BL.%26atitle%3DPhysicochemical%2520factors%2520associated%2520with%2520binding%2520and%2520retention%2520of%2520compounds%2520in%2520ocular%2520melanin%2520of%2520rats%253A%2520Correlations%2520using%2520data%2520from%2520whole-body%2520autoradiography%2520and%2520molecular%2520modeling%2520for%2520multiple%2520linear%2520regression%2520analyses%26jtitle%3DPharm.%2520Res.%26date%3D1990%26volume%3D7%26spage%3D935%26epage%3D941%26doi%3D10.1023%2FA%3A1015997823755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Duve, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Barsy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poole, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trouet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulkens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Hoof, F.</span></span> <span> </span><span class="NLM_article-title">Lysosomotropic agents</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">2495</span>– <span class="NLM_lpage">2531</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(74)90174-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1016%2F0006-2952%2874%2990174-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=4606365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADyaE2MXotVajsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1974&pages=2495-2531&issue=18&author=C.+De%0ADuveauthor=T.+de+Barsyauthor=B.+Pooleauthor=A.+Trouetauthor=P.+Tulkensauthor=F.+Van+Hoof&title=Lysosomotropic+agents&doi=10.1016%2F0006-2952%2874%2990174-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosomotropic agents</span></div><div class="casAuthors">De Duve, Christian; De Barsy, Thierry; Poole, Brian; Trouet, Andre; Tulkens, Paul; Van Hoof, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2495-531</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">A review of the nature, mechanisms of entry, and therapeutic possibilities of lysosomotropic agents, i.e., substances that are taken up selectively into lysosomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg5ghnaqeC-7Vg90H21EOLACvtfcHk0ljn1iseIDXvjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXotVajsg%253D%253D&md5=030336e8550d5fc2988796dac6772170</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2874%2990174-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252874%252990174-9%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BDuve%26aufirst%3DC.%26aulast%3Dde%2BBarsy%26aufirst%3DT.%26aulast%3DPoole%26aufirst%3DB.%26aulast%3DTrouet%26aufirst%3DA.%26aulast%3DTulkens%26aufirst%3DP.%26aulast%3DVan%2BHoof%26aufirst%3DF.%26atitle%3DLysosomotropic%2520agents%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1974%26volume%3D23%26issue%3D18%26spage%3D2495%26epage%3D2531%26doi%3D10.1016%2F0006-2952%2874%2990174-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chatman, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anway, S. D.</span></span> <span> </span><span class="NLM_article-title">A strategy for risk management of drug-induced phospholipidosis</span>. <i>Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1005</span>, <span class="refDoi"> DOI: 10.1177/0192623309352496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1177%2F0192623309352496" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=20008549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmvVKrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=997-1005&issue=7&author=L.+A.+Chatmanauthor=D.+Mortonauthor=T.+O.+Johnsonauthor=S.+D.+Anway&title=A+strategy+for+risk+management+of+drug-induced+phospholipidosis&doi=10.1177%2F0192623309352496"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">A strategy for risk management of drug-induced phospholipidosis</span></div><div class="casAuthors">Chatman, Linda A.; Morton, Daniel; Johnson, Theodore O.; Anway, Susan D.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">997-1005</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Drug-induced phospholipidosis (PL) is an excessive accumulation of phospholipids and drug in lysosomes.  Phospholipidosis signals a change in cell membrane integrity and accumulation of intracellular drug or metabolite in tissues.  The sensitivity and susceptibility of preclin. models to detect PL vary with therapeutic agents, and PL is expected to be reversible after discontinuation of drug treatment.  The prevailing scientific opinion is that PL by itself is not adverse; however, some regulatory authorities consider PL to be adverse because a small no. of chems. are able to cause PL and concurrent organ toxicity.  Until a greater understanding of PL emerges, a well-thought-out risk management strategy for PL will increase confidence in safety and improve selection and development of new drugs.  This paper provides a tiered approach to risk management of drug-induced PL.  It begins with use of in silico and in vitro tools to design and select compds. with reduced potential to produce PL.  Early in vivo studies in two species are used to better characterize potential for toxicity and PL.  Finally, routine risk management tools (i.e., translational biomarkers, assessment of reversibility) are used to support confidence in safety of compds. that induce PL in animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAM7cftU9FOLVg90H21EOLACvtfcHk0ljn1iseIDXvjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmvVKrug%253D%253D&md5=9ce40ff60732ea1d6cfe718ed173d84e</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1177%2F0192623309352496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623309352496%26sid%3Dliteratum%253Aachs%26aulast%3DChatman%26aufirst%3DL.%2BA.%26aulast%3DMorton%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DAnway%26aufirst%3DS.%2BD.%26atitle%3DA%2520strategy%2520for%2520risk%2520management%2520of%2520drug-induced%2520phospholipidosis%26jtitle%3DToxicol.%2520Pathol.%26date%3D2009%26volume%3D37%26issue%3D7%26spage%3D997%26epage%3D1005%26doi%3D10.1177%2F0192623309352496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foss, F. W.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, T. L.</span></span> <span> </span><span class="NLM_article-title">In vitro metabolism of a model cyclopropylamine to reactive intermediate: insights into trovafloxacin-induced hepatotoxicity</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">719</span>, <span class="refDoi"> DOI: 10.1021/tx7003085</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx7003085" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisVWksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=711-719&author=Q.+Sunauthor=R.+Zhuauthor=F.+W.+Fossauthor=T.+L.+Macdonald&title=In+vitro+metabolism+of+a+model+cyclopropylamine+to+reactive+intermediate%3A+insights+into+trovafloxacin-induced+hepatotoxicity&doi=10.1021%2Ftx7003085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Metabolism of a Model Cyclopropylamine to Reactive Intermediate: Insights into Trovafloxacin-Induced Hepatotoxicity</span></div><div class="casAuthors">Sun, Qin; Zhu, Ran; Foss, Frank W.; Macdonald, Timothy L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">711-719</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trovafloxacin (Trovan) is a fluoroquinolone antibiotic drug with a long half-life and broad-spectrum activity.  Since its entry into the market in 1998, trovafloxacin has been assocd. with numerous cases of hepatotoxicity, which has limited its clin. usefulness.  Trovafloxacin possesses two substructural elements that have the potential to generate reactive intermediates: a cyclopropylamine moiety and a difluoroanilino system.  The results presented here describe the in vitro metabolic activation of a synthetic drug model (DM) of trovafloxacin that contains the cyclopropylamine moiety.  Cyclopropylamine can be oxidized to reactive ring-opened products-a carbon-centered radical and a subsequently oxidized α,β-unsatd. aldehyde.  Expts. with monoamine oxygenases, horseradish peroxidase, flavin monooxygenase 3, and cDNA-expressed P 450 isoenzymes revealed that P 450 1A2 oxidizes DM to a reactive α,β-unsatd. aldehyde, M1.  Furthermore, myeloperoxidase (MPO) was also demonstrated to oxidize DM in the presence of chloride ion to produce M1.  DM proved to be a suicide inhibitor of MPO while showing no inhibition of P 450 1A2.  The structure of the reactive metabolite was confirmed by LC-MS/MS anal. by comparison with a synthetic std. M1 was further shown to react with glutathione and the related thiol nucleophile, 4-bromobenzyl mercaptan, suggesting the potential of this intermediate to react with protein nucleophiles.  In summary, these data provide evidence that trovafloxacin-induced hepatotoxicity may be mediated through the oxidn. of the cyclopropylamine substructure to reactive intermediates that may form covalent adducts to hepatic proteins, resulting in damage to liver tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr211JADO6oxbVg90H21EOLACvtfcHk0ljn1iseIDXvjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisVWksLY%253D&md5=cb587b2776c7af787f6527a01765ebdb</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Ftx7003085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx7003085%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DZhu%26aufirst%3DR.%26aulast%3DFoss%26aufirst%3DF.%2BW.%26aulast%3DMacdonald%26aufirst%3DT.%2BL.%26atitle%3DIn%2520vitro%2520metabolism%2520of%2520a%2520model%2520cyclopropylamine%2520to%2520reactive%2520intermediate%253A%2520insights%2520into%2520trovafloxacin-induced%2520hepatotoxicity%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26spage%3D711%26epage%3D719%26doi%3D10.1021%2Ftx7003085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsky, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatakrishnan, K.</span></span> <span> </span><span class="NLM_article-title">Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1124/dmd.106.012633</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1124%2Fdmd.106.012633" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=17093004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVKrs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=246-255&issue=2&author=R.+S.+Obachauthor=R.+L.+Walskyauthor=K.+Venkatakrishnan&title=Mechanism-based+inactivation+of+human+cytochrome+P450+enzymes+and+the+prediction+of+drug-drug+interactions&doi=10.1124%2Fdmd.106.012633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions</span></div><div class="casAuthors">Obach, R. Scott; Walsky, Robert L.; Venkatakrishnan, Karthik</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">246-255</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The ability to use vitro inactivation kinetic parameters in scaling to in vivo drug-drug interactions (DDIs) for mechanism-based inactivators of human cytochrome P 450 (P 450) enzymes was examd. using eight human P 450-selective marker activities in pooled human liver microsomes.  These data were combined with other parameters (systemic Cmax, estd. hepatic inlet Cmax, fraction unbound, in vivo P 450 enzyme degrdn. rate consts. estd. from clin. pharmacokinetic data, and fraction of the affected drug cleared by the inhibited enzyme) to predict increases in exposure to drugs, and the predictions were compared with in vivo DDIs gathered from clin. studies reported in the scientific literature.  In general, the use of unbound systemic Cmax as the inactivator concn. in vivo yielded the most accurate predictions of DDI with a mean -fold error of 1.64.  Abbreviated in vitro approaches to identifying mechanism-based inactivators were developed.  Testing potential inactivators at a single concn. (IC25) in a 30-min preincubation with human liver microsomes in the absence and presence of NADPH followed by assessment of P 450 marker activities readily identified those compds. known to be mechanism-based inactivators and represents an approach that can be used with greater throughput.  Measurement of decreases in IC50 occurring with a 30-min preincubation with liver microsomes and NADPH was also useful in identifying mechanism-based inactivators, and the IC50 measured after such a preincubation was highly correlated with the kinact/K1 ratio measured after a full characterization of inactivation.  Overall, these findings support the conclusion that P 450 in vitro inactivation data are valuable in predicting clin. DDIs that can occur via this mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpPRf5ZGrW6LVg90H21EOLACvtfcHk0ljn1iseIDXvjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVKrs7k%253D&md5=71733cfafba3b2c9cc6b47a46e7b3f40</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1124%2Fdmd.106.012633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.106.012633%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DWalsky%26aufirst%3DR.%2BL.%26aulast%3DVenkatakrishnan%26aufirst%3DK.%26atitle%3DMechanism-based%2520inactivation%2520of%2520human%2520cytochrome%2520P450%2520enzymes%2520and%2520the%2520prediction%2520of%2520drug-drug%2520interactions%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2007%26volume%3D35%26issue%3D2%26spage%3D246%26epage%3D255%26doi%3D10.1124%2Fdmd.106.012633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardegger, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinnler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anselm, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ecabert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stihle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gsell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plancher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banner, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haap, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, F.</span></span> <span> </span><span class="NLM_article-title">Systematic investigation of halogen bonding in protein-ligand interactions</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">314</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1002/anie.201006781</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1002%2Fanie.201006781" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1alu73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=314-318&author=L.+A.+Hardeggerauthor=B.+Kuhnauthor=B.+Spinnlerauthor=L.+Anselmauthor=R.+Ecabertauthor=M.+Stihleauthor=B.+Gsellauthor=R.+Thomaauthor=J.+Diezauthor=J.+Benzauthor=J.+Plancherauthor=G.+Hartmannauthor=D.+W.+Bannerauthor=W.+Haapauthor=F.+Diederich&title=Systematic+investigation+of+halogen+bonding+in+protein-ligand+interactions&doi=10.1002%2Fanie.201006781"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic Investigation of Halogen Bonding in Protein-Ligand Interactions</span></div><div class="casAuthors">Hardegger, Leo A.; Kuhn, Bernd; Spinnler, Beat; Anselm, Lilli; Ecabert, Robert; Stihle, Martine; Gsell, Bernard; Thoma, Ralf; Diez, Joachim; Benz, Joerg; Plancher, Jean-Marc; Hartmann, Guido; Banner, David W.; Haap, Wolfgang; Diederich, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">314-318, S314/1-S314/145</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Halogen bonding triggers activity.  Increasing binding affinity was obsd. for a series of covalent human Cathepsin L inhibitors by exchanging an aryl ring H atom with Cl, Br, and I, which undergo halogen bonding with the C=O group of Gly61 in the S3 pocket of the enzyme.  Fluorine, in contrast, strongly avoids halogen bonding.  The strong distance and angle dependence of halogen bonding was confirmed for biol. systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbsbCNMQhVu7Vg90H21EOLACvtfcHk0lhPxzXB1V5lLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1alu73N&md5=1a7f2983a386fd133be0663657fc486b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fanie.201006781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201006781%26sid%3Dliteratum%253Aachs%26aulast%3DHardegger%26aufirst%3DL.%2BA.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DSpinnler%26aufirst%3DB.%26aulast%3DAnselm%26aufirst%3DL.%26aulast%3DEcabert%26aufirst%3DR.%26aulast%3DStihle%26aufirst%3DM.%26aulast%3DGsell%26aufirst%3DB.%26aulast%3DThoma%26aufirst%3DR.%26aulast%3DDiez%26aufirst%3DJ.%26aulast%3DBenz%26aufirst%3DJ.%26aulast%3DPlancher%26aufirst%3DJ.%26aulast%3DHartmann%26aufirst%3DG.%26aulast%3DBanner%26aufirst%3DD.%2BW.%26aulast%3DHaap%26aufirst%3DW.%26aulast%3DDiederich%26aufirst%3DF.%26atitle%3DSystematic%2520investigation%2520of%2520halogen%2520bonding%2520in%2520protein-ligand%2520interactions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2011%26volume%3D50%26spage%3D314%26epage%3D318%26doi%3D10.1002%2Fanie.201006781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
den Berg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwanten, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span></span> <span> </span><span class="NLM_article-title">Evaluation of antiviral efficacy against human respiratory syncytial virus using cotton rat and mouse models</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1030</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1007/978-1-62703-484-5_28</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1007%2F978-1-62703-484-5_28" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=23821282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVSnu7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1030&publication_year=2013&pages=365-372&author=J.+Van%0Aden+Bergauthor=L.+Kwantenauthor=D.+Roymans&title=Evaluation+of+antiviral+efficacy+against+human+respiratory+syncytial+virus+using+cotton+rat+and+mouse+models&doi=10.1007%2F978-1-62703-484-5_28"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of antiviral efficacy against human respiratory syncytial virus using cotton rat and mouse models</span></div><div class="casAuthors">Van den Berg, Joke; Kwanten, Leen; Roymans, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1030</span>
        (<span class="NLM_cas:issue">Antiviral Methods and Protocols</span>),
    <span class="NLM_cas:pages">365-372</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Infection with human respiratory syncytial virus (hRSV) causes a wide spectrum of respiratory disease in infants, young children, and elderly persons.  No vaccine is available today and hRSV treatment options are limited.  As a consequence, the treatment of hRSV infection remains largely supportive and new therapeutic options are needed to treat severe lower respiratory tract hRSV disease.  Several animal models have been developed to study hRSV disease and evaluate novel therapies or preventive measures such as vaccines.  However, each of these models reproduces different aspects of hRSV disease, and therefore, an appropriate model should be selected on the basis of the scientific question under investigation.  In this chapter, we describe how cotton rats and Balb/c mice are used in our lab. to test the in vivo efficacy of small-mol. inhibitors against hRSV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWs2PSt-lynbVg90H21EOLACvtfcHk0lhPxzXB1V5lLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVSnu7%252FP&md5=368ffaca8850e3c74e19ed935e141015</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1007%2F978-1-62703-484-5_28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-62703-484-5_28%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bden%2BBerg%26aufirst%3DJ.%26aulast%3DKwanten%26aufirst%3DL.%26aulast%3DRoymans%26aufirst%3DD.%26atitle%3DEvaluation%2520of%2520antiviral%2520efficacy%2520against%2520human%2520respiratory%2520syncytial%2520virus%2520using%2520cotton%2520rat%2520and%2520mouse%2520models%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2013%26volume%3D1030%26spage%3D365%26epage%3D372%26doi%3D10.1007%2F978-1-62703-484-5_28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ackermann, M. R.</span></span> <span> </span><span class="NLM_article-title">Lamb model of respiratory syncytial virus-associated lung disease: insights to pathogenesis and novel treatments</span>. <i>ILAR J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1093/ilar/ilu003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1093%2Filar%2Filu003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=24936027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpvFCqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=4-15&author=M.+R.+Ackermann&title=Lamb+model+of+respiratory+syncytial+virus-associated+lung+disease%3A+insights+to+pathogenesis+and+novel+treatments&doi=10.1093%2Filar%2Filu003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Lamb Model of Respiratory Syncytial Virus-Associated Lung Disease: Insights to Pathogenesis and Novel Treatments</span></div><div class="casAuthors">Ackermann, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">ILAR Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-15</span>CODEN:
                <span class="NLM_cas:coden">IJLOAC</span>;
        ISSN:<span class="NLM_cas:issn">1084-2020</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Preterm birth is a risk factor for respiratory syncytial virus (RSV) bronchiolitis and hospitalization.  The pathogenesis underlying this is not fully understood, and in vivo studies are needed to better clarify essential cellular features and mol. mechanisms.  Such studies include anal. of lung tissue from affected human infants and various animal models.  The preterm and newborn lamb lung has developmental, structural, cellular, physiol., and immunol. features similar to that of human infants.  Also, the lamb lung is susceptible to various strains of RSV that infect infants and cause similar bronchiolar lesions.  Studies in lambs suggest that viral replication in airways (esp. bronchioles) is extensive by 4 days after infection, along with bronchiolitis characterized by degeneration and necrosis of epithelial cells, syncytial cell formation, neutrophil infiltration, epithelial cell hypertrophy and hyperplasia, and innate and adaptive immune responses.  RSV bronchiolitis greatly affects airflow and gaseous exchange.  RSV disease severity is increased in preterm lambs compared with full-term lambs; similar to human infants.  The lamb is conducive to exptl. assessment of novel, mechanistic therapeutic interventions such as delivery of vascular endothelial growth factor and enhancement of airway epithelial oxidative responses, Club (Clara) cell protein 10, and synthesized compds. such as nanobodies.  In contrast, exposure of the fetal ovine lung in vivo to ethanol, a risk factor for preterm birth, reduces pulmonary alveolar development and surfactant protein A expression.  Because the formalin-inactivated RSV vaccination enhances some inflammatory responses to RSV infection in lambs, this model has the potential to assess mechanisms of formalin-inactivated RSV enhanced disease as well as newly developed vaccines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk3_OBeuTEM7Vg90H21EOLACvtfcHk0lhPxzXB1V5lLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpvFCqurg%253D&md5=923b6391e1374bb791cecc3ddb65baf1</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1093%2Filar%2Filu003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Filar%252Filu003%26sid%3Dliteratum%253Aachs%26aulast%3DAckermann%26aufirst%3DM.%2BR.%26atitle%3DLamb%2520model%2520of%2520respiratory%2520syncytial%2520virus-associated%2520lung%2520disease%253A%2520insights%2520to%2520pathogenesis%2520and%2520novel%2520treatments%26jtitle%3DILAR%2520J.%26date%3D2014%26volume%3D55%26spage%3D4%26epage%3D15%26doi%3D10.1093%2Filar%2Filu003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Derscheid, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackermann, M. R.</span></span> <span> </span><span class="NLM_article-title">Perinatal lamb model of respiratory syncytial virus (RSV) infection</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2359</span>– <span class="NLM_lpage">2378</span>, <span class="refDoi"> DOI: 10.3390/v4102359</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.3390%2Fv4102359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=23202468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVSrtrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=2359-2378&author=R.+J.+Derscheidauthor=M.+R.+Ackermann&title=Perinatal+lamb+model+of+respiratory+syncytial+virus+%28RSV%29+infection&doi=10.3390%2Fv4102359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Perinatal lamb model of respiratory syncytial virus (RSV) infection</span></div><div class="casAuthors">Derscheid, Rachel J.; Ackermann, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2359-2378</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Respiratory syncytial virus (RSV) is the most frequent cause of bronchiolitis in infants and children worldwide.  Many animal models are used to study RSV, but most studies investigate disease in adult animals which does not address the unique physiol. and immunol. that makes infants more susceptible.  The perinatal (preterm and term) lamb is a useful model of infant RSV disease as lambs have similar pulmonary structure including airway branching, Clara and type II cells, submucosal glands and Duox/lactoperoxidase (LPO) oxidative system and prenatal alveologenesis.  Lambs can be born preterm (90% gestation) and survive for experimentation although both preterm and term lambs are susceptible to ovine, bovine and human strains of RSV and develop clin. symptoms including fever, tachypnea and malaise as well as mild to moderate gross and histol. lesions including bronchiolitis with epithelial injury, neutrophil infiltration and syncytial cell formation.  RSV disease in preterm lambs is more severe than in term lambs; disease is progressively less in adults and age-dependent susceptibility is a feature similar to humans.  Innate and adaptive immune responses by perinatal lambs closely parallel those of infants.  The model is used to test therapeutic regimens, risk factors such as maternal ethanol consumption and formalin inactivated RSV vaccines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE9T5kS4AUfrVg90H21EOLACvtfcHk0lh9ksnDFAtIlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVSrtrrO&md5=a9ee493b6cd26a77171d371be4293bea</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.3390%2Fv4102359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv4102359%26sid%3Dliteratum%253Aachs%26aulast%3DDerscheid%26aufirst%3DR.%2BJ.%26aulast%3DAckermann%26aufirst%3DM.%2BR.%26atitle%3DPerinatal%2520lamb%2520model%2520of%2520respiratory%2520syncytial%2520virus%2520%2528RSV%2529%2520infection%26jtitle%3DViruses%26date%3D2012%26volume%3D4%26spage%3D2359%26epage%3D2378%26doi%3D10.3390%2Fv4102359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinon-Torres, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntjens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remmerie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vingerhoets, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFadyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrero, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epalza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics, safety and antiviral effects of multiple doses of the respiratory syncytial virus fusion protein inhibitor, JNJ-53718678, in infants hospitalized with rsv infection: a randomized phase 1b study</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="NLM_elocation-id">ciaa283</span> <span class="refDoi"> DOI: 10.1093/cid/ciaa283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=10.1093%2Fcid%2Fciaa283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=32201897" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=F.+Martinon-Torresauthor=S.+Ruschauthor=D.+Huntjensauthor=B.+Remmerieauthor=J.+Vingerhoetsauthor=K.+McFadyenauthor=F.+Ferreroauthor=E.+Baraldiauthor=P.+Rojoauthor=C.+Epalzaauthor=M.+Stevens&title=Pharmacokinetics%2C+safety+and+antiviral+effects+of+multiple+doses+of+the+respiratory+syncytial+virus+fusion+protein+inhibitor%2C+JNJ-53718678%2C+in+infants+hospitalized+with+rsv+infection%3A+a+randomized+phase+1b+study&doi=10.1093%2Fcid%2Fciaa283"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciaa283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciaa283%26sid%3Dliteratum%253Aachs%26aulast%3DMartinon-Torres%26aufirst%3DF.%26aulast%3DRusch%26aufirst%3DS.%26aulast%3DHuntjens%26aufirst%3DD.%26aulast%3DRemmerie%26aufirst%3DB.%26aulast%3DVingerhoets%26aufirst%3DJ.%26aulast%3DMcFadyen%26aufirst%3DK.%26aulast%3DFerrero%26aufirst%3DF.%26aulast%3DBaraldi%26aufirst%3DE.%26aulast%3DRojo%26aufirst%3DP.%26aulast%3DEpalza%26aufirst%3DC.%26aulast%3DStevens%26aufirst%3DM.%26atitle%3DPharmacokinetics%252C%2520safety%2520and%2520antiviral%2520effects%2520of%2520multiple%2520doses%2520of%2520the%2520respiratory%2520syncytial%2520virus%2520fusion%2520protein%2520inhibitor%252C%2520JNJ-53718678%252C%2520in%2520infants%2520hospitalized%2520with%2520rsv%2520infection%253A%2520a%2520randomized%2520phase%25201b%2520study%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2020%26doi%3D10.1093%2Fcid%2Fciaa283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swamy, K. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N. N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaraman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K. V. P. P.</span></span> <span> </span><span class="NLM_article-title">Mitsunobu and related reactions: advances and applications</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2551</span>– <span class="NLM_lpage">2651</span>, <span class="refDoi"> DOI: 10.1021/cr800278z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr800278z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVagt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=2551-2651&issue=6&author=K.+C.+K.+Swamyauthor=N.+N.+B.+Kumarauthor=E.+Balaramanauthor=K.+V.+P.+P.+Kumar&title=Mitsunobu+and+related+reactions%3A+advances+and+applications&doi=10.1021%2Fcr800278z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Mitsunobu and Related Reactions: Advances and Applications</span></div><div class="casAuthors">Swamy, K. C. Kumara; Kumar, N. N. Bhuvan; Balaraman, E.; Kumar, K. V. P. Pavan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2551-2651</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this review is an attempt to detail the Mitsunobu reaction, along with its modifications, which has been versatile and applicable for a variety of org. transformations.  The ease with which stereochem. at the chiral secondary alc. can be reversed is a valuable asset.  The large no. of publications, particularly in the area of nucleobase alkylation, reflects its popularity, mainly as a result of the mild conditions employed during the reaction.  It is expected that this aspect is going to be much sought after, particularly by the pharmaceutical industry.  Synthetic chemists tend to rely on its various facets, be it natural product synthesis or nucleobase alkylation or etherification.  As far as the future of this reaction is concerned, an efficient and inexpensive way to recycle the reagents or to make the reaction fully catalytic is desirable.  Another aspect worth looking into would be to synthesize a water sol. but degradable phosphine/phosphite of low toxicity, to simplify the purifn. process.  The aforesaid points become important if we desire to employ the Mitsunobu route for large scale synthesis.  Recoverable polymer bound phosphonium salts of type 565 that avoid the wastage of phosphine as well as azodicarboxylate, and hence make the system more atom economical and greener, also need to be considered in the future.  Finally, although a major part of the mechanistic pathways is fairly well understood, the complexity of the initial steps when different P precursors are used is intriguing.  This could also be a fruitful area for a phys. org. chemist to probe in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmJ2PTO4x-17Vg90H21EOLACvtfcHk0lh9ksnDFAtIlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVagt78%253D&md5=f7da5265d707fafe71cb40dea76dc1e9</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fcr800278z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr800278z%26sid%3Dliteratum%253Aachs%26aulast%3DSwamy%26aufirst%3DK.%2BC.%2BK.%26aulast%3DKumar%26aufirst%3DN.%2BN.%2BB.%26aulast%3DBalaraman%26aufirst%3DE.%26aulast%3DKumar%26aufirst%3DK.%2BV.%2BP.%2BP.%26atitle%3DMitsunobu%2520and%2520related%2520reactions%253A%2520advances%2520and%2520applications%26jtitle%3DChem.%2520Rev.%26date%3D2009%26volume%3D109%26issue%3D6%26spage%3D2551%26epage%3D2651%26doi%3D10.1021%2Fcr800278z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="note"><p class="first last">NMR HSQC experiments were performed on all final compounds to confirm their structure as the N-alkylated product and not O-alkylated side-product <b>75x</b>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KWW" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KWW','PDB','5KWW'); return false;">PDB: 5KWW</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VKC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VKC','PDB','6VKC'); return false;">PDB: 6VKC</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VKD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VKD','PDB','6VKD'); return false;">PDB: 6VKD</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VKE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VKE','PDB','6VKE'); return false;">PDB: 6VKE</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i29"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00226">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_60415"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00226?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00226</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00226/suppl_file/jm0c00226_si_001.csv">CSV</a>)</p></li><li><p class="inline"><sup>1</sup>H NMR data, HPLC–MS details, purity determination of all final compounds <b>4</b>–<b>74</b> (except <b>39</b>, <b>41</b>, <b>53</b>, and <b>64</b>); protein crystallization and structure determination protocols; <i>in vivo</i> efficacy results; dose–response data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00226/suppl_file/jm0c00226_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00226/suppl_file/jm0c00226_si_001.csv">jm0c00226_si_001.csv (4.01 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00226/suppl_file/jm0c00226_si_002.pdf">jm0c00226_si_002.pdf (361.95 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Compound <b>39</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VKC">6VKC</a>. Compound <b>41</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VKD">6VKD</a>. Compound <b>64</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VKE">6VKE</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-15%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00226" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00226" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67997826fa073c58","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
